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1. Summary / Zusammenfassung 
 The neurons and glial cells of the central nervous system (CNS) are embedded in a 
specialized extracellular matrix (ECM), which mainly consists of hyaluronan, chondroitin sulfate 
proteoglycans (CSPGs) of the lectican family, link proteins and tenascins. Although this general 
composition is maintained in the course of development, the meshwork becomes tighter during 
CNS maturation as individual members of the three protein families are exchanged. Since 
particularly the CSPGs impede axonal growth in vitro, the strategic accumulation of this adult 
type of extracellular matrix along myelinated fiber tracts and in perineuronal nets is thought to 
limit structural plasticity and contribute to the stabilization of mature neuronal circuits. Moreover, 
the failure of axonal regeneration after CNS injury has been partly attributed to the resident and 
the newly formed glial scar matrix. 
 The V2 splice-variant of versican is one of the main constituents of the mature extracellular 
matrix. The initial expression of this large secreted lectican coincides with myelination. At this 
late phase of CNS development, versican V2 accumulates along the myelinated fiber tracts and 
is preferentially deposited around emerging nodes of Ranvier. In vitro it binds to tenascin-R, 
hyaluronan and link proteins and it is a potent inhibitor of axonal growth.  
 To further explore the putative functions of versican V2 in vivo, we have now generated a 
versican V2-deficient mouse strain using a novel isoform-specific gene targeting approach, 
which circumvents the early embryonic lethality of the complete versican gene knockout. The 
mutant mice are viable and fertile and display no overt morphological or behavioral phenotype. 
Our subsequent molecular and immunohistological analyses of the versican V2-null mice and 
the comparisons with other knockout strains provided however, strong evidence that versican V2 
is required to orchestrate the assembly of the perinodal extracellular matrix around the CNS 
nodes of Ranvier. Additionally, we have demonstrated that the absence of this perinodal matrix 
does not, as previously postulated, affect the clustering of voltage-gated ion channels and the 
formation of paranodal and juxtaparanodal structures.  
 To address the participation of the CNS matrix in restraining regeneration after injury, we 
furthermore analyzed the distributions of distinct CSPGs in different lesion models. In rhizotomy 
experiments, we could observe a selective upregulation of neurocan and versican V1 in the 
dorsal root entry zone, while the levels of the resident versican V2 and brevican were little 
affected. A similar emergence of versican V1 expression was also detected in the newly formed 
glial scar after contusion lesion. These experiments indicate that the inhibitory properties of the 
extracellular matrix are even enhanced after lesion by the temporally increased incorporation of 
lecticans that are usually absent from the mature CNS tissues. Our findings form the basis for 
future experiments aiming at CNS regeneration in mice lacking main components of the resident 
and/or the reactive extracellular matrix.  
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 Neuronen und Gliazellen des zentralen Nervensystem (ZNS) sind von einer spezialisierten 
extrazelluläre Matrix (ECM) umgeben, die mehrheitlich aus Hyaluronan, Chondroitinsulfat-
Proteoglycanen (CSPG) der Lectican-Familie, Link Proteinen und Tenascinen besteht. Obwohl 
diese Zusammensetzung während der neuralen Entwicklung grundsätzlich erhalten bleibt, findet 
im Rahmen des Reifungsprozesses durch Austausch individueller Mitglieder der drei Protein-
familien eine Verdichtung des extrazellulären Geflechtes statt. Da insbesondere die CSPGs das 
Axonwachstum in vitro unterbinden können, wird vermutet, dass die strategische Ansammlung 
der adulten Matrix entlang myelinisierter Fasern und in perineuronalen Netzen die strukturelle 
Plastizität begrenzt und somit zur Stabilisierung ausgereifter neuronaler Schaltkreise beiträgt. 
Auch das Ausbleiben der Axonregeneration nach ZNS-Verletzungen wird teilweise der 
ansässigen ECM und der neuformierten Matrix des glialen Narbengewebes zugeschrieben. 
 Die Versican-Spleissvariante V2 ist eine der Hauptkomponenten der reifen extrazellulären 
Matrix im ZNS. Der Beginn der Expression dieses grossen sezernierten Lecticans fällt zeitlich 
mit dem Myelinisierungsprozess zusammen. In dieser späten Entwicklungphase wird Versican 
V2 in myeliniserten Fasertrakten angelagert und sammelt sich insbesondere in Nähe der sich 
bildenden Ranvierschen Schnürknoten an. In vitro bindet es Tenascin-R, Hyaluronan und Link 
Proteine und funktioniert als potenter Hemmer des Axonwachstums. 
 Zur Erforschung mutmasslicher Versican V2-Funktionen in vivo, haben wir nun einen 
Versican V2-defizienten Mausstamm hergestellt, bei dem wir die frühe embryonale Letalität des 
kompletten Genknockouts mittels eines neuen Isoform-spezifischen Gentargeting-Ansatzes 
umgingen. Die mutanten Mäuse sind lebens- und fortpflanzungsfähig und lassen auf den ersten 
Blick keine Veränderungen der Morphologie oder des Verhaltens erkennen. Unsere molekularen 
und immunhistochemischen Analysen der Versican V2-Null Mäuse und Vergleiche mit anderen 
Knockout-Stämmen haben dann aber klare Indizien für eine zentrale Rolle von Versican V2 bei 
der Orchestrierung des perinodalen ECM-Aufbaus um die Ranvierschen Schnürknoten ergeben. 
Wir konnten allerdings auch aufzeigen, dass das Fehlen dieser perinodalen Matrix, entgegen 
früherer Postulate, die normale Ansammlung spannungsabhängiger Ionenkanäle und die 
Bildung paranodaler und juxtaparanodaler Strukturen unbeeinflusst lässt. 
 Zur Untersuchung der Matrixbeteiligung an der Einschränkung der Regeneration nach ZNS-
Verletzungen, haben wir die Verteilung bestimmter CSPGs auch in verschiedenen Läsions-
modellen analysiert. In Rhizotomie-Experimenten konnten wir in der Eintrittszone der Rücken-
wurzelfasern eine selektive Hochregulation von Neurocan und Versican V1 beobachten, 
während die Anteile der normalerweise vorhandenen Versican V2 und Brevican keine grund-
legenden Veränderungen erfuhren. Ein ähnliches Hervortreten von Versican V1 wurde auch in 
frischen glialen Narbengeweben nach Kontusionsläsionen nachgewiesen. Unsere Resultate 
deuten darauf hin, dass die hemmende Eigenschaft der ECM nach einer Läsion durch den 
temporären Einbau weiterer Lecticane zusätzlich verstärkt wird. Diese Befunde bilden die Basis 
für zukünftige Experimente mit Fokus auf das Regenerationsverhalten in Mäusen, denen 
mehrere Komponenten der regulär ansässigen und/oder reaktiven extrazellulären Matrix fehlen.
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2. General Introduction 
 
2.1.  The extracellular matrix of the central nervous system 
 It was not until 1971 that the existence of an extracellular matrix (ECM) in the brain was 
acknowledged (Tani and Ametani, 1971). Then the predominant presence of hyaluronan and 
chondroitin sulfate proteoglycans (CSPG) in the central nervous system (CNS) (Margolis et al., 
1975), and the virtual absence of otherwise frequent ECM molecules like fibronectin or collagens 
were described (Carbonetto, 1984; Rutka et al., 1988; Sanes, 1989). Today we know that this 
distinctive ECM is mainly composed of proteoglycans of the lectican/hyalectan family and their 
binding partners, hyaluronan, link proteins and tenascins (Ruoslahti, 1996) (reviewed by 
(Ruoslahti, 1996; Rauch, 1997; Bandtlow and Zimmermann, 2000; Novak and Kaye, 2000; 
Yamaguchi, 2000)). In the following, I will introduce the components of this extracellular 
meshwork in more detail. 
 
2.1.1.  Proteoglycans and Hyaluronan 
 Proteoglycans (PGs) are glycoproteins carrying in addition to variable numbers of N- and O-
linked oligosaccharides, at least one glycosaminoglycan (GAG) side chain, which is covalently 
bound to the core protein via a partly conserved attachment site (consensus sequence motifs: 
Ser-Gly-X-Gly or (Asp/Glu)-X-Ser-Gly) (Bourdon et al., 1987)) and a short oligosacharide linker. 
The GAGs themselves are long unbranched polymers of repetitive disaccharide units consisting 
of an uronic acid (glucuronic or iduronic) or galactose and an amino sugar (N-acetylglucosamine 
or N-acetylgalactosamine). According to the combination of these sugars, the GAGs are 
subclassified in heparin/heparan-, keratan- or chondroitin/dermatan-sulfates (fig. 1) (Bandtlow 
and Zimmermann, 2000).  
 The GAG side chains are usually 20-200 disaccharide-repeats long and show complex 
modifications, mainly sulfation of hydroxyl groups and epimerization of the carboxyl group on C-5 
position of D-glucuronic acid to yield L-iduronic acid. The binding of chondroitin/dermatan sulfate 
and heparin/heparan sulfate chains to the core protein is mediated by a serine residue and four 
sequentially added monosaccharides: xylose, two consecutive galactoses and glucuronic acid 
(Kjellén and Lindahl, 1991). In general, this tetrasaccharide-linker is common to the attachment 
region of these GAGs, but can sometimes be slightly altered, for example by phosphorylation of 
the xylose, or sulfation at various positions and epimerization of the glucuronic acid (Prydz and 
Dalen, 2000). Altogether, the numerous modifications of the GAGs lead to a high structural 
variability and open up countless possibilities for the modulation of proteoglycan functions 
(Bulow and Hobert, 2006). Most prominently, GAGs are strongly negatively charged due to their 
high content of acidic sugars and sulfate substitutions and therefore attract and bind water and 
cations (Prydz and Dalen, 2000). 
 
 3
 
Figure 1: Disaccharide units of the GAGs: each modification is shown in different color and with the enzyme that 
catalyzes the reaction (from (Bulow and Hobert, 2006)). Abbreviations: GlcA: glucuronic acid, IdoA: iduronic acid, epi: 
epimerase, ST: sulfotransferase, NDST: N-deacetylase-N-sulfotransferase. 
 
 In contrast to the other glycosaminoglycans, hyaluronan, also known as hyaluronic acid (HA) 
or hyaluronate, is not covalently bound to any core protein, but is directly deposited in the 
extracellular matrix. It is a very large linear polymer built of repetitive disaccharides units that are 
composed of glucuronic acid and N-acetylglucosamine [-(1,4)-GlcA- (1,3)-GlcNAc-]n (fig. 2 ). 
Hyaluronan reaches up to 107 Da in size and extends over lengths of 2-25 µm. Unlike the other 
GAGs, it is not sulfated and the glucuronic acid units are not epimerized (reviewed by (Toole, 
2000, 2004)).  
 
 
Figure 2: Disaccharide units of HA (from (Bandtlow and Zimmermann, 2000)). 
 
 HA is synthesized by specific glycosyltransferases called hyaluronan synthases (HAS). 
Three vertebrate HAS genes have been identified, HAS1, HAS2, and HAS3 (reviewed by 
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(Weigel et al., 1997; Spicer and McDonald, 1998; DeAngelis, 1999)). HAS are in many senses 
unique glycosyltransferases, as they 1) are able to catalyze the incorporation of two different 
monosaccharides into the nascent string, and hence, oppose the dogma “single enzyme, single 
sugar”, 2) elongate the hyaluronan chain through its reducing end and 3) are not present in the 
endoplasmic reticulum or Golgi apparatus like most other glycosyltransferases. HAS are in fact 
positioned at the inner face of the cell membrane from where the growing HA is directly extruded 
into the pericellular space while being still attached to the enzyme (Weigel et al., 1997; Spicer 
and Tien, 2004) (fig. 3).  
 
Figure 3: Model of HA biosynthesis (from (DeAngelis, 1999)). 
(Gray cube: HAS, white and black circles: sugars from UDP-sugars; Me2+: Mn2+ or Mg2+) 
 
 Hyaluronan turnover is regulated by endocytic uptake and through its degrading enzymes, 
the hyaluronidases (Fraser et al., 1997; Tammi et al., 2002). Five human hyaluronidases are 
known, HYAL1-4 and PH-20. Each of them displays different substrate specificities (Csoka et al., 
1999; Csoka et al., 2001). 
 HA is indispensable for normal embryogenesis, as targeted inactivation of HAS2 results in 
severe aberrations in heart development and causes intra-uterine death of E10.5 mice. 
(Camenisch et al., 2000). The crucial steps affected by the HAS2-deficiency are matrix 
expansion and initiation of cell migration during heart formation (McDonald and Camenisch, 
2002). In contrast, mice lacking HAS1 or HAS3 expression are viable and fertile (Spicer et al., 
2002), indicating that HAS2 is the key enzyme during embryogenesis. 
 Hyaluronan is also abundantly present during brain development being however, reduced to 
one fourth of its maximal content during tissue maturation (Margolis et al., 1975). In the adult 
CNS it is diffusely distributed within the neuropil (Costa et al., 2007) and along the myelinated 
fiber tracts (Bignami and Asher, 1992; Girard et al., 1992). It also accumulates in perineuronal 
nets (PNNs), where it builds specialized meshworks with lecticans and tenascins. PNNs wrap 
some highly active neurons and are thought to block the establishment of new synaptic contacts 
(Celio and Blumcke, 1994; Yasuhara et al., 1994). During cerebellar development, HA is 
expressed in the prospective white matter. There it might support neural migration by forming 
arrays of extracellular fibers that are structurally rather different from the PNN lattices (Baier et 
al., 2007).  
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 Recent observations point to diverse functional roles of different size species of HA 
(Sherman et al., 2002). Deposits of high molecular weight HA have been found in chronically 
demyelinated lesions of multiple sclerosis patients. Since this form of the carbohydrate inhibits 
maturation of oligodendrocyte precursor cells, it has been suggested that high molecular 
hyaluronan hinders remyelination (Back et al., 2005).  
 In spite of being a rather simple unbranched polysaccharide, hyaluronan not only acts as a 
structural component that fills the interstitial space, it is also able to signal through cell surface 
receptors. Moreover, it provides the backbone for the assembly of highly hydrated matrices that 
form protective pericellular coats, down-regulate cellular adhesion and allow cells to divide and 
to migrate. Most of these functions are not exerted by hyaluronan alone, but rather in concert 
with its numerous binding-partners of which link proteins and proteoglycans of the 
lectican/hyalectan family are the best characterized (Toole, 2001; Day and Prestwich, 2002). 
 
2.1.1.1. Lecticans/Hyalectans 
 The structurally closely related extracellular matrix chondroitin sulfate proteoglycans 
(CSPGs) that aggregate with hyaluronan to form high molecular complexes have been named 
hyalectans (Iozzo and Murdoch, 1996) or lecticans (Ruoslahti, 1996) in reference to their N-
terminal hyaluronan-binding region (Johansson et al., 1985; LeBaron et al., 1992) and to the 
presence of a C-type lectin-like element near their C-terminus (fig. 4). Members of this CSPG-
family are aggrecan (Doege et al., 1987), versican (or PG-M) (Zimmermann and Ruoslahti, 
1989; Shinomura et al., 1993), neurocan (Rauch et al., 1992) and brevican (Yamada et al., 1994; 
Rauch et al., 1997b) (reviewed by (Ruoslahti, 1996; Bandtlow and Zimmermann, 2000; 
Yamaguchi, 2000; Rauch, 2004)). 
 The N-terminal hyaluronan-binding domain of all lecticans/hyalectans (G1 domain) consists 
of an immunoglobulin (Ig)-like loop and two link-protein-like tandem repeats (“link modules” or 
proteoglycan tandem repeats, PTR). The Ig-like loop and each tandem repeat contain two 
respectively four conserved cysteine residues that form intra-chain disulfide bridges and 
consequently ensure the proper folding of the domain. The G1 domain is essential for 
interactions with hyaluronan and link proteins that stabilize the ternary complex by binding to 
both, lectican and hyaluronan. 
 The C-terminal portion (G3 domain) of the lectican core proteins contains the lectin-like 
element, which is flanked by one or two EGF-repeats and a complement regulatory protein-like 
(CRP)/sushi domain, respectively. Recombinantly expressed G3 domains and/or the C-type 
lectin element alone bind in vitro simple carbohydrates and heparin or heparan sulfate (Ujita et 
al., 1994), fibulins -1 and -2 (Aspberg et al., 1999; Olin et al., 2001), fibrillin-1 (Isogai et al., 
2002), sulfoglycolipids (Miura et al., 1999) and the tenascins Tn-C and Tn-R (Aspberg et al., 
1995; Aspberg et al., 1997; Rauch et al., 1997a).  
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Figure 4: Structural models of lecticans/hyalectans (modified from (Bandtlow and Zimmermann, 2000).  
(Wavy lines represent CS chains and arrowheads ADAMTS cleavage sites; GPI: glycosyl-phosphatidyl-inositol) 
 
 The G1 as well as the G3 domains are highly homologous among lecticans and appear in 
rotary shadowing electron microscopy as compact globular structures at either end of an 
extended central region that carries all GAG side chains. This middle part of the core protein, 
which is in versican subjected to alternative splicing, is poorly sequence-conserved among the 
different lectican family members. It also greatly varies in size and numbers of carbohydrate 
attachment sites. In aggrecan, for example, the central region extends over an average distance 
of 200 nm (Mörgelin et al., 1994) and potentially harbors over 100 GAG side chains, whereas it 
hosts in neurocan only a few GAGs and reaches maximally a length of 90 nm (Retzler et al., 
1996). As a result, the distinct lecticans and their splice-variants form an almost perfect array of 
modular proteins that seem functionally closely related but differ extensively in size (Bandtlow 
and Zimmermann, 2000) (fig. 4).  
 Several CSPGs negatively modulate cell-cell and cell-matrix interactions and hence, are 
thought to inhibit growth of axons during nervous system development and maturation. Inhibitory 
activity on neurite outgrowth in vitro has been described for all lecticans (Snow et al., 1991; 
Friedlander et al., 1994; Yamada et al., 1997; Schmalfeldt et al., 2000), and all of them are 
expressed in the central nervous system at certain stages of development or in adulthood (Milev 
et al., 1998). Consequently, CSPGs and particularly lecticans have lately received special 
attention in regard to their potential role in obstructing CNS regeneration after injuries.  
 The expression and turnover of lecticans is during development highly dynamic. As a result, 
core proteins are in adult tissues often encountered in a fragmented form. Several characteristic 
products result from cleavage with specific ADAMTS proteases (fig. 4). ADAMTSs (a disintegrin 
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and metalloproteinase with thrombospondin motifs) are a group of secreted multi-domain 
metalloenzymes containing as main features a zinc-binding-catalytic domain, a disintegrin 
module and thrombospondin type I repeat(s), some of which are able to interact with 
glycosaminoglycans (Apte, 2004; Porter et al., 2005; Flannery, 2006) (fig. 5). Cleavage activity 
towards aggrecan, versican and/or brevican has been mainly attributed to ADAMTS-1, 
ADAMTS-4, ADAMTS-5 and ADAMTS-9. Neurocan has not yet been identified as substrate of 
these metalloenzymes.  
 
 
Figure 5: Structure and evolutionary relationship of human ADAMTS (from (Jones and Riley, 2005)). 
 
 Based on sequence alignments of the known ADAMTS cleavage sites in aggrecan and 
brevican a rather loose consensus recognition sequence 
{pt(V/I)XX(V/I)(t/d)XXlvEXvtpXXXXeXE*Xrg} has been proposed (where the asterisk represents 
the scissile bond, uppercase residues are 100 % conserved, lowercase residues are about 50 % 
conserved and X represents non conserved residues) (Sandy et al., 2001). The selective 
cleavage of lecticans by ADAMTSs is thought to modulate the functions of these proteoglycans 
by limited proteolysis and/or initiate complete degradation in combination with the action of 
various matrix metalloproteinases (MMPs). 
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2.1.1.1.1. Aggrecan 
 Aggrecan is the first characterized and thus most studied lectican. It is a main ECM 
component of cartilage, where it accumulates to very high concentrations by forming large 
aggregates with hyaluronan and cartilage link protein (Hascall and Heinegard, 1974; Franzen et 
al., 1981). Up to one hundred 1:1-complexes of aggrecan and link protein can associate with one 
single HA chain resulting in a high molecular lampbrush-like structure (108-109 Da). This large 
aggregate is strongly hydrated and consequently confers the resilience to cartilaginous tissues 
(Maroudas et al., 1969) (fig. 6). Although primarily expressed in cartilage, aggrecan is also 
present in other extracellular matrices (e.g. in brain). 
 
 
Figure 6: Aggregates of hyaluronan, aggrecan and link protein in cartilage (from (Alberts et al., 2002)).  
(A: rotary shadowing EM picture and B: cartoon describing the molecular composition) 
 
 Some unique structural features characterize aggrecan and distinguish it to some extend 
from the other lecticans. This includes the presence of an additional globular domain (G2), a 
considerably higher density of GAG-attachment sites and the incorporation of a keratan sulfate 
(KS) bearing subdomain into the core protein (Antonsson et al., 1989). The G2 globule of 
aggrecan is located C-terminally to the G1 domain being separated by an about 130 amino 
acids-long interglobular domain (IGD). Similar to G1, the aggrecan G2 domain consists of two 
link modules, but lacks the Ig-like loop and does not bind to hyaluronan. Alternative splicing 
gives rise to distinct isoforms containing variable numbers of EGF-like elements (0 to 2) and/or 
lack the C-terminal sushi domain (Doege et al., 1987; Baldwin et al., 1989; Fülöp et al., 1993). 
  Around 120 potential GAG-attachment sites are present in aggrecan, largely outnumbering 
the corresponding sites in versican (~ 20 in the largest isoform), neurocan or brevican (7 and 3 
respectively). With an average size of around 20 kDa per CS chain, the 225 kDa core protein of 
cartilage aggrecan accounts for only 10-20% of the total molecular weight of about 2’500 kDa  
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(Hardingham and Fosang, 1992; Dudhia, 2005). Noticeably, number, size and composition of 
GAGs may greatly vary according to the tissue origin of a particular lectican. For instance, the 
aggrecan core protein carries around 100 CS and 30 KS side chains in cartilage, while it is 
substituted with significantly fewer and shorter CS side chains and probably lacks KS in the 
central nervous system (Schwartz et al., 1996). 
 In rat brain, aggrecan deposition starts around embryonic day E14 and increases steadily 
until it reaches plateau at an almost 20-fold higher level around postnatal day P150 (Milev et al., 
1998). Nevertheless, due to its restricted accumulation in perineuronal nets the total tissue 
content of aggrecan remains also in adult brain rather low in comparison to other lecticans. 
 Spontaneous mutations of the aggrecan gene have been described in mice (the cartilage 
matrix deficient cmd strain (Watanabe et al., 1994) and cmd-Bc strain (Krueger et al., 1999)), as 
well as in chicken (nanomelia (nm) (Li et al., 1993)). These mutations provoke in homozygous 
animals severe abnormalities in skeletal development and cause perinatal death probably due to 
respiratory failure. A similar frame-shift mutation in the aggrecan gene has also been identified in 
connection with a heritable human disease (Gleghorn et al., 2005). Similar to the animal model 
strains, only patients heterozygous for this mutation survive. These individuals suffer from a 
relatively mild variant of chondrodysplasia characterized by shortening of the trunk and the limbs 
and a premature degenerative arthropathy (spondyloepiphyseal dysplasia type Kimberley; 
SEDK). 
 Due to the lethal character of the homozygous mutations, the role of aggrecan in the 
postnatal maturation of the CNS could so far not be explored. 
 
2.1.1.1.2. Neurocan  
 The prevalent lectican in the developing brain is neurocan. It is solely present in the nervous 
system and mainly expressed by neurons (Oohira et al., 1994; Zhou et al., 2001). The core 
protein with a predicted molecular weight of 130 kDa carries, apart from 5 N- and up to 40 O-
linked oligosaccharides, three chondroitin sulfate chains. There are no alternative splice variants 
known for neurocan, but a developmentally regulated proteolytic cleavage in the middle of the 
GAG attachment domain renders two well-defined polypeptides with molecular weights of 130 
kDa (N-terminal fragment) and 150 kDa (C-terminal fragment). Each of these fragments carries a 
globular domain, G1 or G3, respectively (Matsui et al., 1994). In addition, the size and sulfation 
of the chondroitin sulfate chains of neurocan change postnatally (Rauch et al., 1991).  
 Neurocan mRNA is first detected in embryonic mouse brain at E10, being slightly 
downregulated between E14.5 to E15.5 and then reaching maximal expression around birth 
(Zhou et al., 2001). On protein level, neurocan decreases significantly during the first month after 
birth (Milev et al., 1998), and becomes confined to specific perineuronal nets in adult brain 
tissues. 
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 Despite its dominant presence during development, the lack of neurocan in mutant mice is 
not lethal and the animals do not develop immediately obvious deficits. Brain anatomy, 
morphology and ultrastructure are normal, and the perineuronal nets do not appear affected. 
Yet, some disturbances of synaptic plasticity in the mutants have been reported. The fact that it 
is dispensable for brain development suggests however that neurocan fulfills only a minor role in 
the control of synaptic function (Zhou et al., 2001). 
  
2.1.1.1.3. Brevican 
 Brevican, the smallest CSPG of the lectican family, is like neurocan exclusively expressed in 
the CNS. Its core protein has a predicted molecular weight of 99.5 kDa. Following selective 
degradation of the CS-chains with chondroitinase ABC, it migrates in non-reducing SDS-PAGE 
as a 145 kDa glycoprotein (Yamaguchi, 1996). A second membrane-bound variant arises from 
alternative transcription termination (Seidenbecher et al., 1995). In this isoform the C-terminal 
globular domain (G3) is replaced by a short peptide module carrying a GPI-anchor. Brevican is, 
like other lecticans proteolytically cleaved by ADAMTS proteases giving rise to a 50 kDa N-
terminal and a 90 kDa C-terminal product. In adult bovine and rat brain, brevican does not carry 
any GAG side chains. It is therefore considered to be a part-time proteoglycan.  
 Brevican mRNA has been detected in astrocytes and oligodendrocytes in culture. In situ 
hybridization (ISH) experiments localized the transcript of the secreted variant in neurons of 
cerebellar and cerebral cortex, hippocampus and thalamic nuclei, and the mRNA of the GPI-
linked isoform in glial cells (Seidenbecher et al., 1998). Unlike the mostly embryonically 
expressed neurocan, brevican immunoreactivity is first noticed after birth in the prospective 
cerebellar white matter (around P21) and reaches in the granular cell layer only a significant 
level at P28, when the migration of these neurons has been completed. After this time point the 
expression steadily increases and maintains its level in the mature brain (Yamada et al., 1997). 
Consequently, brevican evolves to one of the main components of adult extracellular matrix in 
the CNS being mainly associated with myelinated fibers, with neuroglial sheaths of cerebellar 
glomeruli and with PNNs that include the matrix around the axon initial segment (AIS) (Yamada 
et al., 1997; Hagihara et al., 1999; Niederöst et al., 1999; Bruckner et al., 2000; Hedstrom et al., 
2007). 
 Brevican null mice are viable, fertile and have a normal lifespan. Anatomically they are 
indistinguishable from wild type littermates (Brakebusch et al., 2002). Although they show 
significant deficits in the maintenance of hippocampal long-term potentiation (LTP; an indicator 
of memory formation in neuronal circuits), brevican mutants display no impairment of synaptic 
transmission and no statistically significant deficits in memory and learning experiments. 
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2.1.1.1.4. Versican  
 Versican is the most versatile lectican in regard to core protein size variability and expression 
pattern. The alternative usage of exons VII and VIII of the VCAN gene generates at least four 
splice variants including the largest and the smallest core proteins of the lectican family. These 
exons encode the central glycosaminoglycan attachment domains, GAG- and GAG- 
respectively (Dours-Zimmermann and Zimmermann, 1994) (fig. 7). Both of these GAG-carrying 
core protein portions are present in the V0 splice-variant, which has a predicted molecular 
weight of 370 kDa. The smaller V1 (262 kDa) and V2 (180kDa) isoforms either contain only the 
GAG- or the GAG- domain, whereas the fourth and shortest versican splice-variant V3 (71 
kDa) is devoid of both modules, being most probably not a proteoglycan (Zako et al., 1995). 
 
 
 
 Figure 7: Versican splice variants. 
 
 Due to the substitution with various carbohydrates, intact versican proteoglycans are very 
large, reaching relative molecular masses between 5 x 105 and 1.5 x 106. The numbers of 
putative GAG-attachment sites amount to 17-23 in the isoform V0, 12-15 in V1 and 5-8 in the 
V2-variant (Dours-Zimmermann and Zimmermann, 1994). After removal of the chondroitin 
sulfate side chains by digestion with chondroitinase ABC, versican V0, V1 and V2 migrate on 
SDS-polyacrylamide gels at about 550, 500 and 400 kDa (Schmalfeldt et al., 1998). The 
discrepancy to the core protein sizes predicted from the amino acid sequences can be attributed 
to the presence of a few N- and numerous O-linked oligosaccharides (i.e. 9 and more than 80, 
respectively in versican V2) and to the high content of acidic amino acid residues (pIs around 
4.5), which influences the gel migration properties. 
 The versican gene (VCAN/CSPG2) spans over 90-100 kb on chromosome 13 of the mouse 
(Naso et al., 1995; Shinomura et al., 1995) and on chromosome 5 (5q14.3) of the human 
genome (Naso et al., 1994). The arrangement of its 15 exons shows a remarkable concordance 
of the exon-intron architecture and the modular structure of the core protein (fig. 8).  
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 Figure 8: Versican genomic structure of the Versican gene (VCAN). 
 
 The translational start codon is located in exon II, preceded by a 5’-untranslated region 
(UTR) covered by exon I and parts of exon II. The Ig-like loop is encoded by exon III, while the 
tandem repeats responsible for binding to hyaluronan are located in exons IV, V and VI. 
Downstream of the CS attachment coding exons VII and VIII, exons IX and X cover the two 
EGF-like tandem repeats, while exons XI, XII, and XIII give rise to the C-type lectin like motif. 
Exon XIV generates the sushi element and exon XV contains the remaining sequence including 
the C-terminus and the entire 3’-untranslated region.  
 Like all lecticans, the proteoglycan isoforms of versican V0-V2 (and presumably also the V3 
glycoprotein) bind to hyaluronan with a KD in the lower nanomolar range (Kimata et al., 1986; 
LeBaron et al., 1992; Schmalfeldt et al., 1998). The interaction is mediated by the typical link-
protein-like tandem repeat in the N-terminal globular domain. Similar to other lecticans, the C-
type lectin module in the G3 domain of versican binds tenascin-R in the fibronectin type III 
domains 3-5 (KD 15x10-9 M). This binding is calcium-dependent and occurs through a protein-
protein interaction without involvement of carbohydrates (Aspberg et al., 1997). Likewise, the C-
type lectin domain of versicans also binds in vitro to the sulfated cell surface glycolipid, sulfatide. 
This interaction may be physiologically significant for lectican-mediated adhesion of neural cells 
expressing sulfated glycolipids on their surface (Miura et al., 1999).  
 The large versican isoforms V0 and V1 are highly expressed in morphogenetically active 
regions during embryogenesis and in particular in condensing mesenchyme prior to cartilage 
formation (Shinomura et al., 1990) as well as in tissues that impede neural crest cell migration 
and sensory and motor axons extension (Landolt et al., 1995). This first evidence for a putative 
involvement of versican in guidance processes e.g. during innervation of the limbs prompted in 
vitro experiments, in which the potentially inhibitory properties of these versican isoforms were 
tested. Using stripe-choice assays Dutt et al. could indeed demonstrate that versican V0/V1 
inhibits neural crest stem cell migration (Dutt et al., 2006), as well as neurite outgrowth from 
chick retinal ganglion cell explants and DRGs (Dutt, S. and Zimmermann, D.R., unpublished 
observations).  
 The relatively high levels of versican V0/V1 expression during embryonic development are in 
general greatly reduced in mature extracellular matrices of healthy individuals. Exceptions are 
large blood vessels and the loose connective tissues of some internal organs, where versican 
V0/V1 or its proteolytic fragments are retained throughout adulthood (Bode-Lesniewska et al., 
1996). Versican V0/V1 is also present in the basal layer of the epidermis positively correlating 
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with cell proliferation - an observation that could be confirmed in cultures of primary 
keratinocytes and skin fibroblasts (Zimmermann et al., 1994). 
 Using a slot blotting radioimmunoassay with antibodies against versican GAG-attachment 
domains Milev et al. have shown that the isoforms V0/V1 are in rat brain extracts predominantly 
present during embryogenesis and at very early postnatal stages mostly disappearing upon CNS 
maturation (Milev et al., 1998). On the contrary, the extent of the GAG- immunoreactivity (V0 or 
V2 isoforms) steadily increases from 2 weeks to 3 months after birth, subsequently persisting at 
a constantly high level in adult brain. By RT-PCR, biochemical and immunohistochemical studies 
we have obtained strong indications that this increase is associated with the expression of 
versican V2, an isoform which is exclusively present in the mature CNS (Dours-Zimmermann 
and Zimmermann, 1994; Schmalfeldt et al., 1998). By in situ hybridization we have identified 
cells of oligodendrocytic lineage as main source of versican V2 expression (Schmalfeldt et al., 
2000). Our immunohistochemical analyses of mouse CNS tissues show versican V2 staining 
primarily along myelinated fibers with particularly high levels of versican deposition at the nodes 
of Ranvier (Schmalfeldt et al., 2000; Oohashi et al., 2002). In line with these observations, 
versican V2 has been detected in one of the neurite growth inhibitory fractions of CNS myelin 
preparations (Niederöst et al., 1999) and we have demonstrated that isolated versican V2 
isoform indeed exerts a potent inhibitory activity towards neurite outgrowth in vitro (Schmalfeldt 
et al., 2000). All these findings have provided further support for the hypothesis that versican V2 
enriched matrices suppress axonal growth also in vivo and consequently restrict structural 
plasticity and regenerative capacity of the adult CNS. 
 While the formation of versican-rich matrices during tissue development is highly dynamic, 
establishing an efficient and selective cleavage of versicans may be crucial for its functional 
attenuation. Like other lecticans, versicans are specifically recognized by ADAMTS proteases as 
revealed in vitro and by neo-epitope immunostaining in vivo (Sandy et al., 2001; Westling et al., 
2004). ADAMTS-1 and -4 digest versican V1 at the Glu441-Ala442 bond within the sequence 
DPEAAE441-A442RRGQ and liberate a 70 kDa product corresponding to the G1 domain of 
versican. Analogously a 220 kDa fragment is generated, when V0 is cleaved at this site. Both 
products have been identified in aortic and skin extracts supporting the physiological character of 
the process. Similarly, a 64 kDa product, abundant in human brain white matter, results from 
ADAMTS-4 cleavage of versican V0 or V2 at the Glu405–Gln406 that follows the sequence 
NIVSFE405 (Westling et al., 2004). This fragment has previously been regarded as independent 
hyaluronan-binding protein and has been named hyaluronectin or GHAP (Delpech and Halavent, 
1981; Perides et al., 1989). Apart from ADAMTS-1 and -4, ADAMTS-5 and -9 have been 
considered to function as "versicanases" (Somerville et al., 2003). Cleavage of versican 
(probably mediated by ADAMTS-1) seems to be essential for cumulus-oocyte-complex 
expansion and ovulation (Russell et al., 2003), whereas its putative role in regulating axon 
growth inhibiting properties of ECMs in the nervous system is currently only speculative. 
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 Constitutive abolition of versican expression by random transgene integration into the 
CSPG2 (VCAN) gene on chromosome 13 (Yamamura et al., 1997) leads to intrauterine death of 
homozygous hdf (heart defect) mice at  E10.5 (Mjaatvedt et al., 1998). The mutant embryos, 
lacking all known versican variants, exhibit aberrations along the anterior-posterior cardiac axis, 
fail to form the future right ventricle and conus/truncus of the single heart tube and lack the 
endocardial cushions in the atrioventricular and conus/truncus regions. Remarkably, hdf and the 
HAS2 null mice show very similar phenotypes, implying that both versican and hyaluronan are 
required for the stabilization of the ECM in the developing heart. While the early recessive 
lethality of the CSPG2-null mutants proves the necessity of versican for heart development, it 
unfortunately prevents the elucidation of other functional aspects, for example during CNS 
development. 
 The importance of versican gene expression is also underscored by the existence of a 
heritable human disease. The Wagner Syndrome is an autosomal dominant vitreoretinopathy 
linked to specific mutations in the human versican gene (Miyamoto et al., 2005; Kloeckener-
Gruissem et al., 2006; Mukhopadhyay et al., 2006). Similar to the hdf mice only heterozygous 
Wagner patients survive. Although they do not suffer from systemic abnormalities, they present 
with an optically empty vitreous cavity with fibrillary condensations, avascular preretinal 
membrane and other deteriorations causing severe visual impairments already early in 
adulthood. The mutations of the versican gene in the originally described Swiss family and in 
subsequently identified Japanese and Dutch families involve the highly conserved splice donor 
or acceptor sites in the introns 8 and 7, respectively. They all interfere with the correct splicing of 
exon VIII consequently reducing the expression of versican V1, the main isoform in the vitreous 
humor. It seems therefore conceivable that the compensatory up-regulation of the smaller V2 
and V3 variants perturbs the normal formation of large aggregates of hyaluronan, versican V1 
and fibrillin-1 and weakens the mechanical stability of this delicate gel-like structure. 
 
2.1.1.2. Phosphacan 
 Apart from the lectican family members, phosphacan, a secreted CSPG-isoform of the 
receptor-type protein-tyrosine phosphatase  (RPTP), plays a prominent role in the brain ECM 
(Levy et al., 1993; Barnea et al., 1994; Maurel et al., 1994). Arising from alternative mRNA 
splicing, it contains like the other isoforms of RPTP a carbonic anhydrase domain (CAH), a FN 
type III repeat and a spacer element (S), but lacks the transmembrane domain and the 
cytoplasmic tyrosine phosphatase modules (fig. 9).  
 Phosphacan and the largest membranous variant (~2300 amino acids) of RPTP include an 
additional 860 residues long insert, which carries the chondroitin sulfate side chains. The core 
glycoprotein of phosphacan migrates on SDS-PAGE in the range of the 400 kDa standard. 
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Figure 9: Isoforms of RPTP (from (Peles et al., 1998)). 
 
 The expression of all RPTP isoforms is restricted to CNS tissues (Shintani et al., 1998) and 
is mostly associated with glial cells and also some neurons. During development 
RPTP/phosphacan is present along radial glial fibers and on astrocytes, in a pattern suggesting 
an involvement in neuronal migration (Canoll et al., 1993; Maeda et al., 1995). Glial progenitor 
cells located in the subventricular zone express predominantly the transmembrane isoforms, 
while more mature glial cells synthesize the secreted phosphacan (Canoll et al., 1996). In adult 
mice transcripts are limited to the olfactory bulb, cerebral cortex, hippocampus and cerebellum 
(Canoll et al., 1996; Shintani et al., 1998), whereas immuno-staining is mainly observed at the 
nodes of Ranvier (Xiao et al., 1997), molecular layer of the cerebellum and in PNNs (Maeda et 
al., 1995; Haunso et al., 1999; Bruckner et al., 2000).  
 RPTP/phosphacan has been shown to interact in vitro with various cell adhesion molecules 
like N-CAM, Ng-CAM, Nr-CAM (Milev et al., 1994; Sakurai et al., 1997). Also contactin (F3/F11), 
another Ig-CAM, which is expressed on primary tectal neurons, acts as cellular receptor for glial-
derived RPTP. The binding, which involves the carbonic anhydrase (CAH) domain of RPTP, 
mediates neuronal adhesion and neurite outgrowth (Peles et al., 1995) possibly by inducing 
receptor-dimerization (Peles et al., 1998). The abnormal distribution of RPTP/phosphacan in 
the hippocampi of contactin null mice underlines the physiological relevance of this interaction 
(Murai et al., 2002). Moreover, tenascin-R, a neural ECM protein, binds to phosphacan through 
its EGF-like repeats in a Ca2+ dependent manner (Xiao et al., 1997) (fig. 10).  
 Finally, the CAH domain of RPTP/phosphacan participates in interactions with the 
extracellular region of sodium channels and the first intracellular phosphatase domain of the 
receptor isoforms appears to bind to both ( and ) subunits of sodium channels (Ratcliffe et al., 
2000). It has therefore been speculated that these contacts would be needed for recruiting 
and/or clustering of sodium channels. 
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Figure 10: Extracellular binding partners of RPTP /phosphacan (from (Peles et al., 1998)).  
(Blue arrows represent protein-protein interactions; green arrows, carbohydrate-mediated interactions) 
 
 In spite of the multitude of proposed functions of RPTP/phosphacan in neurite outgrowth, 
axon guidance and gliogenesis, mice deficient in all three isoforms are viable, fertile and show 
no gross anatomical alteration in the nervous system. The migratory patterns of neurons in the 
null animals are normal and the ultrastructures of nodal and paranodal regions are not modified. 
Even the number and clustering of NavCh are unaltered and the nerve conduction velocity is not 
significantly reduced in RPTP-/- mutants. Only a certain tendency for an increased myelin 
fragmentation has been noted on electron microscopical level, although the sheath organization 
appeared normal (Harroch et al., 2000). Further analysis subsequently revealed that these mice 
display an impaired recuperation from EAE (experimental autoimmune encephalomyelitis), an 
experimental model of multiple sclerosis. After being challenged by MOG peptide-injection 
(myelin oligodendrocyte glycoprotein) the mutants remained paralyzed for at least 2 months. In 
analogy, an up-regulation of RPTP was also found in lesions from multiple sclerosis patients, 
further fueling speculations about a role for RPTP in oligodendrocyte survival and recovery 
from demyelinating disease (Harroch et al., 2002).  
 Similarly, another knockout strain, in which all isoforms of RPTP were abrogated by 
insertion of the LacZ gene (Shintani et al., 1998), showed first no obvious abnormalities. 
However, animals older than thirteen weeks developed subsequently an age-dependent 
impairment of spatial learning and an enhanced LTP in the CA1 region of hippocampal slices. 
The defect in memory formation has been attributed to the lack of modulation of RhoGTPase 
activity in the mutants (Niisato et al., 2005; Tamura et al., 2006). 
 
2.1.2.  Link proteins 
 The interaction between HA and lecticans is strengthened by small link proteins recently 
summarized under the term HAPLNs (hyaluronan and proteoglycan binding link proteins) (Spicer 
et al., 2003). This family of ancillary glycoproteins consists of four members, including the 
classical cartilage link protein (HAPLN1=Crtl1) discovered more than three decades ago. In the 
meantime, it has been noted that Crtl1/HAPLN1 expression is not limited to cartilage tissues 
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alone, but is also present in placenta, the gastrointestinal tract and in the CNS, while 
Lp3/HAPLN3 is even more widely distributed being produced by smooth muscle cells  (Spicer et 
al., 2003; Ogawa et al., 2004). The remaining two family members, the brain link proteins-1 and -
2 (Bral1/HAPLN2 and Bral2/HPLN4), are restricted to the CNS (Hirakawa et al., 2000; Bekku et 
al., 2003). In fact, all link proteins, except for the vessel associated Lp3/HAPLN3, are at some 
point expressed in the brain parenchyma (Ogawa et al., 2004). While Crtl1 is predominantly 
observed during embryogenesis, Bral1 and Bral2 are almost exclusively found in adult brain, 
where they are secreted by neurons (Oohashi et al., 2002; Bekku et al., 2003).  
 Being built-up of an Ig-fold and a hyaluronan-binding tandem repeat, the link protein structure 
strongly resembles the G1 domain of lecticans. This close relationship is also reflected in their 
genomic organization and location. Intriguingly, each of the link protein genes is paired up with 
one of the lectican genes: HAPLN1 with VCAN, HAPLN2 with BCAN, HAPLN3 with AGC and 
HAPLN4 with NCAN. Whereas three of these pairs are joined in a tail-to-tail fashion, only 
HAPLN2 and BCAN follow the same genomic orientation. Despite this particularity, the 
expression of link protein and lecticans seems to be uncoupled from their genomic setup. For 
instance, the HAPLN1/Crtl1 protein is co-expressed with aggrecan in cartilage and versicans V0 
and V1 are synthesized together with Lp3/HAPLN3 by smooth muscle cells, while they possibly 
team up with HAPLN1/Crtl1 during neural development. The Bral1/HAPLN2 protein co-localizes 
with versican V2 along the myelinated fiber tracts and, with accentuation, at the CNS nodes of 
Ranvier (Oohashi et al., 2002). Finally, Bral2/HAPLN4 associates with brevican in the 
perineuronal nets of the adult brain, being mostly lost upon elimination of brevican in the 
knockout mouse strain (Bekku et al., 2003). 
 
2.1.3.  Tenascins  
 Apart from HA, lecticans and link proteins, tenascins represent the fourth class of molecules 
that form the basic constituents of the brain ECM. Tenascins are very large multimeric 
glycoproteins that are well conserved among vertebrates (reviewed by (Jones and Jones, 2000; 
Joester and Faissner, 2001; Chiquet-Ehrismann and Chiquet, 2003; Hsia and Schwarzbauer, 
2005)). In mammals, the family includes four members: tenascin-C, -R, -X and -W (-N), (fig. 11). 
The macromolecular structures of the different tenascin monomers are highly alike as they follow 
the same modular arrangement. They consist of an amino-terminal cysteine-rich oligomerization 
region composed of three to four -helical heptad repeats, EGF-like elements, fibronectin type 
III-repeats (FN III) and a carboxyl-terminal fibrinogen-like globular domain.  
 The heptad domains allow an N-terminal association of the individual subunits that primarily 
form homotrimers. In the case of tenascin-C and tenascin-W, an additional cysteine residue in 
this region permits that these trimers then further assemble into a hexameric quarternary 
structure. Although this cysteine is also present in tenascin-R, only trimers of this ECM molecule 
have been observed so far.  
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Figure 11: Structures of the tenascins (from (Hsia and Schwarzbauer, 2005)). 
 
 While the number of EGF-like repeats vary only between the different tenascins, some of the 
FN III domains are also subjected to alternative splicing. Since different combinations of these 
variable FNIII repeats are possible, several isoforms of the individual tenascin exist (Norenberg 
et al., 1992; Ikuta et al., 1998). For instance, the tenascin-C monomers bear 14.5 EGF-repeats 
plus 17 FN III repeats, 9 of which can be alternative spliced. As a result, up to 27 different 
tenascin-C transcripts are expressed during mouse brain development (Joester and Faissner, 
1999), each subunit comprising molecular weights in the range of 180-300 kDa. In contrast, 
tenascin-R, which includes 4.5 EGF and 9 FN III repeats, gives only rise to two splice variants of 
180 an 160 kDa per subunit. This difference depends on the presence or absence of the sixth 
FN III repeat. There is evidence that alternative splicing of FN III repeats also occurs in Tn-W/-N 
(monomer 170-180 kDa) and the biggest family member, tenascin-X (monomer around 450-500 
kDa). 
 Tenascin-C (Tn-C) is expressed already during gastrulation and somite formation in the chick 
embryo (Crossin et al., 1986) and then all along the development of neural, skeletal and vascular 
tissues. In the CNS, glia-derived Tn-C particularly accumulates around the fibers of radial and 
Bergmann glial cells that direct the migration of neuronal precursors during cortical and 
cerebellar development, respectively. Finally upon maturation, the expression of Tn-C is being 
reduced to tendon-associated ECMs, but it strongly returns when remodeling processes, such as 
wound repair, neovascularization, inflammation and tumorigenesis take place.  
 In contrast to Tn-C, the CNS-specific Tn-R is mainly present in mature tissues, where it is 
produced by oligodendrocytes and by small subsets of motor- and interneurons (Pesheva and 
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Probstmeier, 2000). The beginning of Tn-R expression coincides with the onset of myelination. 
Tn-R is first deposited along the presumptive white matter and concentrates later in adult 
animals around the nodes of Ranvier. Moreover, it forms part of the ECM of the granular cell 
layer of the cerebellum and associates with perineuronal nets covering the cell bodies of large 
neurons in selected nuclei. 
 In vitro, tenascins support cell adhesion only weakly or they display under certain conditions 
even anti-adhesive properties. For this reason, tenascins have been considered to act as 
adhesion-modulating ECM proteins. For instance, Tn-C is permissive for axonal growth, if 
offered as unique substrate, but growth cones turn away from Tn-C, as soon as neurite 
promoting molecules, like laminin-1, are offered as alternative. The axon growth inhibitory 
capacity of Tn-R is a matter of debate (Rathjen et al., 1991; Pesheva et al., 1993). The effect of 
Tn-C on neurite growth seems to depend partly on the neuronal origin, as it supports axon 
elongation of rat hippocampal neurons, while it restricts neurite outgrowth from retinal ganglion 
cells. This apparent inconsistency in behavior is possibly linked to the partly opposing effects of 
interactions between distinctive tenascin domains and their highly diverse sets of cellular 
receptors (fig. 12) and thus, may rather reflect specific differences in the integral of all of these 
interactions. 
 
 
Figure 12: Binding partners and different functions of Tn-C (from (Joester and Faissner, 2001). 
 
 Most cell membrane receptors for Tn-C and Tn-R belong to the integrins or to the cell 
adhesion molecules of the immunoglobulin superfamily (Ig-CAMs contactin/F11/F3, axonin/TAG-
1 and neurofascin). Other cell surface binding partners are annexin II and the receptor protein 
tyrosine phosphatase (RPTP-). Albeit of uncertain physiological relevance, a low affinity of the 
EGF-like repeats of Tn-C for EGF-receptors has also been reported. Finally heparin/heparan 
sulfate (proteoglycans), fibronectin, phosphacan and lecticans are included among the ECM 
binding partners of tenascins.  
 The key partner for Tn-R on the neuronal cell surface appears to be the GPI (glycosyl-
phosphatidylinositol)-anchored protein contactin (Brummendorf et al., 1993; Pesheva et al., 
1993; Xiao et al., 1996), which may mediate the inhibitory effect of Tn-R on the attachment and 
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neurite outgrowth of various CNS neurons in vitro (Pesheva et al., 1993). Under certain 
conditions, the association of Tn-R and contactin could also lead to increased neurite 
fasciculation due to a reduced substrate adhesion (Pesheva et al., 1993). 
 In the mature CNS, Tn-R, lecticans and hyaluronan are the main components of the 
perineuronal nets that surround the cell bodies and the associated synapses of large motor- and 
interneurons (Celio et al., 1998). Since the lecticans and possibly also Tn-R impede axonal 
growth and neuronal interactions in vitro, one might hypothesize that these ECM components 
build a molecular barrier, which prevents the establishment of new synaptic connections. The 
fact that the formation of perineuronal nets coincides with the completion of the experience-
dependent plasticity further supports this notion. Moreover, the ability of Tn-R to bind to the -
subunits of voltage-gated sodium channels (NavCh) in vitro (Srinivasan et al., 1998; Xiao et al., 
1999) suggests a potential role for the oligodendrocyte derived Tn-R in clustering or activity 
modulation of sodium channels at the CNS nodes of Ranvier, while the interaction of Tn-R with 
sulfoglycolipid sulfatide in vitro points towards a regulatory function in the adhesion and 
differentiation of oligodendrocytes (Pesheva et al., 1997). 
 Considering this profusion of interactions, it is quite surprising that Tn-C and Tn-R null mice 
are viable, fertile and display grossly normal phenotypes (Saga et al., 1992; Forsberg et al., 
1996; Weber et al., 1999). A more detailed analysis (Mackie and Tucker, 1999) of the Tn-C mice 
subsequently revealed subtle deficits in motor coordination and in exploratory behavior 
(Fukamauchi et al., 1996; Fukamauchi et al., 1997; Kiernan et al., 1999). Defects in wound 
healing (Forsberg et al., 1996) and impairments in the recovery from an experimental 
glomerulonephritis (Nakao et al., 1998) have also been described. Similarly mild deficiencies 
were reported for Tn-R null mice. This includes a decrease in axonal conduction velocity in the 
CNS as well as less developed perineuronal nets and a reduced and diffuse deposition of 
phosphacan at the nodes of Ranvier (Weber et al., 1999). In addition, an aberrant migration 
behavior of neuroblasts in the mature olfactory bulb has been observed (Saghatelyan et al., 
2004). In behavioral tests Tn-R mice displayed lessened motor coordination, deficit in 
associative learning, differences in the exploratory behavior, and in general an impairment of 
functions that involve the cerebellum and the hippocampus (Freitag et al., 2003; Montag-Sallaz 
and Montag, 2003). 
 The only tenascin family member that could be linked to a heritable disease in humans so far 
is Tn-X (Burch et al., 1997). Defects in the tenascin-X gene cause an autosomal recessive form 
of the Ehlers-Danlos Syndrome, a disorder presenting with hyperelastic skin, hypermobile joints 
and increased connective tissue fragility. Because Tn-X seems not to reach significant levels in 
the central nervous system (Matsumoto et al., 1994) and because the neural expression of the 
only recently described mammalian Tn-W/Tn-N is currently still unclear (Neidhardt et al., 2003; 
Scherberich et al., 2004), these two other tenascins are not discussed in more detail here.  
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2.1.4.  Supramolecular organization of the neural extracellular matrix 
 The ability of the brain ECM-components to selectively aggregate, allows them to establish 
large, relatively loose and flexible meshworks, where hyaluronan acts as backbone. The 
filamentous HA-molecules associate with the G1 domains of multiple lecticans and with link 
proteins that stabilize the complex. At the other end of the lectican core protein the G3 domains 
engage in an interaction with one of the arms of the tenascin oligomers. This way tenascins may 
cross-link up to three (Tn-R) or up to six lecticans (Tn-C) and consequently bridge neighboring 
HA-lectican-link protein-complexes to complete the extracellular network ((Norenberg et al., 
1992; Ruoslahti, 1996; Rauch, 1997; Yamaguchi, 2000)) (fig. 13). Although this model of the 
supramolecular assembly has mainly been postulated on single interactions in vitro, it has 
recently been supported by rotary shadowing electron micrographs displaying such large 
complexes (Lundell et al., 2004). 
 
 
Figure 13: Putative assembly of aggregates of HA, link proteins, lecticans and Tn-R (from (Lundell et al., 2004)). 
  
 Because of the high proportion of negatively charged carbohydrates these supramolecular 
complexes attract large amounts of water and cations and consequently form gel-like structures 
that occupy the large extracellular spaces within the central nervous system. Estimates of the 
extracellular space reach in adults values of about 20% of the total tissue volume being even 
double as high in the developing brain (Nicholson and Sykova, 1998). Concomitant with this 
significant volume reduction during tissue morphogenesis, the expression of lecticans and 
tenascins changes from the larger ECM-family members and splice-forms (versican V0, V1,  
neurocan and Tn-C) to their smaller relatives (versican V2, brevican and Tn-R). The altered  
expression together with a selective enzymatic cleavage of the components of the juvenile matrix  
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(Tortorella et al., 1999; Matthews et al., 2000; Westling et al., 2004) transforms the brain ECM to 
a much tighter and less hydrophilic network (Rauch, 1997; Bandtlow and Zimmermann, 2000). 
This transition terminates the highly dynamic periods of cell and axonal migrations and the 
establishment of a functional neuronal circuitry and it heralds the phase of attenuated plasticity 
and structural maintenance of the mature central nervous system. 
 Despite this clear correlation between ECM reorganization and nervous tissue maturation a 
quadruple knockout approach abrogating the expression of neurocan, brevican, tenascin-C and 
tenascin-R has recently led to viable and fertile mice that display an unexpectedly mild 
phenotype (Rauch et al., 2005). Due to the compensatory up-regulation of the fibulins-1 and -2 
and the perpetuation of the versican expression, a structurally similar ECM can still form in the 
brain despite its altered composition. It has therefore been hypothesized that the brain ECM can 
withstand major changes as long as the basic rules for assembling of the meshwork are kept, i.e. 
the formation of hyaluronan-lectican aggregates and the cross-linking and stabilization by 
lectican-binding and hence, tenascin substituting fibulin-dimers.  
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2.2. Myelin and myelinated nerve fibers 
 
2.2.1. Myelinated nerve fibers 
 Rapid conduction of nerve impulses became a priority in the course of evolution. Yet, the fast 
transmission of an action potential in a metabolically efficient way and under space constraints is 
difficult, given the long distances that often separate the neuronal cell bodies from their axonal 
targets. Accelerating the conduction velocity can be reached in two ways: 1) by creating giant 
axons and 2) by developing an envelope that insulates the nerve fibers. 
Axons that are several times larger in diameter than the average, the so-called giant axons, 
have lower interior resistance. They form part of fast neuronal circuits in many lower organisms, 
from worms to squids and from lobsters to fruit flies (Hartline and Colman, 2007). Giant axons, 
although effective, occupy much space. For instance, in order to achieve a comparable 
transmission speed (25 m/sec) the giant squid axon requires 5000 times more energy and 
occupies 1500 times more space than a myelinated nerve fiber of 12 m diameter in the frog. 
Insulating the nerve fiber with a lipid-rich multilayered coat, the myelin sheath, represents the 
second option to improve transmission. Myelin confers high resistance and low capacitance to 
the axonal membrane and consequently increases the conduction velocity. However, specific 
interruptions in the insulation are required for a rapid exchange of ions propagating the nerve 
impulses en route. These periodic gaps are called nodes of Ranvier. At these myelin-free axonal 
 
 
 
 
 
 
 
 
 
Figure 14: Action potential conduction 
along unmyelinated and myelinated axons: 
the inputs depolarize the axonal 
membrane, triggering the opening of local 
Nav channels and the generation of an 
action potential at this point (t=1). The 
originated current flows passively along the 
axon, depolarizing the adjacent region in 
unmyelinated axons (t=2, t=3). Current 
flows much farther in the myelinated axon 
due to the insulation properties of myelin, 
which prevents leaking and thus 
accelerates the current transmission (from 
(Purves et al., 2001)).
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zones, voltage-dependent sodium channels (Nav) cluster to very high densities (~2000/µm2) 
(Rasband and Trimmer, 2001). The periodicity of the intervals between the nodes of Ranvier 
corresponds to about 100 times the axonal diameter. Because the axon is exposed only at the 
nodes, depolarization occurs exclusively there and the generated action potential must jump 
from one node to the next, greatly accelerating transmission by this “saltatory” conduction (from 
Latin saltare, to jump). On the contrary, in unmyelinated fibers the voltage-dependent channels 
are distributed all along the axon and the action potential travels lengthwise by successive 
depolarization of neighboring patches (fig. 14).  
 Myelination proves to be very efficient as the conduction velocities of action potentials in rat 
optic nerve, for example, change from less than 0.2 m/sec in premyelinated axons to 10 m/sec 
after myelination and nodes of Ranvier formation (Rasband and Trimmer, 2001). Myelin sheaths 
of similar architecture and apparently identical function enwrap specific axons in most 
vertebrates (from sharks to humans) and in some invertebrates (Hartline and Colman, 2007). 
 
2.2.1.1. Structure of myelinated fibers 
 The multilamellar myelin coat is in fact the extremely extended cytoplasm of a myelinating 
cell that spirals around the axon. The cells producing myelin are the Schwann cells in the 
peripheral nervous system (PNS) and the oligodendrocytes in the CNS, both belonging to the 
“neural glue”, the glia (fig. 15). Although both function similarly, PNS and CNS myelin differ from 
each other not only in their origins. Also their cellular morphology and parts of their molecular 
components are distinct (reviewed by (Fields and Stevens-Graham, 2002; Poliak and Peles, 
2003; Salzer, 2003; Sherman and Brophy, 2005; Simons and Trajkovic, 2006)). 
 
 
Figure 15: Glial cells in the nervous 
system. A) Electron micrograph of a 
Schwann cell myelinating an axon; 
dark laminas represent the myelin 
sheath. B) to E) Pictures from cells 
grown in culture and labeled by 
immunofluorescence with the 
antibodies indicated between 
brackets: B) Astrocytes [GFAP-Ab], 
C) Oligodendrocytes [O4-Ab],  
D) Schwann cells [S-100 Ab] and  
E) Microglia [OX-42 Ab] (from  
(Fields and Stevens-Graham, 2002)). 
 
 In the PNS each Schwann cell myelinates only one single segment of a single axon. The 
nucleus of the myelinating cell is located on the outside of the sheath, and a ring of cytoplasm 
persists both on the outer layer (the abaxonal compartment, also called outer mesaxon) and  
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adjacent to the axon (the adaxonal compartment or inner mesaxon). There is a periaxonal space 
between the axon and the inner glial membrane. Within the myelin sheath, cytoplasmic channels 
wind around the axon. They are called the Schmidt-Lanterman clefts or incisures. They form a 
conduit between the inner and outer cytoplasmic compartments. The lateral edges of the 
outermost membrane layer of the Schwann cells extends microvilli that cover the nodes of 
Ranvier, while their outside surface is completely engulfed in a basal lamina (figs. 16 and 17). 
 
Figure 16: Schematic drawing of an “unrolled” myelinating Schwann cell. Tight junctions are depicted as green 
continuous lines; gap junctions and adherens junctions are shown as little ovals, orange and purple respectively.  
A “rolled-up” myelinating cell is shown in the second segment (from (Scherer and Arroyo, 2002)). 
 
Figure 17: In the PNS, each Schwann cell builds a single myelin segment, while in the CNS 
an oligodendrocyte myelinates more than one axon (from (Poliak and Peles, 2003)). 
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 Oligodendrocytes, the counterpart of Schwann cells in the CNS, are neither covered by a 
basal lamina nor do they develop microvilli that contact the nodes. Moreover, one 
oligodendrocyte may enwrap segments of up to forty separate axons (fig. 17). This translates 
into up to 5000 µm2 of myelin sheath, which may be generated in approximately one day 
(Hudson, 2001). To achieve such a high level of production, some of the myelin components 
are synthesized far from the cell body. For this purpose, RNA-granules and ribosomes are 
transported by a microtubular system to the corresponding assembly sites (fig. 18).  
 
 
Figure 18: Ensheathment of an axon by an oligodendrocyte: some myelin proteins are synthesized at sites distal from the 
cell body (from (Sherman and Brophy, 2005)). 
 
 After contacting an axon, an oligodendrocytic process rolls multiple times around the axon. 
The newly formed membranous stack is subsequently depleted of most of the cytoplasm 
rendering a compact myelin sheath. In analogy to the Schwann cells in the PNS, each process 
of the CNS-specific oligodendrocytes gives rise to a myelin segment (named internode), which is 
delimited by two bare spaces (the nodes of Ranvier). 
 The axon communicates with the extracellular environment at the nodes. Whereas microvilli 
of the Schwann cells contact the nodal axolemma in the peripheral nervous system, processes 
of specialized perinodal astrocytes touch the axonal cell surface at the CNS-nodes of Ranvier 
(Black and Waxman, 1988; Butt et al., 2002) (fig. 17). Lateral to the nodes the compact layers of 
the Schwann cell or the oligodendrocytic processes fan out and the edge of each lamina 
apposes the axon, forming a structure called the paranodes. These highly organized regions  
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serve as diffusion barriers to solutes and membrane proteins. In longitudinal nerve sections, the 
paranodes appear as a series of cytoplasm-filled loops (up to 40 paranodal loops) with the 
outermost loop closest to the node of Ranvier (fig. 19). The paranodes are the sites of the 
tightest contacts between the myelinating cell and the axon (3-5 nm versus approximately 15 nm 
in the internodes). Ultra-structural analysis reveals several septate-like junctions between each 
loop and the axolemma. These transverse bands are a characteristic attribute of mature 
junctions, as they only develop after all contacts between paranodal loops and axon have been 
established. They separate the nodal sodium and potassium channels from the juxtaparanodal 
potassium channels. Apart from their interaction with the axon, the paranodal loops bind firmly to 
each other in both, the PNS and CNS. In the PNS, tight-, adherens- (desmosome-like) and gap- 
junctions stabilize the region (fig. 16). The paranodal gap junctions are the largest known 
continuous intercellular contacts, reaching a surface of 1 mm2 in large fibers (Salzer, 2003). 
Unlike in the internode, the paranodal region of the myelin sheath is not compacted. 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Cartoon of a longitudinally cut 
myelinated axon demonstrating the differences 
between PNS (up) and CNS (low) at the axoglial 
junction (from (Poliak and Peles, 2003)). 
Abbreviations: SpJ: septate-like junctions 
(transverse bands), JXP: juxtaparanode,  
PL: paranodal loop.
 The axonal domain adjacent to the paranode, the juxtaparanode, lays under a compact 
myelin sheath. In this area the delayed rectifier K+ channels Kv1.1 and Kv1.2 (with their -
subunits) concentrate near the paranodes, disseminating gradually towards the internodes. 
These K+ channels stabilize conduction and help to maintain resting potential in the internodes 
(fig. 20). 
  The internode is the region where the most uniform and extended interaction between the 
myelinating glia and the axon occurs. The distance between the axon and the inner glial 
membrane keeps constant (15 nm). There are no specialized structures in the internodes and 
ion-channels are not clustered, but diffusely distributed at low density.  
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Figure 20: Localization of ion channels in a model neuron from myelinated tracts (from (Lai and Jan, 2006)). Nav 
channels are found in the axon initial segment (AIS), the nodes of Ranvier and the presynaptic terminals, Kv1.2 channels 
in the juxtaparanodes and Kv3.1b and KCNQ channels in the nodes of Ranvier. Excitatory and inhibitory inputs (EPSPs 
and IPSPs) diffuse to the AIS, where action potentials are generated by depolarization and reach the presynaptic 
terminals via saltatory conduction. Cav channels become activated in the terminals, increase intracellular Ca levels and 
trigger neurotransmitters release. 
  
2.2.1.2. Molecular composition of axonal regions 
 The analyses of the molecular assembly of the distinct axonal regions emphasizes the 
importance of the communication between axons and glia. In fact, the signal that induces 
Schwann cells to myelinate fibers of >1 µm diameter is emitted by the contacted axons 
themselves. The axon also dictates the number of myelin layers, which are in general 
proportional to the fiber diameter. In turn, glial signals affect the axonal cytoskeleton, promote 
the polarization of the neuron and induce the clustering of voltage-gated channels. 
 A common feature of all axonal regions are specific complexes between cell adhesion 
molecules (CAMs) and ion-channels that bind to membrane ligands exposed on the surface of 
adjacent glial processes. These complexes are in addition linked to cytoskeletal proteins that 
stabilize the structures. In the PNS, the assembly starts at the nodes and proceeds subsequently 
to the paranodes and juxtaparanodes. In the following, I will describe these specific protein 
accumulations in more detail. 
 
2.2.1.2.1. Nodes of Ranvier 
 The most remarkable attribute of the nodes is the presence of highly clustered voltage-gated 
sodium channels (Nav). They are heterotrimeric aggregates of a pore forming -subunit 
(molecular mass around 260 kDa) and two -subunits (30-35 kDa) that regulate the kinetics of 
the channel and its surface expression (Catterall, 2000). In mammals, there exist ten Nav - and 
four -subunits. The -subunits consist of four domains, each of which has six transmembrane 
segments. The loop between segments 5 and 6 (S-5 and S-6) forms the pore, through which the 
sodium ions flow (fig. 21). At the node of Ranvier, the expression of the -subunit alters upon  
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compact myelin formation changing from the Nav1.2 to Nav1.6 channel in both, PNS and CNS 
(Boiko et al., 2001). As the two channels differ in their activation kinetics, this developmentally 
regulated adjustment may be linked to an acceleration of the conduction velocity in the course of 
network maturation.  
 
 
Figure 21: Structural topology of voltage-gated sodium channels showing the -chain  
and the corresponding -subunits (from (Lai and Jan, 2006)). 
 
 
 Each -chain of the Nav channel associates with one disulfide-linked and one non-covalently 
bound -subunit (fig. 22). The -subunits belong to the Ig-superfamily of cell surface proteins. 
They are transmembrane CAMs with short cytoplasmic tails (Malhotra et al., 2000). They 
promote interactions with other CAMs. For instance, 1 binds to the axonal members of the L1-
subfamily, NrCAM (NgCAM-related-CAM) and Nfasc186 (neurofascin-186), as well as to 
contactin. On the cytoplasmatic side, Nfasc186 and NrCAM attach to ankyrin-G, which in turn 
interacts with IV spectrin. This way they link the -subunits with the actin cytoskeleton. 
Furthermore, the -subunits contribute to the assembly by binding to ankyrin-G through a highly 
conserved linker motif in the loop II-III. Also the mostly glial-derived ECM proteins tenascin-C, 
tenascin-R and phosphacan, have been reported to associate with the -subunits of sodium 
channels.  
 The -subunit of voltage-gated potassium (Kv) channels (Kv1 to Kv12) are divided into twelve 
distinct families. In mammals they are encoded by around 40 genes. The -subunits form homo- 
or heterotetrameric channels. Some of these Kv channels, like KCNQ (or Kv7) and Kv3.1b, are 
localized at selected nodes of Ranvier in the CNS and PNS. These nodal potassium channels 
are slow delayed rectifiers that activate at sub-threshold levels and reduce excitability. 
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Figure 22: Complex formation of the voltage-gated 
sodium channels: the CAMs contactin, Nfasc186 
and NrCAM interact with the 1-subunit (*), which 
binds to the S5-S6 loop in domain IV (DIV) of the 
-subunit. Connections to the cytoskeleton are 
also shown (from (Lai and Jan, 2006)).  
AIS: axon initial segment, PAT: domain rich in 
proline alanine and threonine. 

 The prominent Ig-CAM in the nodal axolemma is the neurofascin isoform 186 (Nfasc186), while its 
glial variant, Nfasc155, accumulates at the paranodes. Mice deficient in both isoforms display at first 
sight only mild defects in myelination, but nevertheless die a few days after birth (around P7), when the 
transition to saltatory conduction should occur. The cause is most likely a failure in the clustering of 
NrCAM (PNS), ankyrin-G, IV spectrin and Nav channels at the nodes, and the lack of recruitment of 
contactin and Caspr to the paranodes. Transgenic expression of Nfasc155 in the myelinating glia of 
Nfasc-/- mutants rescues the paranodal phenotype, but the Nav channels remain diffusely distributed 
along the axon (Sherman et al., 2005). Conversely, when Nfasc186 is expressed in the Nfasc-/- 
background the nodal complex is rescued, allowing the transgenic animals to survive longer (Zonta et 
al., 2008). These observations provide evidence that Nfasc186 pioneers the assembly of the nodal 
structures, whereas Nfasc155 directs the formation of the paranodal junctions. Although NrCAM is 
detected at the PNS nodes as early as Nfasc186 expression, NrCAM null mice are viable and display, 
apart from a slightly retarded Nav channel clustering, no nodal phenotype (Custer et al., 2003). In 
conclusion, only Nfasc186, but not NrCAM is a key regulator of node formation in the PNS (reviewed by 
(Schafer and Rasband, 2006)). 
 The initial signal for the node formation in the PNS seems to originate from the Schwann cells. Likely 
mediator is gliomedin, a transmembrane protein, which is shed by proteolytic cleavage and bound to the 
surface of the Schwann cell in a heparan sulfate-dependent manner. After oligomerization, gliomedin 
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facilitates axonodal clustering of Nfasc186 and NrCAM (Eshed et al., 2005; Eshed et al., 2007), which 
apparently induce the docking of ankyrin-G, the subsequent accumulation of Nav and Kv channels and 
the retention of IV spectrin (fig. 23) (reviewed by (Schafer and Rasband, 2006). While cell-cell contact 
seems to be needed for node induction in the PNS it has been suggested that a diffusible, but not yet 
closely characterized factor produced by oligodendrocytes is sufficient to cause clustering of Nav 
channels in culture of retinal ganglion cells (Kaplan et al., 1997).  
 
 
Figure 23: Formation of axoglial junctions. a) to c) display sequence of the initial steps of the assembly, which finally lead to the 
supramolecular complexes in PNS nodes (e) and paranodes (f) (from (Schafer and Rasband, 2006)). 
 
 The initial steps of node formation are followed by structural stabilization. Microvillar processes of 
Schwann cells extending into the nodel gap in the PNS express the cytoskeleton linkers, ezrin, radixin 
and moesin, the ezrin binding protein EBP50 and the Rho-A GTPase (reviewed by (Poliak and Peles, 
2003). Also the heparan sulfate proteoglycan syndecan-3 is highly enriched at the PNS nodes of 
Ranvier (Melendez-Vasquez et al., 2005). Tenascin-C, versican V1 and the NG2 proteoglycan 
accumulate between the axon and the basal lamina, and last but not least, dystroglycan abundantly 
expressed on the abaxonal surface of Schwann cells is also present at the nodal gap. In contrast, the 
nodes of the CNS, which lack the microvillar component, show major deposits of the ECM proteins 
tenascin-R, phosphacan, versican V2 and the neuronal link protein Bral1 instead. Perinodal astrocytes 
synthesize NG2, but not common astrocytic markers like glial fibrillary acidic protein (GFAP) and 
vimentin.  
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 Several of the molecules of the nodal zone are also associated with another myelin-free portion of 
the axon, which emerges from the soma. This area, called the axon initial segment (AIS), generates the 
action potentials. Sodium channel Nav1.2 subunits and Nfasc186 are clustered here by the action of 
ankyrin-G, which also connects to IV spectrin. Suppression of ankyrin-G prevents the recruitment of all 
the other proteins to the AIS suggesting an inside out sequence of the protein complex assembly. This 
mechanism contrasts the formation of the nodal structure, where the initial signal seems to emanate 
from outside and Nfasc186 precedes the ankyrin-G accumulation (Dzhashiashvili et al., 2007). 
Moreover, ion channel clustering at the AIS does not require Nfasc186 and NrCAM, but Nfasc186 is 
needed for the incorporation of brevican into the ECM that surrounds the AIS (Hedstrom et al., 2007).  
 
2.2.1.2.2. Paranodes 
 Highly concerted axo-glial interactions form the basis for the assembly of the paranodes (fig. 24). It 
initiates with the binding of the glial isoform of neurofascin (Nfasc 155) to the axonal GPI-linked CAM 
contactin, which in turn associates in cis with the transmembrane protein Caspr (contactin associated 
protein or paranodin). Caspr subsequently anchors the complex to the cytoskeleton through the 4.1B 
protein (Rios et al., 2000; Charles et al., 2002; Gollan et al., 2002; Gollan et al., 2003) (reviewed by 
(Simons and Trajkovic, 2006)).  
 
 
Figure 24: Molecular assembly of the paranode (modified from (Gollan et al., 2002)). 
 
 Gene inactivation experiments in mice confirm the key role of Nfasc 155 in the building of the 
paranodes (Sherman et al., 2005) and the reciprocal requirement of contactin and Caspr, as the lack of 
one causes the loss of the other in these structures (Bhat et al., 2001; Boyle et al., 2001). In all three 
mutants the transverse bands that connect the paranodal loops with the axolemma are missing and 
anomalous displacements of Kv channels and Caspr-2 from juxtaparanodes into the paranodal region is 
observed (Bhat et al., 2001; Boyle et al., 2001; Zonta et al., 2008).  
 The paranodes are not only disrupted in mice devoid of Nfasc 155, contactin or Caspr. An 
unexpected high number of gene knockouts targeting myelin components lead to paranodal aberrations. 
This includes animals deficient in the synthesis of myelin glycolipids (galactosylceramide and/or  
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sulfatide) or lacking the expression of myelin and lymphocyte protein (MAL) and the 2’,3’-cyclic 
nucleotide 3’-phosphodiesterase (CNP) (reviewed by (Poliak and Peles, 2003; Salzer, 2003; Simons 
and Trajkovic, 2006)). These molecules are all involved in membrane sorting or cytoskeletal connection 
(table 1). 
 
2.2.1.2.3. Juxtaparanodes 
 The formation of the juxtaparanodal region starts with the homophilic interaction between axonal 
and glial TAG-1 molecules in trans, followed by their association with the axonal Caspr-2 (fig. 25). TAG-
1 (called axonin-1 in chick) is a GPI-linked CAM belonging to the Ig-superfamily. It is structurally closely 
related to contactin. Conversely, Caspr-2, the transmembrane binding-partner of TAG-1, displays 
sequence similarities with the paranodal Caspr. In mice lacking TAG-1 or Caspr-2 the clustering of 
Kv1.1 and Kv1.2 is impaired, strongly indicating that these molecules are needed to maintain the 
delayed rectifier potassium channels in the juxtaparanodal region (Poliak et al., 2003; Traka et al., 
2003). Since both, Caspr-2 and Kv1 channels include at their C-terminus a PDZ-binding motif, they may 
be linked by a currently unidentified PDZ-domain scaffolding protein. Moreover, the anchoring of the 
complex to the cytoskeleton seems also to be mediated by the cytoplasmic domain of Caspr-2, which 
binds to the intacellular protein 4.1B. 
 
 
Figure 25: Molecular composition of different substructures of the nodal region (from (Simons and Trajkovic, 2006)). 
 
2.2.1.2.4. Internodes 
 The molecules participating in axo-glial interactions in the internodes are currently little known. L1 
and MAG (myelin associated glycoprotein), two internodal Ig-CAMs initially thought to be essential for 
myelination, turned out to be functionally redundant in single knockout mouse models. Other candidates 
for interactions are nectin-like proteins (Nectl). They have recently been identified in a screen for surface  
molecules expressed at the onset of myelination. Nectl proteins are also transmembrane Ig-CAMs with  
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a short cytoplasmic tail, through which they bind protein 4.1B. They are differentially expressed by 
neurons and glia and can interact homophilically as well as heterophilically. Necl-1 and Necl-2 are 
present on axons along the internode, while Necl-4 (also known as SynCAM4) is localized on the 
surface of myelinating Schwann cells. The Necl-1 and the Necl-4 are both early detected at axoglial 
contact sites (Maurel et al., 2007; Spiegel et al., 2007) and are known to interact with each other. 
 
2.2.2. Myelin components 
 In relation to most biological membranes, myelin contains a significantly higher proportion of lipids 
(70-85% of its dry weight) in comparison to proteins (15-30%). This applies for both CNS and PNS 
myelin. There are no lipids exclusively associated with the myelin, but the most typical components are 
galactocerebroside (GalC) and its sulfated form, sulfatide. Other lipids present are cholesterol, lecithin, 
sphingomyelin and gangliosides (Siegel et al., 1999).  
 To study the functions of GalC and sulfatides, the genes coding for the enzymes that catalyze the 
last steps of their biosynthesis have been targeted. By ablating UDP-galactose ceramide 
galactosyltransferase (CGT) in mice, the synthesis of both, GalC and sulfatide has been completely 
disrupted. Yet, structurally closely related glucocerebroside-surrogates replace at least in part these 
major lipids. As a result, the mutants are still able to form myelin. The nerve sheaths are, however, 
thinner and more fragile. Consequently, the insulation capacity is greatly reduced leading to severe 
tremor and early death of the mutants. Ceramide sulfotransferase (CST)-knockout mice, lacking only 
sulfatide, show a milder phenotype, but their myelinated fiber tracts similarly degenerate with age. In 
conclusion, these knockout experiments indicate that GalC is essential for proper myelin formation, 
while sulfatides are required for its maintenance (Bosio et al., 1996; Coetzee et al., 1996; Honke et al., 
2002; Marcus et al., 2006) (table 1). 
 Some proteins are constituents of both CNS and PNS myelin, but their proportion varies. For 
example, the Myelin Basic Protein (MBP) accounts for up to 30% of the whole protein in the CNS, 
whereas it reaches only levels of 5-18% in the PNS. Several isoforms of MBP with molecular masses 
between 14 and 21 kDa arise from alternative splicing. By being localized on the cytoplasmic side of the 
myelin membranes, where myelin compaction takes place, MBP influences the apposition of the myelin 
layers.  
 Another well-studied component of both, CNS and PNS myelin, is MAG (Myelin Associated 
Glycoprotein), a relatively large (100 kDa), but not very abundant glycoprotein. MAG is composed of five 
extracellular Ig-like domains, a transmembrane region and cytoplasmic portion, which changes in the 
course of development (from L-MAG to S-MAG). MAG interacts with the axonal surface and is not 
present in compact myelin, but enriched at the inner glial membrane. The fact that it belongs to the Ig-
CAM family suggests that it participates in adhesion and signaling between the glia and the axolemma 
and is involved in myelin formation and stabilization. 
 The most prominent protein in compact myelin of the CNS is the Proteolipid Protein (PLP) with an 
isoform lacking 35 amino acids called DM-20. PLP and MBP represent together up to 80% of the total 
protein in CNS myelin preparations. PLP has several membrane-spanning domains reaching a  
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molecular weight of approximately 30 kDa. PLP plays a structural role in myelin and is needed for 
oligodendrocyte differentiation.  
 The Myelin Oligodendrocyte Glycoprotein (MOG) is an additional myelin component that is 
exclusively expressed in the CNS myelin. MOG, a transmembrane protein with one Ig-like domain, is 
like MAG absent from the compact laminas and consequently represents a rather minor myelin 
constituent. Of note, MOG is concentrated in the abaxonal membrane of the myelin sheath. Finally, 
Oligodendrocyte Myelin Glycoprotein (OMgp), a GPI-linked membrane protein, has been localized to 
the glial-axonal interface. In contrast to the other myelin components in the CNS, it is not solely 
expressed by oligodendrocytes, but also by diverse groups of neurons.  
 PNS myelin differs from CNS myelin by the presence of P0, a 30 kDa transmembrane protein with 
one Ig-like domain. P0 accounts for more than half of the total protein of the nerve sheath and is 
involved in cell-cell interactions. It is able to form tetramers through homophilic binding of its 
extracellular domain. P0 plays a significant structural role. Also PMP-22, a 22 kDa protein with four 
transmembrane domains is exclusively present in PNS myelin.  
 Similarly to the CNS, some proteins, like ECM receptors, are only present in the outer lamina 
(abaxonal membrane) of PNS myelin, while adhesion molecules, such as MAG, are enriched in the 
adaxonal membrane and interact with the axon.  
 Several spontaneous mutations in mice have been helpful to study the functions of the numerous 
myelin components (reviewed in (Nave, 1994)). For example, jimpy mice suffering from severe 
hypomyelination in the CNS carry a frame-shifting deletion in the PLP gene. A milder form of this 
phenotype has also been observed in the rumpshaker strain, which contain a missense mutation that 
affects only PLP, but not its alternative splice variant DM-20. A natural knockout of the MBP gene, 
which leads to an almost total lack of CNS myelin, gives rise to the shiverer strain and a point mutation 
in the the first transmembrane domain of PMP-22 is responsible for the severe PNS hypomyelination 
phenotype in the trembler mouse. 
 Although essential for the structural formation of myelination per se, some myelin components may 
also be responsible for the regeneration-suppressing properties of CNS white matter that inhibits re-
growth of axons after lesion. 
 Table 1: Mouse mutants affecting nodal structures 
 
Mutant / Gene Node Paranodes Juxtaparanodes References 
Cgt null (paranodal) 
CNS: elongated nodes, abnormal shape; 
heminodes; some clusters do not 
surround the full circumference. PNS: 
minor expansion of Na+ channel clusters 
and ankyrin-G. Age-dependent decrease 
in number and intensity of Nav1.6 clusters; 
increased nodal length. 
Absence of transverse bands. Caspr and 
contactin almost completely absent from 
paranodes; diffuse staining of Caspr 
adjacent to narrow labeling of paranodal K+ 
channels; reduced paranodal labeling of 
Nfasc155. Reduced accumulation of 
paranodal 4.1B. 
K+ channels, Caspr2 and TAG-1 are 
mislocated to paranodes in PNS and are 
diffused along the internode in CNS; 
some paranodal concentration of K+ 
channels is observed in spinal cord. 
(Dupree et al., 1999), (Poliak 
et al., 2001), (Dupree et al., 
1998), (Rosenbluth et al., 
2003), (Rasband et al., 
2003) 
Contactin null (paranodal) 
PNS: normal appearance of Na+ 
channels. CNS: fewer and elongated Na+ 
channel-labeled nodes. 
Absence of transverse bands. Absence of 
Caspr from paranodes (found in soma); 
reduced paranodal Nfasc155. Protein 4.1B 
is diffusely distributed along the axon. 
PNS: K+ channels and Caspr2 are found 
in paranodes. 
(Kazarinova-Noyes and 
Shrager, 2002), (Boyle et al., 
2001), (Gollan et al., 2002), 
(Poliak et al., 2001) 
Caspr null (paranodal) 
Elongated nodes (labeled with Na+ 
channels, NrCAM and spectrin IV); CNS 
nodes progressively disperse; normal 
ERM positive microvilli. Aberrant Na+ 
channel isoform-switch in CNS; switch is 
delayed in PNS. Increased contactin in 
CNS nodes. 
Absence of transverse bands. Absence of 
contactin and Nfasc155 from paranodes. 
Progressive detachment of paranodal 
loops in CNS. 
K+ channels and Caspr2 are found in 
paranodes; more diffuse in CNS than in 
PNS. Kv1.1 clusters are lost over time in 
CNS. Increased juxta-incisural lines 
along internodes. 
(Gollan et al., 2003), (Bhat et 
al., 2001), (Rios et al., 2003) 
Cst null (paranodal) 
CNS: elongated nodes, abnormal shape 
and intensity; binary clusters. Decreased 
clustering with age (12% at 22 weeks). 
Disrupted axoglial junction. Caspr diffusely 
distributed along the axon. 
CNS and PNS: diffuse K+ channels with 
some concentration at paranodes. 
Decreased clustering with age (8% at 22 
weeks). 
(Honke et al., 2002), 
(Ishibashi et al., 2002) 
Caspr2 null (juxtaparanodal) 
Normal appearance. Normal appearance. Reduced K+ channels clustering. 
Absence of TAG-1. Intense 
juxtamesaxonal labeling of K+ channels. 
(Poliak et al., 2003) 
TAG-1 null (juxtaparanodal) 
Normal appearance. Normal appearance. Reduced K+ channels clustering. 
Absence of Caspr2. Small decrease in 
juxtaparanodal labeling of 4.1B. 
(Traka et al., 2003), (Poliak 
et al., 2003) 
Dystroglycan (nodal) 
Reduced Na+ channels clustering (90%); 
channels dispersed along a broader 
region (7%): Normal distribution of 
ankyrin-G, moesin and Nfasc186. 
Abnormal microvilli morphology. 
Normal localization of Nfasc155 Normal localization of K+ channels and 
Caspr2. 
(Saito et al., 2003)  
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Mutant / Gene Node Paranodes Juxtaparanodes References 
quivering Spectrin IV (nodal) ND ND Kv1.1 is upregulated and redistributed along the length of the axon. 
(Parkinson et al., 2001)  
 
Spectrin IV-genetrap (nodal) 
55% reduction in number of nodes as 
measured by Nav1.6 immuno-reactivity. 
Reduced intensity of Na+ channels 
compared with WT. 
ND ND (Komada and Soriano, 2002) 
  
NrCAM null (nodal) 
Delayed Na+ channel and ankyrin-G 
clustering in PNS. 
Normal Caspr localization. ND (Custer et al., 2003) 
Na+ channel 2 null (nodal) 
Normal appearance; Nav1.6 appears 
within a normal time course. Reduced Na+ 
current in optic nerve; CAP data 
consistent with loss of nodal Na+ 
channels. 
Normal Caspr localization. ND (Chen et al., 2002) 
Na+ channel 1 null (nodal) 
PNS: normal axonal conduction. CNS: 
altered CAP in optic nerve, deficit in 
rapidly conducting fibers. Number of 
nodes reduced in optic nerve. Nav1.6 
normally localized.  
In ~20-30% of axons: absence of 
transverse bands adjacent to nodal 
gaps. Normal contactin and Caspr 
localization. 
Normal localization of K+ channels and 
Caspr2. 
(Chen et al., 2004) 
Neurofascins (nodal and 
paranodal) 
Absence of Nfasc186: Na+ channels, 
NrCAM, ankyrin-G and IVSpectrin are 
not concentrated at the nodes.  
Absence of Nfasc155: no contactin or 
Caspr in paranodes. Loss of septate 
junctions and wider junctional gap. 
ND (Sherman et al., 2005)  
MAL 
Normal number and clustering of Na+ 
channels. 
CNS: reduced Caspr and Nfasc155 
expression (~70-90%). Normal formation 
but impaired maintenance of paranodes 
(everted paranodal loops and irregular 
transverse bands).  
CNS: reduced Kv1.2 expression (~70%) 
but no translocation to the paranodes.  
(Schaeren-Wiemers et al., 
2004) 
CNP  
Initial normal clustering of Na+ channels, 
become progressively disorganized and 
decrease with age. 
Progressively aberrant localization of 
Caspr with age. Number of Caspr positive 
paranodes gets reduced. 
ND (Lappe-Siefke et al., 2003), 
(Rasband et al., 2005) 
 
ND: not described, CAP: compound action potential, MAL: myelin and lymphocyte protein, CNP: cyclic nucleotide phosphodiesterase (modified from Poliak and Peles, 2003). 
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2.2.3. Inhibitors of axonal regeneration 
 In the CNS, the ability of late embryonic and early postnatal axons to regenerate is virtually 
lost in the course of glial cell maturation and the onset of myelination. This change also coincides 
with a decrease in expression of growth-associated proteins. Although a limited intrinsic growth 
capability is upheld in adult CNS neurons, enabling them to extend short sprouts after a lesion, 
the full program required for robust axon elongation cannot be activated and/or maintained 
anymore.  
 In addition, the CNS environment has a significant inhibitory effect on axonal regeneration, as 
underscored by two fundamental observations: 1) peripheral neurons, which extend their axons 
well in their own milieu, show limited growth, when transplanted into adult brain or spinal cord; 
and 2) adult CNS axons are able to cross after a lesion over bridges of peripheral nerve grafts, 
but fail to continue their advance as soon as they encounter central nervous tissue (Richardson et 
al., 1980; David and Aguayo, 1981).  
 The main inhibitory activity is associated with the CNS myelin itself (Caroni and Schwab, 
1988b; Bandtlow et al., 1990) being inherent to its proteins and not to its lipids. Several myelin 
components act as potent inhibitors of axonal growth (fig. 26). This includes the afore-mentioned 
MAG and OMgp as well as Nogo-A, ephrin-B3 and semaphorin 4D (for recent reviews, see 
(Schweigreiter et al., 2006; Viapiano and Matthews, 2006; Yiu and He, 2006; Zheng et al., 2006; 
Zurn and Bandtlow, 2006; Gonzenbach and Schwab, 2008; Xie and Zheng, 2008).  
 During earlier developmental stages, MAG may also exert some growth-promoting property, 
as demonstrated in neurite outgrowth experiments with embryonic neurons in vitro. MAG 
becomes however, a non-permissive substrate, when older neurons are tested in these assays. 
Also the GPI-anchored OMgp exerts an inhibitory activity in vitro. In vivo it has been localized to 
the nodal area, where it is believed to prevent collateral sprouting (Huang et al., 2005).  
 The most extensively studied inhibitor of axonal growth is Nogo (fig. 26). Nogo has been 
identified as the antigen of the monoclonal antibody IN-1, which exhibits neutralizing activity 
towards myelin-derived inhibition (Caroni and Schwab, 1988a; Chen et al., 2000; GrandPre et al., 
2000). Three isoforms of Nogo arise from alternative splicing (A and B) or alternative promoter 
usage (C). Nogo is a member of the reticulon (RTN) family of proteins, which carry an ER-
retention motif. In consequence, it is at least partly associated with the ER and possibly involved 
in membrane trafficking and/or sorting. The C-terminal domain of 188 amino acids length (the 
reticulon-homology domain) holds two long hydrophobic regions and is shared by all Nogo 
isoforms. Between these transmembrane domains, a stretch of 66 amino acids (aa) forms a loop 
called Nogo-66. It inhibits neurite outgrowth and provokes growth cone collapse in vitro. Also an 
800 aa long portion, termed NiG or central inhibitory domain, interferes with axonal growth and 
cell spreading. This domain is unique to Nogo-A. Since there is evidence that cell surface Nogo-A 
can adopt two different topologies, NiG may either face the extracellular space or the cytoplasma. 
Finally the N-terminal region shared by Nogo-A and -B constitutes an additional active site 
impeding fibroblast spreading and stimulating endothelial cell migration.  
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Figure 26: Structure and membrane topology of myelin-derived axonal growth inhibitors (from (Filbin, 2003)). 
 
 Apart from these cell surface associated components, the CSPGs brevican and versican V2, 
localized in between the myelin sheaths, strongly impede axonal growth in vitro (Yamada et al., 
1997; Schmalfeldt et al., 2000). Both proteoglycans are co-purified from myelin preparations 
revealing an inhibitory activity comparable to the Nogo-A containing fraction (Niederöst et al., 
1999). 
 The inhibitors so far described are normal constituents of mature myelin and its surrounding 
extracellular matrix. They are up-regulated late in development reaching constant levels only at 
time points when fully myelinated fiber tracts have been established and axonal growth is mostly 
terminated. Their properties contribute to the limitation of structural plasticity and the consequent 
stabilization of the CNS network. Apart from this, they are also responsible for the lack of 
regeneration in the CNS. After a lesion, they are released into the environment as myelin debris, 
being the first inhibitory molecules encountered by the damaged axons. Since most CNS injuries 
disrupt the blood brain barrier, a strong inflammatory response with migration of neutrophils, 
macrophages and meningeal cells usually follows. Moreover, reactive microglia and astrocytes 
are recruited to the site. They form within a few days an astroglial scar tissue that contains 
additional inhibitors of nerve elongation including the CSPGs NG2, versican V1, neurocan and 
phosphacan. Hence, lesioned axons are after injury confronted with the resident myelin inhibitors 
and the impenetrable barriers that the scar tissues impose. It is therefore not surprising that the 
initial axon sprouting is in the CNS fast aborted. 
 In order to exert their function, most inhibitory proteins depend on neuronal receptors (fig. 27). 
The first receptor described is NgR (now NgR1). It binds with very high affinity to the Nogo-66 
domain of Nogo. As NgR1 is a GPI-linked molecule, it needs a transmembrane co-receptor for  
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signaling. The co-receptors so far identified are the neurotrophin receptor p75NTR and LINGO-1, a 
CNS specific protein with a short cytoplasmic domain. A p75NTR homologue called TROY can 
replace the neurotrophin receptor in the complex with NgR/LINGO-1. Unlike p75NTR, TROY is 
widely expressed in the adult CNS. Surprisingly, MAG and OMgp, two structurally completely 
unrelated molecules, interact also strongly with NgR. In contrast, the neuronal receptors for NiG 
(amino-Nogo) and for the various CSPGs have not been identified yet. Other axonal receptors 
that are likely to mediate the inhibitory signal emanating from the injury site are EphA4, a receptor 
tyrosine kinase that binds B-class ephrins and thus ephrin-B3, and Plexin-B1 that induces growth 
cone collapse when associated to its ligand Sema4D. 
 
 
Figure 27: Glial inhibitors and their signaling mechanisms (modified from (Yiu and He, 2006)).  
 
 For most of these receptors, intracellular signaling appears to converge in RhoA. RhoA 
belongs to the Rho family of small GTPases that comprises Rho, Rac and Cdc42. These 
GTPases regulate cytoskeletal rearrangements by cycling between an inactive GDP-bound form  
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and an active GTP-bound state. Rho-activation induces growth cone collapse. Rho mediates this 
way repulsive signals from guidance cues that direct axonal growth during development. Amino-
Nogo-A, Nogo-66, MAG and versican V2 activate RhoA, which in turn activates ROCK (Rho 
associated kinase). This results in the phosphorylation of several other effectors that control actin 
polymerization (fig. 27). Additional intracellular signal mediators for CSPGs and myelin inhibitors 
are protein kinase-C (PKC) as well as regulators of neuronal Ca2+ and cAMP levels.  
 
2.2.3.1. Models to study nerve injuries in the CNS and at the PNS/CNS interface 
 Common traumas to the CNS range from minor contusions to open injuries of diverse 
severity. Different types of lesions deploy distinctive cellular and molecular reactions and 
consequently vary in their perspectives for a partial recovery. Numerous paradigms have been 
applied to study the CNS responses to injury. These include simple nerve crush, transection and 
contusion lesions, stab injuries or stroke-simulations to optic nerve, spinal cord, dorsal roots and 
brain tissues, respectively (recent reviews: (Silver and Miller, 2004; Maier and Schwab, 2006; 
Scott et al., 2006; Yiu and He, 2006; Zurn and Bandtlow, 2006). Analogous to the clinical 
situation, these lesion models differ from each other in the extent that they affect nervous tissue 
structures. If the blood-brain barrier (BBB) and/or the meninges are disrupted, for instance, the 
damage caused reaches generally a much higher dimension (fig. 28).  
 Some cellular processes, like reactive gliosis, astrocyte-hypertrophy and Wallerian 
degeneration are common to most lesions. Gliosis implies proliferation of astrocytes, 
oligodendrocyte precursor cells (OPC) and microglia (or macrophages). Astrocytes become 
hypertrophic by enhancing their production of intermediate filaments with high levels of GFAP and 
vimentin (Silver and Miller, 2004). Wallerian degeneration denotes the deterioration of the axon 
segment and nerve terminals distal to the lesion; the proximal part of the axon and the neuron 
itself may survive, if the insult occurs far from the cell body. Wallerian degeneration is induced 
immediately after injury by the release of activated proteases that initiate the degradation of 
myelin sheaths and the axonal cytoskeleton. This in turn leads to activation of microglia and 
cytokine secretion that attract and engage other cells in the process. 
 
2.2.3.1.1. Spinal cord lesions 
 Spinal cord injuries cause frequently a disruption of the BBB, ischemia and edema. They 
result in significant neuronal cell death, degeneration of axons, astrocyte proliferation, and 
infiltration of immune cells and/or fibroblasts in their acute phase. The primary lesion is over time 
magnified by a secondary damage caused by reactive gliosis, inflammation and the development 
of cystic cavities and glial scars (fig. 28).  
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Figure 28: Three stereotypical spinal cord lesions and sequence of the damage processes (from (Silver and Miller, 2004)). 
 
 The glial scars are formed mostly by reactive astrocytes that up-regulate their production of 
cell surface and ECM molecules, in particular CSPGs and tenascin-C. The role of the glial scar is 
not completely clarified yet. On one hand, the astrocytic reaction may partly protect neuronal 
function (Faulkner et al., 2004) and contribute to repair the BBB (Bush et al., 1999), as long as the 
meninges are not contacted by the wound. On the other hand, a large infiltration of fibroblasts 
might take place in more severe cases, augmenting the secretion of ECM molecules and 
transforming the scar into a sturdy physical barrier. Activated microglia and invading 
macrophages (after BBB breakdown) releasing cytokines finally trigger the recruitment of OPC to 
the lesion site and consequently further promote the CSPG deposition. 
 
2.2.3.1.2. Dorsal root lesions 
 Another model of CNS lesion targets the sensory neurons of the dorsal root ganglia (fig. 29). 
These neural crest cell-derived neurons extend a single axon that bifurcates into a peripheral and 
a CNS projecting branch. The sensory afferents enter during development the spinal cord at the 
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DREZ (Dorsal Root Entry Zone, also called transitional zone), which constitutes an interface 
between CNS and PNS. If the sensory nerve of an adult animal is transected at the dorsal root 
the cut fibers start to sprout, but are blocked from crossing into the DREZ. Thus, the sensory 
axons fail to restore the connections with the dorsal horn of the spinal cord (reviewed by (Ramer 
et al., 2001; Scott et al., 2006)). 
 
 
Figure 29: Model of DREZ lesion (modified from (Ramer et al., 2001)). 
 
This type of lesion is in the context of e.g. motorcycle accident or complications during child’s birth 
of clinical relevance and is in the experimental setting emulated by the dorsal rhizotomy model. In 
this paradigm, the centrally projecting branches are carefully cut between the cell bodies and the 
DREZ without affecting the meninges. Rhizotomy induces gliosis and Wallerian degeneration, but 
avoids the scar formation in the CNS. Consequently, studies of the axonal growth inhibition are in 
this model focused onto the CNS-resident factors and exclude the molecular impediments 
associated with the secondary scar tissue. Furthermore, the contra-lateral dorsal root area 
provides a convenient control for experimental attempts to neutralize the growth inhibition 
potentially allowing axonal regeneration in the central nervous system. 
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Abstract The basic concept, that specialized extracellular
matrices rich in hyaluronan, chondroitin sulfate proteogly-
cans (aggrecan, versican, neurocan, brevican, phosphacan),
link proteins and tenascins (Tn-R, Tn-C) can regulate cellu-
lar migration and axonal growth and thus, actively partici-
pate in the development and maturation of the nervous
system, has in recent years gained rapidly expanding experi-
mental support. The swift assembly and remodeling of
these matrices have been associated with axonal guidance
functions in the periphery and with the structural stabiliza-
tion of myelinated Wber tracts and synaptic contacts in the
maturating central nervous system. Particular interest has
been focused on the putative role of chondroitin sulfate pro-
teoglycans in suppressing central nervous system regenera-
tion after lesions. The axon growth inhibitory properties of
several of these chondroitin sulfate proteoglycans in vitro,
and the partial recovery of structural plasticity in lesioned
animals treated with chondroitin sulfate degrading enzymes
in vivo have signiWcantly contributed to the increased
awareness of this long time neglected structure.
Keywords CSPG · Lectican · Hyalectan · ADAMTS · 
Hyaluronan synthase · Perineuronal net · Node of Ranvier · 
Knockout · Tenascin · Link protein · Central nervous 
system
Introduction
It was not until 1971 that the existence of an extracellular
matrix (ECM) in the central nervous system (CNS) was
generally acknowledged (Tani and Ametani 1971). Then a
predominance of hyaluronan and chondroitin sulfate prote-
oglycans (CSPG) (Margolis et al. 1975) and the paucity of
otherwise frequent ECM molecules, like Wbronectin or col-
lagens, have been described (Carbonetto 1984; Rutka et al.
1988; Sanes 1989). Today we know that this distinctive
ECM is mainly composed of proteoglycans of the lectican/
hyalectan-family and their binding partners, hyaluronan,
link proteins and tenascins (Bandtlow and Zimmermann
2000; Novak and Kaye 2000; Rauch 1997, 2004; Ruoslahti
1996; Yamaguchi 2000). In the following, we will focus on
the structure, expression and putative functions of this
major matrix components that form this extraordinary
extracellular meshwork. Not discussed in this review are
less abundant, but nonetheless functionally important
macromolecules of the nervous system, such as reelin,
agrin and thrombospondins. For detailed information about
these large glycoproteins, which are involved in the control
of neuronal migration and establishment of synapses we
would like to refer the reader to recent reviews and publica-
tions (Bezakova and Ruegg 2003; Christopherson et al.
2005; Herz and Chen 2006; Tissir and GoYnet 2003).
Structures and ligands of the major constituents 
of the neural ECM
Proteoglycans and hyaluronan
Proteoglycans (PGs) are glycoproteins carrying, in addition
to variable numbers of N- and O-linked oligosaccharides, at
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least one glycosaminoglycan (GAG) side chain, which is
covalently bound to a core protein. The GAGs themselves
are long unbranched polymers of repetitive disaccharide
units consisting of an uronic acid (glucuronic or iduronic)
or galactose and an amino-sugar (N-acetylglucosamine or
N-acetylgalactosamine). According to the combination of
these sugars, the GAGs are subclassiWed into heparin/hepa-
ran-, keratan- or chondroitin/dermatan-sulfates (Bandtlow
and Zimmermann 2000; Kjellén and Lindahl 1991; Prydz
and Dalen 2000). The GAG chains are in general 20–200
disaccharide-repeats long. Whereas keratan sulfates are
usually attached to the core proteins via short standard N-
or O-glycan links to asparagine or serine/threonine, respec-
tively, the binding of chondroitin/dermatan sulfate and of
heparin/heparan sulfate chains is mediated by a serine resi-
due and a speciWc linker tetrasaccharide composed of a
xylose, two consecutive galactoses and a glucuronic acid
molecule. Numerous modiWcations that include O- and N-
sulfation and epimerization of glucuronic acid at the C5-
position lead to a high structural variability and open up
countless possibilities for the modulation of GAG-depen-
dent interactions (Bulow and Hobert 2006; Kusche-Gull-
berg and Kjellen 2003). Moreover, the highly negatively
charged GAGs attract and bind considerable amount of
water and cations.
In contrast to the protein-bound GAGs, hyaluronan (also
known as hyaluronic acid or hyaluronate) is incorporated
into the extracellular matrix as a core protein-free glycos-
aminoglycan (Toole 2000, 2004). Hyaluronan is a very
large linear polymer built of repetitive disaccharides units
consisting of glucuronic acid and N-acetylglucosamine.
This carbohydrate Wlament reaches a molecular mass of up
to 107 Da and extends over lengths of 2–25 m. Unlike the
other GAGs, hyaluronan is not sulfated and the glucuronic
acid units are not epimerized.
While the more complex core protein-bound GAGs are
assembled and modiWed by a large set of glycosyl- and sul-
fotransferases, the structurally simpler hyaluronan is syn-
thesized by a single enzyme, the hyaluronan synthase
(HAS). Three vertebrate genes (HAS1, HAS2, and HAS3)
giving rise to three HAS isoenzymes have been identiWed
(DeAngelis 1999; Itano and Kimata 2002; Spicer and
McDonald 1998; Weigel et al. 1997). The HAS are rather
unique, as they catalyze the incorporation of two diVerent
monosaccharides and are, in contrast to most other glyco-
syltransferases, localized at the inner surface of the cell
membrane. From there the growing hyaluronan string
directly extrudes into the pericellular space, while being
still attached to the producing enzyme (Spicer and Tien
2004; Weigel et al. 1997).
The most prominent binding partners of hyaluronan in
the nervous system are the extracellular matrix proteogly-
cans of the lectican family (also called hyalectans)
(reviewed by Bandtlow and Zimmermann 2000; Iozzo and
Murdoch 1996; Rauch 2004; Ruoslahti 1996; Yamaguchi
2000). In mammals, four distinct lectican genes encode
brevican, neurocan, aggrecan and versican (Table 1;
Fig. 1). Shared features among these large chondroitin sul-
fate proteoglycans are the highly homologous G1 and G3
domains, which appear in rotary shadowing electron
microscopy as compact globular structures at either end of
an extended, but Xexible central region (Mörgelin et al.
1989; Retzler et al. 1996). This poorly sequence-conserved
middle part carries most of the O- and N-linked oligosac-
charides and all glycosaminoglycan side chains. It varies
among the diVerent family members in size and also in the
number of carbohydrate substitutions. Occasionally, the
GAGs might even be absent, like in a fraction of the part-
time preoteoglycan brevican, or they may be greatly dimin-
ished, as in CNS-derived aggrecan in relation to its carti-
lage counterpart. Apart from the variations within the
carbohydrate moiety, alternative splicing also greatly adds
to the structural diversity of lecticans. Four versican iso-
forms (V0, V1, V2 and V3) exist as a result of alternative
usage of two giant exons encoding the central GAG- and
GAG- domains (Dours-Zimmermann and Zimmermann
1994; Zako et al. 1995; Zimmermann and Ruoslahti 1989).
Versican V0 contains both of these GAG-attachment mod-
ules, whereas versican V1 and V2 include only the GAG-
or GAG-, respectively. Versican V3, the smallest lectican,
Table 1 Extracellular matrix 
CSPGs in the central nervous 
system
Name Core sizea GAGs Cellular origin CNS-
speciWc
Calculatedb SDS-PAGEc Type Number
Aggrecan 244 370 CS ? Neurons/astrocytes No
Versican V0 371 t550 CS 17–23 Neurons/astrocytes? No
Versican V1 263 t500 CS 12–15 Astrocytes? No
Versican V2 180 400 CS 5–8 Oligodendroglial lineage Yes
Neurocan 141 245 CS 3 Astrocytes/neurons Yesd
Brevican 97 145 CS 0–5 Glial cells/neurons Yes
Phosphacan
(-KS)
172 400 CS/(KS) 3–4 Glial cells/neurons Yes
a kDa
b Mature polypeptide
c Core glycoprotein after gly-
cosaminoglycan removal
d Minor expression in peripheral 
nervous system
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lacks both of these alternatively spliced elements and con-
sequently carries no glycosaminoglycans.
In contrast to these largely diversiWed GAG-binding
regions, the modules that form the globular G1 and G3
structures display little variability. For instance, all N-ter-
minal G1 regions of the diVerent lecticans include an
immunoglobulin (Ig)-like loop and two link-protein-like
tandem repeats that are involved in the binding of hyaluro-
nan and link proteins (LeBaron et al. 1992; Mörgelin et al.
1989; Neame et al. 1987; Rauch et al. 2004). The G3 globule
at the other end of the core protein contains a C-type
lectin-like element, which is Xanked by one or two EGF-
repeats and a Sushi (SCR/CCP) domain, respectively. The
entire G3 region is only absent in a GPI-anchored brevican-
variant arising from alternative transcription termination
(Seidenbecher et al. 1995). Recombinantly expressed G3
domains and/or the C-type lectin elements alone bind in
vitro simple carbohydrates and heparin or heparan sulfate
(Ujita et al. 1994), Wbulin-1 and -2 (Aspberg et al. 1999;
Olin et al. 2001), Wbrillin-1 (Isogai et al. 2002), sulfogly-
colipids (Miura et al. 1999) and the tenascins, Tn-C and
Tn-R (Aspberg et al. 1995, 1997; Day and Prestwich 2002;
Rauch et al. 1997). Of note, the majority of the G1- and G3-
ligands are recognized by all lecticans, albeit diVerences in
the aYnities exist. Completing the structural models of the
lecticans and their splice-variants by including the singular
GAG-attachment regions between the largely homologous
globular ends makes evident that this proteoglycan family
forms an almost perfect array of functionally closely related
but diVerently sized modular proteins (Fig. 1).
Besides the large aggregating proteoglycans of the lecti-
can family, phosphacan, a secreted CSPG-isoform of the
receptor-type protein-tyrosine phosphatase  (RPTP),
plays a prominent role in the brain ECM (Barnea et al.
1994; Maurel et al. 1994; Shitara et al. 1994). Like the
other alternative splice products of the RPTP gene, it is
composed of a carbonic anhydrase domain, a Wbronectin
type III repeat and a spacer element, but lacks the trans-
membrane domain and the cytoplasmic tyrosine phospha-
tase modules. An additional element, present in phosphacan
and the larger phosphatase variant, carries three to four
chondroitin sulfate chains and sporadically also a few kera-
tan sulfates (Rauch et al. 1991).
Phosphacan/RPTP binds in a calcium-dependent man-
ner to the ECM glycoproteins tenascin-R and tenascin-C
(Milev et al. 1997; Xiao et al. 1997). It furthermore inter-
acts in vitro with various cell adhesion molecules of the
Ig-superfamily (IgCAMs) including N-CAM, Ng-CAM,
axonin-1 (TAG-1) and contactin (F3/F11) (Milev et al.
1994, 1996; Peles et al. 1995), and it binds to the extracel-
lular portion of voltage-gated sodium channels (RatcliVe
et al. 2000). The interaction with contactin and the sodium
channels seems to be mediated by the carbonic anhydrase
(CAH) domain of RPTP/phosphacan (Peles et al. 1995;
RatcliVe et al. 2000).
Link proteins
The interaction between hyaluronan and lecticans is rein-
forced by small link proteins, collectively denominated
Fig. 1 Structural models of the chondroitin sulfate proteoglycans of the lectican family. ADAMTS cleavage sites and binding regions of the poly-
clonal antibodies used in immunohistochemical stainings displayed in the following Wgures are indicated
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HAPLNs (hyaluronan and proteoglycan binding link pro-
teins) (Spicer et al. 2003). This family of ancillary glyco-
proteins consists of four members, including the classical
cartilage link protein (HAPLN1 = Crtl1) (Neame and Barry
1993). Since its discovery several decades ago, HAPLN1
Crtl1 has also been detected in brain, where it joins two
other link proteins, the CNS-restricted HAPLN2/Bral1 and
HPLN4/Bral2 (Bekku et al. 2003; Hirakawa et al. 2000).
Only HAPLN3/Lp3 seems to be absent from the brain
parenchyma, however, being expressed by the smooth mus-
cle cells of larger blood vessels (Ogawa et al. 2004; Spicer
et al. 2003).
The structure of the link proteins strongly resembles the
globular G1 regions of lecticans, as they are all built-up of
an Ig-fold and a hyaluronan-binding tandem repeat. There
is some evidence that the interaction with lecticans may
either be mediated by the Ig-fold (aggrecan) or by the tan-
dem repeat of the link protein (versican). This functional
relationship between HAPLNs and lecticans is also reXected
in their chromosomal location and genomic organization.
Intriguingly, each of the link protein genes is paired up with
one of the lectican genes: HAPLN1 with VCAN, HAPLN2
with BCAN, HAPLN3 with AGC and HAPLN4 with NCAN
(Spicer et al. 2003). Despite this particularity, the expres-
sion and binding preferences of link proteins and lecticans
seem to be uncoupled from their genomic setup. For
instance, HAPLN1/Crtl1 is co-expressed and interacts with
aggrecan in cartilage and possibly in brain, while versican,
V0 and V1, and HAPLN3/Lp3 are both synthesized in
smooth muscle tissues and may bind to each other at these
locations (Ogawa et al. 2004). Alternatively, the same vers-
ican isoforms or neurocan may team up with HAPLN1/
Crtl1 to form ternary complexes with hyaluronan during
brain development (Hirakawa et al. 2000; Matsumoto et al.
2003; Rauch et al. 2004; Seyfried et al. 2005; Shi et al.
2004). Finally, there are strong indications that pairs of
HAPLN2/Bral1 and versican V2 (Oohashi et al. 2002) and
of HAPLN4/Bral2 and brevican associate in mature brain
tissues with hyaluronan (Bekku et al. 2003).
Tenascins
Apart from hyaluronan, lecticans and link proteins, tenasc-
ins represent the fourth class of molecules that form the
basic constituents of the brain ECM. Tenascins (Tn) are
very large multimeric glycoproteins that are well conserved
among vertebrates (reviewed by Chiquet-Ehrismann and
Chiquet 2003; Hsia and Schwarzbauer 2005; Joester and
Faissner 2001; Jones and Jones 2000). In mammals, the
family consists of four members namely tenascin-C, -R, -X
and -W (-N). The macromolecular structures of the diVerent
tenascin monomers are highly alike as they follow the same
modular arrangement. They are built of an amino-terminal
cysteine-rich oligomerization region composed of three to
four -helical heptad repeats, EGF-like elements, Wbronec-
tin type III-repeats (FN III) and a carboxyl-terminal Wbrino-
gen-like globular domain.
The heptad domains allow an N-terminal association of
the individual subunits that primarily form homotrimers. In
tenascin-C and tenascin-W, an additional cysteine residue
in this region permits these trimers to further assemble into
large hexameric structures, the so-called hexabrachions.
Although this cysteine is also present in tenascin-R, only
trimers of this ECM molecule have been observed so far.
While the number of EGF-like repeats varies only
between the diVerent tenascins, some of the FN III domains
are also subjected to alternative splicing. Since diVerent
combinations of these variable FNIII repeats are possible,
several isoforms of the individual tenascins exist (Jones and
Jones 2000). For instance, the tenascin-C monomers bear
14.5 EGF-repeats plus 17 FN III repeats, 9 of which can be
alternative spliced. As a result, up to 27 diVerent tenascin-C
transcripts may be expressed during mouse brain develop-
ment (Joester and Faissner 1999), each subunit comprising
molecular weights in the range of 180–300 kDa. In con-
trast, tenascin-R, which includes 4.5 EGF and 9 FN III
repeats, gives rise only to two splice variants of 180 and
160 kDa per subunit. This diVerence depends on the pres-
ence or absence of a supplementary FN III module between
the FN III-repeats 5 and 6 (Fuss et al. 1993). Alternative
splicing seems also to generate diVerent isoforms of Tn-X
(Ikuta et al. 1998) and Tn-W/Tn-N, the latter representing
variants originating from the same gene (Neidhardt et al.
2003; Scherberich et al. 2004). Because the neural expres-
sion of Tn-W/Tn-N is currently still rather controversial
(Neidhardt et al. 2003; Scherberich et al. 2004) and because
Tn-X does not reach signiWcant levels in the central ner-
vous system (Matsumoto et al. 1994), we will focus in the
following only onto the two other tenascin-family mem-
bers.
Both, tenascin-C and tenascin-R bind to a wealth of
extracellular matrix and cell surface ligands (Jones and
Jones 2000). These interactions are mainly mediated by
the FN III modules. The majority of the cellular receptors
for tenascin-C and tenascin-R belong to the integrins, to
the cell surface heparan sulfate proteoglycans (syndecans,
glypicans) or to the cell adhesion molecules of the immu-
noglobulin superfamily (Ig-CAMs contactin/F11/F3, axo-
nin/TAG-1 and neurofascin). Other cell surface binding
partners are annexin II and the receptor protein tyrosine
phosphatase (RPTP-/). Albeit of uncertain physiological
relevance, a low aYnity of the EGF-like repeats of Tn-C
for EGF-receptors has also been reported (Swindle et al.
2001). Among the major ECM binding partners of these
tenascins are Wbronectin, phosphacan and particularly
lecticans.
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Supramolecular assembly
The ability of the brain ECM-components to selectively
aggregate, leads to the establishment of large, relatively
loose and Xexible meshworks where hyaluronan acts as
backbone. The current concept of supramolecular organiza-
tion and assembly is mainly based on aYnity measurements
in vitro (mentioned before) and on recent rotary shadowing
electron micrographs displaying the corresponding large
multi-molecular complexes (Lundell et al. 2004). In this
model, Wlamentous hyaluronan-molecules extruding from
the neuronal cell membrane associate Wrst with the G1
domains of distinct lecticans and link proteins that stabilize
the complex. At the other end of the lectican core protein,
the G3 domains engage in an interaction with one of the
arms of the tenascin oligomers. This way tenascins may
cross-link up to three (Tn-R) or up to six lecticans (Tn-C)
and consequently bridge neighboring hyaluronan/lectican/
link protein-complexes to complete the extracellular net-
work. Supposing that the diVerent components are propor-
tionally expressed, the mesh size of this structure will be
determined by the length of the tenascin arm, the distance
between the lectican G1/link protein-aggregates along the
hyaluronan molecules and most importantly by the dimen-
sion of the lectican core protein. Hence, the network would
become roughly twice as dense by replacing for instance
the V0 isoform of versican by the V2 variant and switching
from Tn-C to Tn-R. Along with the change of lectican
expression, the proportion of negatively charged carbohy-
drates and consequently the amounts of attracted water and
cations may alter the gel-like properties of the extracellular
matrix that occupies the intercellular spaces within the cen-
tral nervous system. Indeed, the estimated change of the
extracellular volume from roughly 40% in the developing
brain to about 20% in adults (Nicholson and Sykova 1998)
may at least partly be linked to the general tendency to
express smaller lectican variants in the course of tissue
maturation.
Expression and distribution
Gaining a clear insight into the expression and distribution
of ECM components in development and adulthood has not
been an easy task as especially antibodies widely employed
in the earlier immunohistochemical studies were often not
monospeciWc. Since ex vivo isolates of the highly glycosyl-
ated molecules were frequently used for immunization,
several monoclonal antibodies have recognized carbohy-
drate epitopes, which could be found in glycans of several
glycoproteins and/or were sometimes only present in sub-
fractions of a particular ECM component (Lander et al. 1997;
Matthews et al. 2002; Yamagata et al. 1993; Zako et al.
2002). Another cause for antibody cross-reactivity has also
been the high protein sequence conservation, as in the G1
and G3 domains of the lecticans, and the consequent epi-
tope sharing (Bignami et al. 1993; Perides et al. 1993;
Yamada et al. 1997b). With the increasing availability of
cDNAs and the advent of recombinant expression systems
in bacteria, however, antibody production could be directed
against more selective sites in little or non-glycosylated
regions of the proteins (Milev et al. 1998b; Schmalfeldt
et al. 1998; Zimmermann et al. 1994) (Fig. 1). Conse-
quently, a set of highly speciWc and sensitive polyclonal
antibodies with well-deWned immunoreactivity has
revealed a more consistent picture of ECM expression.
Tenascins C and R, phosphacan, most of the link pro-
teins and all lecticans, including alternative splice-variants,
are at some stage present in the central nervous system
(Bandtlow and Zimmermann 2000; Jones and Jones 2000;
Rauch 2004; Yamaguchi 2000). While Tn-R, phosphacan,
HAPLN2/Bral1, HAPLN4/Bral2, brevican, neurocan and
versican V2 are uniquely expressed in brain and spinal
cord, Tn-C and the versican isoforms V0, V1 and V3 are
also found in many mesenchymal tissues during embryo-
genesis and later in association with remodeling processes
induced by, e.g., injury, neovascularization, inXammation
or neoplasia. Likewise, aggrecan and HAPLN1/Crtl1,
which participate in the establishment of some specialized
brain ECMs, are primarily components of developing and
mature cartilage. Finally, hyaluronan, which interacts with
all the lecticans, displays the widest tissue distribution,
being (also outside the nervous system) most abundantly
produced by morphogenetically active zones during
development and adult remodeling processes (Toole 2001,
2004).
Juvenile matrix type
During late embryonic and early postnatal phases of mam-
malian development, a juvenile type of extracellular matrix
is initially formed in the CNS (Fig. 2). It mostly consists of
hyaluronan, neurocan, versican V0, versican V1, tenascin-
C and HAPLN1/Crtl1 (Milev et al. 1998b; Rauch 2004). In
addition, prominent CNS-expression of aggrecan has been
reported in chick embryos (Schwartz and Domowicz 2004),
while only very small amounts have been detected in prena-
tal rodent brains (Matthews et al. 2002; Milev et al. 1998c).
Cellular origin of neurocan and the large versican variants
are neurons (Engel et al. 1996; Yamagata and Sanes 2005),
whereas aggrecan appears to be mainly expressed by cells
of astroglial lineage at this early time point (Domowicz
et al. 2008). The transient deposition of neurocan and versi-
can V0/V1, peaks in rats shortly after birth (Fig. 3) (Meyer-
Puttlitz et al. 1995; Milev et al. 1998a). Preferential accu-
mulations are the marginal zone and the subplate of the
640 Histochem Cell Biol (2008) 130:635–653
123
neocortex, parts of the hypothalamus, the amygdala and the
developing hippocampus and dentate gyrus (Meyer-Puttlitz
et al. 1996; Miller et al. 1995; Popp et al. 2003). Early post-
natally, neurocan and the versican isoforms V0 and V1 are
also found in the presumptive white matter and in the inter-
nal granule cell layer of the cerebellum (Meyer-Puttlitz
et al. 1996; Popp et al. 2003). Starting from the second
week after birth they are down-regulated and Wnally only
persist in a few specialized locations in the adult CNS.
The time course of this early lectican expression is paral-
leled by their ligands, hyaluronan and the HAPLN1/Crtl1
link protein. In fact, the content of hyaluronan peaks in
rodent brain shortly after birth, being subsequently reduced
to one-fourth of its maximal level in the adult tissue (Mar-
golis et al. 1975). In the developing cerebellum, hyaluronan
is mostly present in the granular cell layer and prospective
white matter (Ripellino et al. 1988), where it seems to be
organized into extracellular arrays of Wber-like structures
(Baier et al. 2007). There is evidence that glial cells synthe-
size hyaluronan in the early phase of the CNS formation
(Deyst and Toole 1995), the hyaluronan synthase responsi-
ble for its production at this early stage has yet to be identi-
Wed. Similar to hyaluronan, HAPLN1/Crtl1, which may
stabilize the interaction of hyaluronan with neurocan, versi-
can and aggrecan, is up to about postnatal day 10 increas-
ingly expressed and then gradually diminishes in the
maturating nervous tissue (Hirakawa et al. 2000).
A relatively early CNS expression is also observed for
the glia-derived ECM glycoprotein Tn-C. It Wrst accumu-
lates around the Wbrous processes of radial and Bergmann
glial cells that direct the migration of neuronal precursors
during cortical and cerebellar development, respectively
(Crossin et al. 1986; Prieto et al. 1990). In rodents, it is
rather widely distributed shortly after birth and displays at
least in the cerebral cortex, hippocampus and cerebellum
partial overlaps with neurocan and versican V0/V1 deposi-
tions (Bartsch et al. 1992; Laywell and Steindler 1991;
Meyer-Puttlitz et al. 1996; Popp et al. 2003). Particularly
intriguing is the transient association of Tn-C with the glial
boundary tissues surrounding the functional sets of neu-
rons, like for instance the vibrissae-related barrel Welds of
the developing somatosensory cortex (Steindler et al.
1989). About 2–3 weeks after birth, Tn-C levels decrease
continuously, maintaining only a signiWcant expression
level in the neurogenetically active areas of the adult brain
that encompass the subependymal zone and the hippocampus
Fig. 2 Immunohistochemical 
analyzes of the lectican distribu-
tion in the head region of E18.5 
mouse embryos. Note the strong 
brain-speciWc staining of anti-
bodies against neurocan. The 
antibodies against versican de-
tect at this time point mainly the 
versican splice-variants V0 
(GAG- and GAG- reactive) 
and V1 (only GAG- reactive). 
These versicans are deposited in 
the CNS and in most of the mes-
enchymal tissues of the embryo. 
Aggrecan is practically absent 
from the brain, but is strongly 
expressed in cartilaginous tis-
sues. No brevican staining can 
be detected at this embryonic 
stage. Sagittal sections. Bar 
100 m
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(Bartsch et al. 1992; Dorries and Schachner 1994; Gates
et al. 1995; Thomas et al. 1996).
Mature matrix type
Initiating about 2 weeks after birth, a major remodeling
process takes place (Fig. 3), which replaces most of the
juvenile type of matrix by its mature form (Rauch 2004).
This exchange transforms the relatively loose embryonic
and early postnatal ECM to a signiWcantly Wrmer mesh-
work, which is subsequently maintained throughout adult-
hood. The large majority of the early matrix components
are along the conversion substituted by a diVerent, but
homologous set of ECM proteins that include versican V2,
aggrecan, brevican, phosphacan, tenascin-R and the brain
link proteins HAPLN2/Bral1 and HAPLN4/Bral2 (Bekku
et al. 2003; Hirakawa et al. 2000; Meyer-Puttlitz et al.
1995; Milev et al. 1998b; Pesheva et al. 1989).
In the adult CNS, various combinations of lecticans and
link protein, which are generally associated with hyaluro-
nan, Tn-R and phosphacan condense at some strategic
locations (Fig. 4.). Versican V2 and the secreted brevican
isoform emerge around the second and third week postpar-
tum and subsequently evolve to the predominant constitu-
ents in the adult brain and spinal cord (Schmalfeldt et al.
1998; Yamaguchi 1996). Matrices that contain mainly
versican V2 and some brevican are most prevalent in the
white matter surrounding the myelinated Wbers of all cali-
bers (Ogawa et al. 2001; Schmalfeldt et al. 2000). Particu-
larly dense accumulation of versican V2, HAPLN2/Bral1,
Tn-R and phosphacan appear as ring-like structures around
the CNS nodes of Ranvier (Dours-Zimmermann et al.
unpublished; Melendez-Vasquez et al. 2005; Oohashi et al.
2002; Pesheva et al. 1989; Xiao et al. 1997). Origins of the
Tn-R and versican V2 deposits in the white matter are pri-
marily oligodendrocytes and their precursors (Asher et al.
2002; Pesheva et al. 1989; Schmalfeldt et al. 2000), while
HAPLN2/Bral1 expression has been attributed to neurons
(Oohashi et al. 2002) or oligodendrocytes (Carulli et al.
2006). Interestingly, the brevican expression shifts at the
end of myelination from oligodendroglial to astrocytic line-
age in the white matter (Ogawa et al. 2001). Starting from
postnatal day 28, astrocytes seem to give rise to another
particularly brevican-rich zone that forms after completion
of the neuronal migration in the granular cell layer of the
rat cerebellum. This more compact extracellular matrix
ensheathes cerebellar glomeruli, in which the incoming
mossy Wbers contact the local neuronal processes (Yamada
et al. 1997a).
The by far best studied extracellular matrix condensation
in the adult central nervous system is the perineuronal net
(PNN). This lattice-like structure engulfs the cell bodies,
proximal dendrites and axon initial segments of speciWc
Fig. 3 Time course of lectican levels in extracts of embryonic and
postnatal rat brains. Note the transition from the expression of the juve-
nile-type of matrix to its mature form around postnatal day 20.
Diagrams adapted from (Milev et al. 1998b)
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subsets of neurons and embeds, with exception of the syn-
aptic clefts, the presynaptic boutons that contact them
(Bruckner et al. 1993, 2006; Celio and Blumcke 1994;
Celio et al. 1998; Galtrey and Fawcett 2007; Murakami and
Ohtsuka 2003; Rhodes and Fawcett 2004; Yamaguchi
2000). PNNs can be observed in many areas of the CNS
including the cerebral cortex, the hippocampus, the thala-
mus, the cerebellum, the brain stem and the spinal cord.
They most frequently surround parvalbumin-expressing
GABAergic interneurons and certain cortical pyramidal
neurons, as well as projection and large motor neurons of
the brain stem and spinal cord. The formation of perineuro-
nal nets occurs relatively late in postnatal development (in
rodents 2–5 weeks after birth) and coincides with the end-
ing of the experience-dependent reWnement of the synaptic
network and the closure of the critical period, e.g., in the
visual system and spinal cord (Guimaraes et al. 1990; Kalb
and HockWeld 1988, 1990; Pizzorusso et al. 2002).
This specialized matrix consists of hyaluronan, diVerent
lecticans, the link proteins HAPLN1/Crtl1 and HAPLN4/
Bral2, Tn-R, and phosphacan (Asher et al. 1995; Bekku
et al. 2003; Bruckner et al. 2000; Carulli et al. 2006;
Haunso et al. 1999; Maeda et al. 1995). The perineuronally
accumulating hyaluronan is synthesized by HAS2 and
HAS3 expressed in the net-carrying neurons, while HAS1
is generally absent from the CNS (Carulli et al. 2006,
2007). During the PNN-formation, HAS3 may slightly pre-
cede HAS2. The expression of both of these hyaluronan
Fig. 4 Localization of lecticans and tenascins in coronal sections
through adult cerebellum and medulla at Bregma ¡6.18 mm. Note the
perineuronal net staining of aggrecan, tenascin-R and phosphacan in
the deep cerebellar nuclei (DCN) and the brain stem (BS). Brevican and
neurocan are only present in some of the PNNs. Versican V2, which
stains exclusively with GAG--, but not with GAG--speciWc antibod-
ies is accumulating at the nodes of Ranvier in the white matter (WM),
while brevican staining is rather diVused in the myelinated Wber tracts.
Versican V0 and V1, which are recognized by the GAG--speciWc
antibodies are absent from these brain regions in adult mice. Graphics
modiWed from the Allen Brain Atlas (http://www.brain-map.org) (Lein
et al. 2007)
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synthases is subsequently attenuated, but pertains through-
out adulthood.
Among the lectican family members, aggrecan is the
most common perineuronal net component. Although pres-
ent in all PNNs, it may contribute to a certain sub-specializa-
tion by varying its glycan structures between distinctive
sets of neuronal coats (Matthews et al. 2002). Brevican and
neurocan display in many CNS regions an expression pat-
tern similar to aggrecan (Fig. 4) and there is indeed some
evidence that they co-localize within the same perineuronal
structure (Carulli et al. 2006; Galtrey et al. 2008). At least
hyaluronan, aggrecan and Tn-R seem to be rather uniformly
distributed within a single net covering the cell body, proxi-
mal dendrites and the axon initial segment (AIS) irrespec-
tive of the presence of synapses (Bruckner et al. 2006). In
contrast, a certain preference of brevican deposition around
the AIS has been observed in neuronal cell cultures (Hed-
strom et al. 2007; John et al. 2006). Using a monoclonal
antibody (12C5) against the hyaluronan-binding G1
domain of versican, immunohistological examinations of
brain and spinal cord sections have also suggested that the
fourth lectican member is present in PNNs (Carulli et al.
2006; Deepa et al. 2006). Surprisingly, none of our antibod-
ies against the two GAG-attachment regions (Fig. 1) has
displayed a similar perineuronal net staining (Fig. 4). It is
therefore conceivable that the 12C5 antibody, in fact does
not detect intact versican V2 in the PNNs, but rather a pro-
teolytic remnant of the early postnatal versican V0 and V1
expressions that correspond to the versican fragment, for-
merly named as glial hyaluronate-binding protein (GHAP)
or hyaluronectin (Delpech and Halavent 1981; Perides et al.
1989). Also neurocan in the PNNs may at least partly be
present in form of a hyaluronan-binding truncation product
(Neurocan-N) (Deepa et al. 2006), which eventually has
become trapped after the conversion of the juvenile matrix.
No matter whether the lecticans are intact or truncated,
their interactions with hyaluronan seem to be either stabi-
lized by HAPLN1/Crtl1 or by HAPLN4/Bral2 (Bekku et al.
2003; Carulli et al. 2006, 2007). Both of these link proteins
form an integral part of perineuronal nets. Whereas HAP-
LN1/Crtl1 seems to bind to its classical partner aggrecan
and probably also to neurocan or neurocan-N, there is some
indication from knockout mice that brevican may be
required for the PNN localization of HAPLN4/Bral2
(Bekku et al. 2003).
Most of the perineuronal net constituents seem to be
expressed by the engulfed neurons themselves (Carulli
et al. 2006). Nonetheless, contributions from surrounding
astrocytes that extend cellular processes into the reticular
structure cannot be excluded (Carulli et al. 2007). This con-
cerns particularly brevican and to some extent also neuro-
can, which may be produced bilaterally by the ensheathed
neurons and the contacting astrocytes. Co-culture experi-
ments of primary hippocampal neurons and glial cells
indeed revealed that the perineuronal deposits of brevican
are in vitro primarily astrocyte-derived (John et al. 2006),
although perineuronal net-like structures develop appar-
ently also in the virtual absence of glial cells (Miyata et al.
2005).
Lesion-associated reactive matrix
Once established, the composition of the mature type of
extracellular matrix is rather stable with little or no turnover
of their components. This changes, however, radically,
when lesions to the adult central nervous system occur.
Under these circumstances, the expression of various extra-
cellular matrix molecules is highly up-regulated and major
depositions are observed in and around the lesion site, in
particular, in association with the glial scar tissue that
forms (Bradbury and McMahon 2006; Galtrey and Fawcett
2007; Gonzenbach and Schwab 2008; Morgenstern et al.
2002; Zurn and Bandtlow 2006). The freshly produced
ECM components may be secreted by reactive astrocytes,
oligodendrocyte precursors, microglia/macrophages and
eventually by meningeal cells. The lesion and consequent
reactive processes induce a matrix accumulation that
strongly resembles the juvenile-type of meshwork previ-
ously observed during early nervous system development.
For instance, surgical incisions in the cerebral cortex or spi-
nal cord provoke a relatively fast and transient up-regula-
tion of Tn-C and neurocan (Asher et al. 2000; Haas et al.
1999; Jones et al. 2003; Laywell et al. 1992; Matsui et al.
2002; McKeon et al. 1999; Tang et al. 2003). Also the
expression of versican V2, brevican and phosphacan appear
to be aVected. Yet, recent reports about alterations in the
production of versican V2 (direction of regulation) and
brevican (timing) are somewhat controversial (Asher et al.
2002; Jones et al. 2003; Tang 2003). There are nevertheless
indications that the lecticans brevican, aggrecan and versi-
can V2 follow the time course of phosphacan, whose con-
tent Wrst diminishes during the acute phase and then
increases in a late attempt to restore the mature type of
matrix at the injury site (Lemons et al. 2001; Tang et al.
2003).
A similar post-traumatic upregulation of Tn-C and lecti-
cans has also been observed after disruption of sensory
axons at the dorsal root (Beggah et al. 2005; Pindzola et al.
1993). Importantly, this type of lesion near the PNS/CNS
interface lacks a scar formation within the CNS, but still
leads to a reactive gliosis in the dorsal root entry zone
(DREZ) and Wallerian degeneration of the central axon
branches, now separated from their cell bodies. Despite the
absence of a glial scar tissue, elevated depositions of neuro-
can and versicans (also V1 isoform) are prominent in the
DREZ suggesting that the remodeling process temporally
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reactivates a juvenile matrix-like expression proWle analo-
gous to direct damages to the CNS.
Matrix turnover
The rapid switch from embryonic and early postnatal extra-
cellular matrices to their mature form in the normal adult
CNS (Rauch 2004), the fast disappearance of CSPGs from
the predestined axonal pathways observed in the develop-
ing periphery (Landolt et al. 1995; Oakley and Tosney
1991), as well as the reactive changes following nervous
system lesions (Galtrey and Fawcett 2007; Zurn and Bandt-
low 2006) cannot solely be attributed to adjustments in the
ECM expression patterns, but must also depend on highly
active proteolytic processes (Agrawal et al. 2008; Ethell
and Ethell 2007; Flannery 2006; Gottschall et al. 2005;
Milward et al. 2007; Porter et al. 2005). The selective turn-
over of lecticans may in this context be essential for alter-
ing the cell migration and axon growth properties of many
nervous tissues. Metalloendopeptidases of the ADAMTS
family seem to be primarily responsible for the lectican
catabolism (ADAMTS: a disintegrin and metalloproteinase
with thrombospondin motifs). Conversely, matrix metallo-
proteases (MMPs) may only play a subordinate role in the
proteoglycan degradation, but they could preferentially tar-
get the link proteins and tenascins of the central nervous
system. In any case, the proteolysis is tightly controlled by
the tissue inhibitors of metalloproteinases (TIMPs), which
are physiological antagonists of both enzyme types, MMPs
(TIMP-1 to -4) and ADAMTSs (TIMP-3).
Various ADAMTS-enzymes cleave lecticans at a few
speciWc sites in vitro and corresponding digestion products
have been identiWed in vivo (Flannery 2006; Gottschall et al.
2005; Porter et al. 2005). The secreted ADAMTSs are close
relatives of the cell membrane-bound ADAM metallopro-
teases. ADAMs and ADAMTSs are expressed as zymogens
containing a prodomain and a zinc-binding catalytic element
linked to a disintegrin-like motif. In ADAMTSs, several
additional modules may control tissue localization and con-
tribute to the substrate speciWcity. This C-terminal set of
ancillary domains includes a central thrombospondin type I
repeat, a cysteine-rich region, a spacer element and several
supplementary thrombospondin motifs in most of the family
members. The ADAMTS-zymogens are in the trans-Golgi
or at the cell surface activated by N-terminal propeptide
cleavage mediated by furin or furin-like convertases. Addi-
tional proteolytic or autocatalytic removal of a C-terminal
portion has been demonstrated to modulate the enzymatic
activity of some of these metalloproteases (Gao et al. 2002;
Rodriguez-Manzaneque et al. 2000; Zeng et al. 2006).
Five ADAMTS sites have been characterized in the
aggrecan core protein (Caterson et al. 2000; Lemons et al.
2001), two to four in the proteoglycan isoforms of versican
(V2–V0) (Jonsson-Rylander et al. 2005; Sandy et al. 2001;
Westling et al. 2004) and one in brevican (Matthews et al.
2000; Yamada et al. 1995). Interestingly, in all of these
lecticans one ADAMTS-site is located next to the globular
G1-domain allowing the selective release of the large
GAG-carrying portions from the complex with hyaluronan
and link proteins. Finally, also neurocan, which is in adult
tissues often present in form of two well-deWned N- and C-
terminal fragments, may be cleaved by an ADAMTS- or
MMP-protease. Based on comparisons of known sub-
strates, speciWc sites for by MMP-2- and ADAMTS-pro-
cessing have been postulated. Whereas MMP-2 indeed
cleaves neurocan in vitro, the susceptibility to ADAMTS-
digestion still has to be conWrmed in an experimental set-
ting (Sandy et al. 2001; Turk et al. 2001).
Among the 19 ADAMTSs, seven exhibit cleavage
capacity towards lecticans (ADAMTS-1, -4, -5, -8, -9, -15
and -20; ADAMTS-5 and -11 are identical). The classical
aggrecanases are ADAMTS-4 and -5 (Abbaszade et al.
1999; Tortorella et al. 1999). Albeit less eYcient, aggrecan-
processing activities have also been observed of
ADAMTS-1, -8, -9 and -15 (Collins-Racie et al. 2004;
Flannery 2006; Kuno et al. 2000; Somerville et al. 2003).
At least four ADAMTS-proteases including ADAMTS-1,
-4, -9 and -20 recognize versican substrates in vitro (Sandy
et al. 2001; Silver et al. 2008; Somerville et al. 2003; Wes-
tling et al. 2004), whereas only cleavage by ADAMTS-4
and -5 has been demonstrated for brevican (Matthews et al.
2000; Nakada et al. 2005; Nakamura et al. 2000).
Until now, only a few studies have explored the expres-
sion of distinct ADAMTSs during nervous system develop-
ment and virtually no data are available for peri- and early
postnatal phases that are particularly interesting regarding
the remodeling of the neural ECM. From the limited
insights one can currently conclude, that ADAMTS-1 and
-9 are expressed relatively early in the embryonic CNS
(Gunther et al. 2005; Jungers et al. 2005; Thai and Iruela-
Arispe 2002), while ADAMTS-4 appears only in adult ner-
vous tissues (Abbaszade et al. 1999; Jungers et al. 2005).
Moderate to low expression of ADAMTS-4, for instance
has been detected in pyramidal neurons of various cortical
areas and in granule cells of the dentate gyrus in normal
adult brain (Yuan et al. 2002).
This base-expression of ADAMTSs rises considerably in
the presence of diVerent types of lesions. After a kainate-
induced excitotoxic insult, a transient up-regulation of
ADAMTS-4 and ADAMTS-1 coincides with a marked
increase of brevican proteolysis (Mayer et al. 2005; Yuan
et al. 2002). A similar reaction is also observed in an experi-
mental model of cerebral ischemia (Cross et al. 2006).
Moreover, motor axon disruption induces the ADAMTS-1
production in the aVected neurons (Sasaki et al. 2001) and
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there is growing evidence that the same enzyme is also
over-expressed in association with various neurodegenera-
tive disorders (Miguel et al. 2005; Satoh et al. 2000). In
addition, glioblastomas display elevated levels of brevican
and its proteolytic fragments (Nutt et al. 2001) are associ-
ated with an increased expression of ADAMTS-5 and,
although somewhat controversial, possibly also with
ADAMTS-4 (Held-Feindt et al. 2006; Nakada et al. 2005).
This close relationship between ECM remodeling and
ADAMTS expression under traumatic and pathogenic con-
ditions, provides an indirect indication for an analogous
functional involvement of ADAMTSs in the matrix conver-
sion of normal neural development.
Putative functions
The progress in unraveling the precise functions of the
extracellular matrix in the central nervous system has for
long been rather slow due to the high structural variability
of its main constituents and the great complexity of the
dynamic remodeling process involved in normal develop-
ment and disease conditions. Albeit correlations of the dis-
tribution of speciWc ECM components with cellular
processes like proliferation, migration, axonal growth or
synapse formation have been very valuable for gaining
insights into the putative functions in vivo, they may have
been somewhat distorted by the fact that most antibodies
used in these studies are unable to discriminate between
intact and ADAMTS- or MMP-processed forms of a particular
molecule. This distinction could be of considerable
importance as the speciWc cleavage may attenuate or even
neutralize certain ECM functions without becoming appar-
ent in the immunohistological stainings.
Moreover, partial overlapping rather than completely
diVerent functions of structurally related matrix proteins
may be responsible for the unexpectedly mild phenotypes
of several knockout mice, while the absence of potential
key components has in contrast resulted in embryonic or
perinatal lethality that prevents the study of their role in the
mainly postnatal neural development (Table 2). Neverthe-
less, evidence for an extracellular matrix involvement in
neural migration, axon guidance, plasticity restriction and
Wber tract stabilization has in recent years come from vari-
ous in vitro and in vivo observations.
Axon growth inhibition
Phosphacan and all lecticans of the central nervous system
inhibit in their intact form axonal growth in vitro (Bandtlow
and Zimmermann 2000; Yamaguchi 2000). This functional
property appears to be mostly core protein-dependent in
versican V0, V1 and V2 (Dutt, Stöckli and Zimmermann
unpublished; Niederöst et al. 1999; Schmalfeldt et al.
2000;), neurocan (Margolis et al. 1996) and phosphacan
(Maeda and Noda 1996), whereas no inhibition of brevican
(Yamada et al. 1997a) and cartilage-derived aggrecan
(Snow et al. 1990) has been detected after chondroitinase
ABC digestion. Notably, we also observed two- to three-
fold reductions, but never an abolition of the inhibitory
capacity of versican V2 in stripe choice experiments after
complete glycosaminoglycan-removal (Schmalfeldt et al.
Table 2 Available ECM-knockout mouse strains
LTP Hippocampal long-term potentiation, EAE experimental autoimmune encephalomyelitis, PNN perineuronal net, ND not described
Brevican (Brakebusch et al. 2002); neurocan (Zhou et al. 2001); versican (Mjaatvedt et al. 1998); aggrecan (Watanabe et al. 1994); RPTP-/phos-
phacan (Harroch et al. 2000, 2002; Niisato et al. 2005); TnR (Bruckner et al. 2000; Freitag et al. 2003; Haunso et al. 2000; Montag-Sallaz and
Montag 2003; Saghatelyan et al. 2004; Weber et al. 1999); TnC (Evers et al. 2002; Forsberg et al. 1996; Fukamauchi et al. 1996; Kiernan et al.
1999; Saga et al. 1992); HAPLN1/Crtl1 (Watanabe and Yamada 1999); HAS2 (Camenisch et al. 2000); HAS3 (Bai et al. 2005)
Gene Viability CNS phenotype
Brevican (Bcan) Normal Reduced LTP
Neurocan (Ncan) Normal Reduced LTP
Versican (Vcan/hdf-strain) Die at E10.5 –
Aggrecan (Acan/cmd-strain) Die at birth ND
RPTP-/phosphacan (Ptprz1) Normal Enhanced LTP; impaired recovery from EAE 
(transmembrane variants?)
Tenascin-R (Tnr) Normal Aberrant PNNs; reduced conduction velocity; 
disturbed neuroblast migration in olfactory bulb; 
some behavioral abnormalities
Tenascin-C (Tnc) Normal Reduced LTP; mild behavioral abnormalities
HAPLN1/Crtl1 (Hapln1) Die at birth ND
HAS2 (Has2) Die at E10.5 –
HAS3 (Has3) Normal ND
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2000). This moderate decrease might be related to the par-
tial collapse of the extended core protein structure after
elimination of the highly negatively charged chondroitin
sulfate side chains.
The axonal growth inhibition is likely dependent on the
presence of a pericellular hyaluronan coat that covers many
cell types and often includes variable amounts of lecticans,
link proteins and tenascins (Evanko et al. 2007). Synthesis
of hyaluronan alone promotes in various cell types the for-
mation of plasma membrane protrusions (Kultti et al. 2006;
Rilla et al. 2008). It is therefore conceivable that a coat con-
taining exclusively hyaluronan has a similar eVect in gener-
ating growth cone Wlopodia exploring the environment at
the tip of growing axons. In situations, in which these Wlo-
podia encounter areas expressing lecticans, they may incor-
porate the CSPGs into the pericellular hyaluronan structure
and consequently increase the hydration capacity and thus
the thickness of their coat. Depending on the extent of this
coat swelling, the contacts to the surface of neighboring
cells or the extracellular matrix may be increasingly com-
promised by sterical hindrance. Accordingly, the advancing
growth cone should slow down, turn away or retract from
the lectican-containing zones. Furthermore, the expression
level, core protein size and carbohydrate substitution of the
encountered lecticans would control the coat dimensions
and thus, modulate the inhibitory eVect. In line with this
hypothesis are the concentration-dependency of the versi-
can inhibition (Schmalfeldt et al. 2000) and a certain ten-
dency to accentuate the eVect by using larger splice-
variants in vitro (Dutt, Stöckli and Zimmermann, unpub-
lished). In addition, neurons may regulate the coat size by
the extent of the hyaluronan synthesis and/or by secreting
ADAMTS-proteases, which would reduce the inhibitory
activity through release of the GAG-carrying core protein
portions from the pericellular structure.
While high-versican concentrations provoke retraction,
low concentrations still allow a reduced growth, but
promote enlargement of presynaptic varicosities in chick
retinal axons in vitro (Yamagata and Sanes 2005). This
Wnding is corroborated by RNA interference experiments
in vivo, where depletion of versican causes a signiWcant
size reduction of the varicosities in the retinal arbors of the
optic tectum suggesting that low-versican expression
attenuates axonal growth and induces lamina-speciWc
presynaptic maturation. Conversely, high expression of
versican V0/V1 may also contribute to the formation of
molecular barriers that block axon extension and may in
addition, direct migratory neural crest cells in the develop-
ing peripheral nervous system (Dutt et al. 2006; Landolt
et al. 1995; Oakley and Tosney 1991). Unfortunately,
these suspected modulator functions of the V0/V1 iso-
forms cannot be veriWed in versican null mice (hdf strain),
as they suVer from problems in heart segmentation and
consequently die early, at around embryonic day 10.5
(Mjaatvedt et al. 1998).
Although the highest matrix protein expression in the
CNS during early neural development has been attributed
to Tn-C and neurocan, their in vivo functions in the juve-
nile-type of matrix are still largely unknown. Single knock-
outs of neurocan and Tn-C showed no apparent anatomical
abnormalities in the CNS (Steindler et al. 1995; Zhou et al.
2001). A potential compensation by up-regulation of the
closely related brevican or Tn-R, respectively, has not been
observed. Nonetheless, recent generation of a Tn-C, Tn-R,
neurocan and brevican quadruple knockout suggested a
partial replacement of the tenascins by Wbulin-1 and -2,
which are generally not expressed in the brain parenchyma,
but may similarly cross-link the C-terminal domains of the
remaining lecticans (Rauch et al. 2005). This complex may
however, be less stable as suggested by the partly disturbed
structure of the perineuronal nets in these quadruple and in
the Tn-R single knockout mice (Bruckner et al. 2000;
Haunso et al. 2000; Rauch et al. 2005; Weber et al. 1999).
Regulation of plasticity
There are increasing indications that the transition from the
juvenile type of matrix to its mature form terminates the
highly dynamic periods of cell and axonal migrations and
restricts plasticity and regeneration in the adult central ner-
vous system (Galtrey and Fawcett 2007; Rauch 2004). In
white matter, specialized matrices rich in brevican and
versican V2 contribute to axon growth inhibitory environ-
ment associated with CNS myelin (Niederöst et al. 1999)
and possibly prevent abnormal axon branching by accumu-
lating at the nodes of Ranvier. In addition, the establish-
ment of perineuronal nets seems to stabilize the neuronal
circuitry by suppressing the formation of new synaptic
contacts (Galtrey and Fawcett 2007; HockWeld et al. 1990;
Rauch 2004; Yamaguchi 2000). These speculations that
are mostly based on the inhibitory properties of lecticans in
vitro, have been further nourished by observations that
injections of bacterial chondroitinase into the visual cortex
of rats aVect the integrity of perineuronal nets and restore
ocular dominance plasticity even after closure of the criti-
cal period (Berardi et al. 2004; Hooks and Chen 2007; Piz-
zorusso et al. 2002, 2006). Similarly enhanced plasticity
after chondroitinase treatment has been reported from
experimental brain and spinal cord injuries (Barritt et al.
2006; Bradbury et al. 2002; Moon et al. 2001). In these
studies, the digestion of chondroitin sulfates at the lesion
sites resulted in increased axonal sprouting and some
axonal re-growth across the normally non-permissive glial
scar tissue, which expresses CSPGs abundantly. In addi-
tion, in adult brevican and neurocan double-knockout
mice, the obstruction of the lectican-rich dorsal root entry
Histochem Cell Biol (2008) 130:635–653 647
123
zone appears to be partly lifted, as a signiWcant number of
sensory axons cross back into the DREZ after proximal
nerve disruption and subsequent growth stimulation
through a late conditioning lesion of the peripheral branch
(Quaglia et al. 2008). Because the suppression of a single
myelin- or ECM-associated CNS-inhibitor typically leads
to less than 10% robust re-growth of cut axons in all diVer-
ent experimental lesion systems tested (Bradbury and
McMahon 2006; Gonzenbach and Schwab 2008; Zheng
et al. 2006), such multimodal strategies may be required to
achieve an improved neutralization of the inhibition and a
more eVective promotion of the regenerative response in
the CNS.
Other putative functions
Apart from these putative roles connected to axon growth
inhibition, the condensed matrices in the mature central
nervous system may take part in axo-glial interactions and
regulate the ion homeostasis required for the rapid and
timely induction and propagation of action potentials at the
axon initial segments (AIS) and at the nodes of Ranvier,
respectively (Bruckner et al. 1993, 2006; Hedstrom and
Rasband 2006; Poliak and Peles 2003; Salzer 2003). In this
context it is interesting to note, that neurocan, brevican,
RPTP-/phosphacan and also Tn-C null-mice display cer-
tain alterations of hippocampal long-term potentiation (in
RPTP- knockout mice probably only linked to transmem-
brane variants), while a decreased axonal conductance has
been measured in the optic nerve of Tn-R mutants (Brak-
ebusch et al. 2002; Evers et al. 2002; Weber et al. 1999;
Zhou et al. 2001).
It has also been suggested that proteoglycans in the
extracellular meshwork surrounding myelin-free and thus,
exposed nodal regions and axon initial segments may be
implemented in neuroprotective functions (Miyata et al.
2007; Morawski et al. 2004).
Finally, abrogation of Tn-R expression impairs in adult
knockout mice the detachment and radial migration of neu-
roblasts into the outer layers of the olfactory bulb. In con-
trast, ectopic expression reroutes the neuroblasts that
originate from the subventricular zone of the lateral ventri-
cles and Wrst move tangentially in the rostral migratory
stream. This suggests that Tn-R alone may also act as posi-
tive cue for adult neuroblast migration (Saghatelyan et al.
2004).
Despite the panoply of putative functions of the extra-
cellular matrix in the nervous system presented in the last
years, the picture of its main roles in development and
maturation has remained largely fragmented. It is to hope,
that after a long period of neglect, the recently renewed
research interests will boost the assembly of this fascinating
puzzle.
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3. Aims of the project 
 Prior to the initiation of this PhD project we had shown that the versican isoform V2 is a major 
constituent of the adult brain ECM (Dours-Zimmermann and Zimmermann, 1994; Schmalfeldt et 
al., 1998) and we described its characteristic expression pattern in myelinated fiber tracts of the 
CNS (Schmalfeldt et al., 2000). Moreover, we had demonstrated its potent inhibitory properties on 
axonal growth in vitro.  
 These data from our previous experiments together with additional work from other laboratories 
indicated that versicans could function in axonal guidance during development, participate in the 
stabilization of the myelinated fiber tracts during CNS maturation and contribute to the suppression 
of structural regeneration in the mature brain and spinal cord after injury. 
 
 In order to obtain a mouse model and to study the potential role of versican V2 in vivo, following 
specific goals were formulated: 
 
1) To generate a mutant mouse constitutively lacking the versican splice-variant V2. 
2) To screen the mutants for gross anatomical, histological and molecular aberrations focusing in 
particular on the myelinated fiber tracts in the CNS. 
3) To produce domain-specific antibodies against mouse versicans and other mouse lecticans in 
order to detect alterations of their deposition in knockout mice.  
4) To analyze the differential expression pattern of CSPGs in CNS injury models by discriminating 
between the different lecticans (in collaboration with other laboratories). 
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Abstract 
 The central nervous system-restricted versican splice-variant V2 is a large chondroitin sulfate 
proteoglycan incorporated in the extracellular matrix surrounding myelinated fibers and particularly 
accumulating at nodes of Ranvier. In vitro, it is a potent inhibitor of axonal growth and therefore 
considered to participate in the reduction of structural plasticity connected to myelination. To study 
the role of versican V2 during postnatal development, we designed a novel isoform-specific gene 
inactivation approach circumventing early embryonic lethality of the complete knockout and 
preventing compensation by the remaining versican splice-variants. These mice are viable and 
fertile, display however, major molecular alterations at the nodes of Ranvier. While the clustering of 
nodal sodium channels and paranodal structures appear in versican V2-deficient mice unaffected, 
the formation of the extracellular matrix surrounding the nodes is largely impaired. The conjoint loss 
of tenascin-R and phosphacan from the perinodal matrix provide strong evidence that versican V2, 
possibly controlled by a nodal receptor, organizes the extracellular matrix assembly in vivo. 
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Introduction 
 Neuronal and glial cells of the adult central nervous system (CNS) are surrounded by 
specialized extracellular matrices (ECM) that assemble during maturation and replace the loose 
meshwork of the late embryonic and early postnatal phase (for reviews see (Bandtlow and 
Zimmermann, 2000; Yamaguchi, 2000; Rauch, 2004; Zimmermann and Dours-Zimmermann, 
2008)). Both, juvenile and mature forms of the CNS-matrix are composed of chondroitin sulfate 
proteoglycans (CSPG), tenascins, link proteins and hyaluronan. The majority of the CSPGs belong 
to the lectican family that includes brevican, neurocan, aggrecan and versican. Lecticans share N- 
and C-terminal globular structures (G1 and G3, respectively) separated by unique 
glycosaminoglycan (GAG) carrying middle portions of variable size. Moreover, alternative 
incorporation of the two glycosaminoglycan attachment regions, GAG- and GAG-, results in four 
versican splice-variants (V0 contains the GAG- and GAG--domain, V1 only GAG-, V2 only 
GAG- and V3 neither of these domains) (Dours-Zimmermann and Zimmermann, 1994; Zako et 
al., 1995). 
 All lecticans bind via their G1-domain to hyaluronan. This interaction is stabilized by one of 
four link proteins (HAPLN1-4) (Spicer et al., 2003). In addition, the lectin-like element in the C-
terminal G3-domain displays in vitro moderate to high binding-affinities towards tenascin-R (TnR) 
(Aspberg et al., 1997), tenascin-C (TnC) (Day et al., 2004) and sulfated glycolipids (Miura et al., 
1999). The trimeric TnR and the hexameric TnC glycoproteins may crosslink the G3 domains of 
lecticans and thus, tie up the extracellular network (Lundell et al., 2004). Finally, phosphacan, a 
secreted CSPG-form of the receptor-like protein tyrosine phosphatase  (RPTP) (Maurel et al., 
1994), joins the complex. 
 In the adult CNS, versican V2 and HAPLN2/Bral1 are the prominent components of the white 
matter ECM and particularly accumulate at the nodes of Ranvier (Schmalfeldt et al., 1998; 
Schmalfeldt et al., 2000; Oohashi et al., 2002; Melendez-Vasquez et al., 2005). Conversely, 
aggrecan, HAPLN4/Bral2 and neurocan associate with perineuronal nets (Bruckner et al., 2000; 
Bekku et al., 2003). Brevican, hyaluronan, TnR and phosphacan are observed in both of these 
meshworks.  
  Since lecticans strongly inhibit axonal growth in vitro, these specialized ECMs might 
participate in consolidating myelinated fiber tracts, limiting structural plasticity and restricting 
regeneration in the maturating CNS (Yamaguchi, 2000; Zurn and Bandtlow, 2006; Galtrey and 
Fawcett, 2007; Zimmermann and Dours-Zimmermann, 2008). Furthermore, they may regulate the 
assembly of axo-glial complexes and facilitate the induction and propagation of action potentials at 
the axon initial segments (AIS) and the nodes of Ranvier (Bruckner et al., 1993; Poliak and Peles, 
2003; Salzer, 2003; Sherman and Brophy, 2005; Bruckner et al., 2006; Hedstrom and Rasband, 
2006) or they could fulfill neuroprotective functions (Morawski et al., 2004). 
 To further explore these potential roles in vivo, we have now suppressed the expression of 
versican V2, one of the main constituents of the mature neural ECM. We avoided the early 
embryonic lethality of the complete gene knockout (Mjaatvedt et al., 1998) by employing an  
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unconventional isoform-specific gene targeting strategy. The newly generated mouse strain is 
viable and fertile, but displays major aberrations in the matrix assembly. 
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Materials and Methods 
Generation of versican V0/V2 KO mice 
 Using a targeting vector containing a floxed neomycin–thymidine kinase (neo–tk) selection 
cassette under the control of the HSV-tk promoter, we introduced an ER-retention signal followed 
by an early translational stop codon into the GAG- encoding exon VII of the mouse versican gene 
(codon-insertion KDELstop after E749, Swiss-Prot Q62059; figure 1). The two 3.9 kb-long genomic 
arms of the construct included corresponding parts of exon VII plus adjacent intron sequences, 
previously cloned from syngeneic DNA by PCR (primer sequences and PCR-conditions available 
on request). Electroporation of the linearized construct into R1 129Sv embryonic stem (ES) cells 
(Nagy et al., 1993), selection and screening of ES cell clones were done as previously described 
(Talts et al., 1999). Homologous recombinants were identified by Southern blot analysis using a 
digoxigenin (DIG)-labeled probe (Roche Applied Science) downstream of the target site. The ES 
cells were injected into C57Bl/6J blastocysts and transferred into a foster mother. The chimaeric 
offsprings were cross-bred with C57Bl/6J WT mice. Germline transmission of the mutated versican 
allele was verified by Southern blotting and long-distance PCR. 
 The floxed neo-tk selection cassette was removed in vivo by cross-breeding heterozygous 
V0/V2 neo-tk animals with a mouse strain expressing the CRE transgene under the control of the 
cytomegalovirus promoter (Schwenk et al., 1995). Correct target integration and recombination was 
verified by PCR and sequencing of the modified allele. The mutant mice, named VCAN(tm1Zim), were 
back-crossed to establish 129Sv inbred and C57BL/6J outbred strains.  
 
Northern blotting and Quantitative RT-PCR 
 Primary fibroblasts were isolated from E14.5 embryos and maintained in culture (Talts et al., 
1999). Total RNA extraction, Northern blotting and DIG-labeling of a riboprobe hybridizing with the 
hyaluronan-binding region of the mouse versican mRNA (HABR, positions 458 to 1203, GenBank 
D28599) were done as described (Zimmermann et al., 1994). 
 To determine relative amounts of versican mRNA expression in the mutant versus WT mouse 
brains, quantitative RT-PCR was performed with an ABI PRISM 7700 Sequence Detection System 
using the QuantiTect SYBR Green RT-PCR Kit (Qiagen). Total RNAs from brains of littermates 
were extracted with RNeasy Protect kit (Qiagen). Primers detecting the different splice-variants of 
versican were designed to cover the isoform specific exon-exon boundaries (supplementary table). 
Threshold cycle-values (CT) from at least three animals per genotype and per developmental time 
point were normalized against glyceraldehyde-3-phosphate dehydrogenase mRNA (mGAPDH, 
GenBank M32599) as endogenous control. Relative mRNA amounts (2–∆∆CT) were calculated on the 
basis of the comparative CT method, applying the formulaCT = (CT KO - CT WT). The CT of 
each measurement was determined by subtracting the GAPDH-CT from the versican-CT value 
(CT= VC CT - GAPDH CT). 
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Antibodies  
 All polyclonal antibodies have been raised against recombinant core protein fragments as 
described previously (Zimmermann et al., 1994). The GAG- specific antibodies (Schmalfeldt et al., 
2000) recognize the N-terminal portion of this domain of mouse versican (amino acids 362 to 585, 
Swiss-Prot Q62059), also present in the potentially translated truncated V0/V2-polypetide of the 
mutant mice. The GAG- antigen comprised amino acids 2750 to 3040. Both versican fragments 
were used to generate rabbit and guinea pig antisera in parallel. Recombinant portions of aggrecan 
(mAC-IGD: residues 368-481 and mAC-GAG: 1678-1896; Swiss-Prot Q61282) and neurocan 
(mNC-C: residues 645-944; Swiss-Prot P55066) served as antigens for the immunization of guinea 
pigs. Rabbit antisera against rat brevican (Thon et al., 2000) and TnR (Day et al., 2004) were kind 
gifts of Takako Sasaki and Anders Aspberg, respectively.  
 The anti-phosphacan monoclonal antibody 3F8 (Rauch et al., 1991) was purchased from the 
Developmental Studies Hybridoma Bank (University of Iowa). Other commercial antibodies used 
were: goat anti-human-contactin-1 polyclonal antibodies (R&D Systems), mouse monoclonal 
antibody K14/16 against the Kv1.2 -subunit (Upstate),  
rabbit anti-rat-voltage gated sodium channel 1.6 (Nav1.6) polyclonal antibodies (Alomone Labs, 
Israel), mouse monoclonal antibody anti-Caspr clone K65/35 (obtained from the UC Davis/NIH 
NeuroMab Facility, University of California), rabbit anti-human MBP polyclonal antibodies (Dako), 
mouse anti-human MBP monoclonal antibody 67-74 (Chemicon), rabbit polyclonal antibodies 
against bovine GFAP (Dako), mouse (pan-)sodium channel monoclonal antibody K58/35 (Sigma) 
and mouse anti-neurofilament-200 monoclonal antibody NE14 (Sigma). 
 
Protein extraction and immunoblots 
 Brain extracts were prepared as described (Schmalfeldt et al., 1998); each step of sample 
preparations included Pefabloc and 'complete protease inhibitors' (Roche Applied Science). In 
brief, tissues were disrupted in a Polytron homogenizer with 4 volumes of extraction buffer (0.5 M 
NaCl, 50 mM Tris, pH 7.5, 25 mM EDTA, 0.5% Nonidet P-40) and stirred overnight at 4°C. The 
homogenates were centrifuged at 100,000 g for 1 h and the supernatants dialyzed against 
chondroitinase buffer (40 mM Tris, 40 mM sodium acetate, 10 mM EDTA, pH 8). The protein 
concentration was determined with the BCA System (Pierce). 
 Samples were run on 4-15% PHAST polyacrylamide gels (GE Healthcare) under reducing 
conditions and blotted onto Immobilon-P membranes (Millipore) by diffusion transfer at 70°C for 20 
minutes. Alkaline phosphatase-conjugated secondary antibodies (Biosource or Jackson Immuno 
Research Laboratories) and color reaction with Western Blue substrate (Promega) were employed. 
To detect lecticans, samples were digested with chondroitinase ABC (Seikagaku) (1-2 mU/g 
protein) at 37°C overnight prior to electrophoresis. Spent medium from primary embryonic 
fibroblast culture was extensively dialyzed against chondroitinase buffer before chondroitinase ABC 
digestion. 
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Immunohistochemistry and immunofluorescence 
 All animal studies were approved by our institutional review boards. Animals were euthanized 
by CO2-inhalation and decapitated. The tissues were dissected, immediately fixed in 4% 
paraformaldehyde (PFA) in PBS, paraffin embedded and sectioned according to routine protocols. 
If needed, unmasking of the antigen prior to staining was done in a controlled antigen-retrieval 
device (FSG 120-T/T from Milestone), filled with appropriate buffer (10 mM tri-sodium citrate pH 6.0 
or 2 mM Tris, 1.7 mM EDTA, 1 mM tri-sodium citrate, pH 7.8). 
 In some cases, mice were anesthetized with a lethal dose of pentobarbital and transcardially 
perfused with PBS, followed by perfusion-fixation with 4% PFA in PBS as described (Beggah et al., 
2005). Brains and spinal cords were removed, post-fixed overnight at 4°C and either paraffin-
embedded or cryo-protected and rapidly frozen in O.C.T. compound (Tissue-Tek).  
 Immunohistochemistry followed the avidin-biotinylated peroxidase method (VECTASTAIN Elite 
ABC Reagent, Vector Laboratories) using biotinylated secondary antibodies from Jackson Immuno 
Research Laboratories (biotin-SP-conjugated donkey anti-goat, guinea pig or rabbit IgG (H+L)). 
Counterstaining was done with Mayer’s hematoxylin. With mouse monoclonal primary antibodies, 
the M.O.M. kit (Vector Laboratories) was used to avoid non-specific reactions. 
 To stain hyaluronan in tissue sections, biotinylated hyaluronic acid binding protein (B-HABP) 
(Seikagaku) was applied as 0.5 g/ml-solution in PBS overnight at 4°C, then detected with the ABC 
method. 
 Hyaluronan was eliminated from the tissue sections by pre-treatment with either 0.1% 
testicular hyaluronidase (Roche Applied Science) or 10 U/ml hyaluronate-lyase from Streptomyces 
hyalurolyticus (Sigma) in 30 mM sodium acetate, 125 mM NaCl, pH 5.2 containing 'complete 
protease inhibitors'. Digestions went on for 2 hs at 37°C in a humid chamber. Control sections were 
processed in parallel with buffer alone. Sections were washed with PBS before blocking and 
immunostaining. 
 Immunofluorescence staining by standard procedures employed Alexa secondary antibodies: 
Fluor-488 or Fluor-594 highly cross-adsorbed goat anti-rabbit, guinea pig or mouse IgG (H+L), or 
Fluor-594 donkey anti-goat. For triple immunofluorescence: Alexa Fluor-488 donkey anti-rabbit, 
Alexa Fluor-555 donkey anti-goat and Alexa Fluor-647 donkey anti-mouse IgGs. Counterstaining 
was with Hoechst H33258 bis-benzimide (all from Invitrogen). Blocking reagent of the M.O.M. kit 
was used for mouse primary antibodies. 
  Photomicrographs were taken with an Olympus BX61 microscope equipped with a F-view 
camera. The image capture was controlled with the AnalySISPro software (Soft Imaging System, 
Münster, Germany). Confocal Laser Scanning Microscopy was done with a Leica TCS4D, and 3D 
image-processing using IMARIS software (Bitplane, Switzerland).
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Results 
Generation of versican V0 and V2 specific knockout mice 
 The constitutive knockout of all versican isoforms is lethal at an early embryonic stage 
(Mjaatvedt et al., 1998). We therefore chose a splice-variant-specific gene inactivation approach to 
explore the function of versican V2 in the adult mouse CNS in vivo. For this purpose, we introduced 
a translational stop codon into exon VII of the versican gene (VCAN) preceded by an ER-retention 
signal (figure 1). This minimal modification, supplemented only by a loxP site, was sought to 
circumvent potential splicing errors or compensatory expression of other isoforms and to suppress 
the secretion of a truncated protein in the recombinant mice. Due to the splicing modality of the 
versican gene the elimination of the expression of the largest V0 isoform conjointly with versican V2 
has been unavoidable, however.  
 Heterozygous and homozygous mice of the newly generated knockout mouse strain 
VCAN(tm1Zim) are viable and fertile, have a normal life span, exhibit in comparison to their wildtype 
littermates no immediately obvious phenotype in the nervous system and display within the cage 
environment an inconspicuous behavior. Litters of heterozygous breeding pairs follow a normal 
Mendelian inheritance indicating no increased lethality in association with the versican mutant 
genotype. 
 
Expression of the versican transcripts in V0/V2 knockout mice 
 In line with our targeting strategy to abrogate the versican V0 and V2 production only on the 
protein level and to preserve correct splicing and normal expression of versican transcripts, we 
could find mRNAs of all splice variants in knockout animals. Nevertheless, the ratios of the different 
versican transcripts were to some extend affected in the mutant mice. For instance, Northern blot 
analysis of RNA isolated from E14.5 embryonic fibroblasts showed that versican V0 transcripts 
were reduced in cells from heterozygous mice or even evaded detection when they were isolated 
from homozygous animals (figure 2A). In both cases the level of the V1 message remained 
unchanged in embryonic fibroblasts. A more sensitive approach using RT-PCR with isoform-
specific primers confirmed however, the presence of versican V0 transcripts in all mutant fibroblast 
cultures (not shown). Relative quantification of versican transcripts in brains of homozygous versus 
wildtype littermates by real-time RT-PCR finally demonstrated that the total amount of versican 
mRNA was diminished in knockout animals of all ages examined (P0, P30 and P100). In 
homozygous mice this change in expression resulted from a 90%-reduction of versican V2 mRNA 
(all ages tested) and a decline of V0 mRNA to about 20% (P0) or 50% (P30, P100) of the level 
measured in the wildtype animals (figure 2B). In contrast, the relative expression level of versican 
V1 mRNA in brain was not influenced by the mutation and also the V3-transcript stayed rather 
stably low.  
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Proof of absence of versican V0 and V2 core proteins in homozygous mutants 
 The efficient elimination of the V0 and V2 core protein expression in homozygous animals was 
demonstrated in comparisons with adult wildtype and heterozygous littermates. Immunoblots of 
brain extracts with GAG- domain specific antibodies showed that versican V2 protein was 
significantly reduced in heterozygous and abolished in homozygous mice (figure 2C). Moreover, 
the absence of the truncated form of V0 and V2 provided indirect evidence for a successful 
intracellular degradation in neural cells. Similarly, immunoblot of spent medium from primary 
cultures of E14.5 mutant embryonic fibroblasts with anti-GAG- domain antibodies revealed that 
homozygous fibroblasts secreted normal levels of the V1 isoform, but completely lacked the 
versican V0 core protein confirming the effectiveness of our targeting approach also in 
mesenchymal cells (figure 2D).  
 The complete absence of the V0 and V2 core proteins in the homozygote mice could 
ultimately be proven by comparative immunohistological analyses of wildtype animals and mutants 
using our GAG-domain specific antibodies. In wildtype mice, versican V0 is normally present during 
early CNS development mostly disappearing after birth (not shown). In exchange versican V2 
expression initiates postnatally increasing continuously until it reaches a plateau (mRNA level 
around P30 / protein level around P90). At this time point versican V2 has become a major 
component of the brain ECM being associated with the white matter of the central nervous system 
(figures 3 and 4). In the knockout strain, neither the core proteins of versican V0 (includes GAG- 
and GAG-) nor of versican V2 (contains only GAG- could be detected by immunohistochemical 
stainings of embryonic (not shown) or postnatal tissues confirming their effective abrogation 
(figures 3A, 4, 6 and 7 display examples of cerebellum, cerebrum, optic nerve and spinal cord). 
 
Effects of the versican V0/V2 knockout on the expression of other lecticans 
 In accordance with our strategy to minimize the impact on the transcriptional level and to 
evade potential feedback mechanisms, the lack of versican V2 in the adult CNS of homozygous 
mutants was not compensated by increased expression and deposition of the remaining V1 and V3 
splice-variants (fig. 2B, 3). In fact, immunostaining with GAG- specific antibodies revealed that 
versican V1 stayed in wildtype and knockout littermates confined to a few tissues such as the 
choroid plexus, meninges and blood vessels (not shown). Also other lecticans retained their normal 
protein levels and distribution in the absence of versican V2. This is exemplified by 
immunohistochemical stainings of cerebellar white matter and granular cell layer and by 
immunoblotting of whole brain extracts employing antibodies against brevican, neurocan and 
aggrecan (fig 3A and B, respectively). Similarly, brain ECM-structures typically devoid of versican 
V2 (e.g. the specialized perineuronal nets in the deep cerebellar nuclei and/or the brain stem) 
displayed in the knockout mice their characteristic staining patterns for aggrecan, brevican and 
neurocan (fig. 3, insets). Finally, no compensatory upregulation of other brain ECM molecules, like 
tenascin-R (TnR) and its binding partner phosphacan, could be observed in the initial 
immunoblotting experiments (figure 3B).  
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Histological and molecular analysis of myelinated fiber tracts 
 Despite the complete absence of versican V2 and the lack of a compensatory expression of a 
related lectican, postnatal brain development seemed to be mostly unaffected in knockout mice 
(figure 4). Hematoxylin-eosin stainings revealed no significant differences in comparisons of brain 
sections from wildtype and mutant littermates aged P10 or older (not shown). Also the formation of 
the major fiber tracts and myelination appeared normal, since no alterations could be observed by 
light microscopical examination of Nissl stained sections or after immunohistochemistry with 
antibodies against neurofilament-200 (not shown) and myelin basic protein (MBP, figure 4). 
Likewise, the distribution of glial fibrillary acidic protein (GFAP)-positive astrocytes was comparable 
in wildtype and in knockout mice (not shown). 
 Although the CNS-specific versican V2 is in wildtype mice present all along the myelinated 
fibers, it is preferentially deposited at the nodes of Ranvier. Therefore, we focused next onto the 
nodal region. For this purpose, we prepared double and triple immunofluorescence stainings of 
cerebellum, spinal cord and optic nerve sections using antibodies against nodal, paranodal and 
juxtaparanodal markers. Our confocal images displayed in the CNS of wildtype mice a versican V2- 
and TnR-enriched extracellular matrix that engulfs the nodes between the compact MBP-positive 
myelin sheaths (figure 5). Surprisingly, the absence of versican from this structure had in the 
mouse mutants no effect on the distribution of MBP (not shown), the juxtaparanodal voltage-gated 
potassium channel 1.2 (Kv1.2) or the paranodal Caspr and contactin (figures 6 and 7). Also the 
compact clustering of the voltage-gated sodium channel 1.6 (Nav1.6) embedded in the axolemma 
at the node of Ranvier appeared unaltered in versican V0/V2 null mice.  
 
Disturbed assembly of the extracellular matrix around the node of Ranvier 
 In contrast to the normal localization of these membranous components, the molecular 
organization of extracellular matrix surrounding the myelin-free portion of the CNS nodes is in the 
V0/V2 knockout animals severely affected. This rather compact ECM forms a 1 to 2 m-wide ring 
with an outer diameter of 3-4 m (figures 5 to 7). It includes, apart from the tightly intermingled 
versican V2 and tenascin-R (TnR), also phosphacan (the secreted proteoglycan isoform of RPTP) 
and hyaluronan. Intriguingly, this specialized meshwork structure is practically absent in our mutant 
mice, as the selective ablation of the V2 isoform is accompanied by the complete loss of tenascin-R 
and phosphacan, suggesting a key regulatory function of versican in the assembly of the perinodal 
extracellular matrix. Nevertheless, TnR and phosphacan maintain their normal distribution in 
locations where versican V2 is usually not present. This includes the perineuronal nets of the deep 
cerebellar nuclei (TnR and phosphacan, figure 7) as well as the molecular layer of the cerebellum 
(phosphacan/RPTP, not shown). This specific loss of tenascin-R and phosphacan from the nodal 
ECM of versican V0/V2 knockout mice could also be corroborated in other CNS tissues such as 
spinal cord (figure 7) and optic nerve (not shown). 
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 In order to confirm that versican V2 recruits tenascin-R to the nodal matrix and not vice versa, 
we made a comparative analysis of cerebellar sections from a TnR knockout strain (Rauch et al., 
2005) with tissue sections from our versican V0/V2 mutant. These immunohistological experiments 
indeed demonstrated that versican V2 incorporated normally into the extracellular matrix at the 
nodes of Ranvier, even in the absence of tenascin-R, while TnR implicitly required versican V2 for 
its deposition at this location (figure 8). Interestingly, phosphacan was missing from the nodal 
matrix of both knockout strains indicating that its loss in the CNS of versican V0/V2 knockout mice 
is caused indirectly by the absence of TnR (data not shown). 
 Previous in vitro experiments have demonstrated that the C-type lectin domain within the C-
terminal G3-region of versican mediates the binding to tenascin-R (Aspberg et al., 1997), whereas 
the N-terminal G1-domain interacts with hyaluronan (LeBaron et al., 1992). Because versican V2 is 
recruited to the nodal matrix independently of tenascin-R, we subsequently tested, whether 
hyaluronan, its second ligand at the node of Ranvier, could be responsible for anchoring the large 
molecular complex of versican V2, TnR and phosphacan. We therefore removed hyaluronan from 
wildtype cerebellar sections by cleavage with the highly specific Streptomyces hyalurolyticus 
hyaluronate-lyase or with ovine testicular hyaluronidase, an enzyme known to degrade also 
chondroitin and chondroitin sulfate. Despite the effective elimination of hyaluronan by either 
enzyme the distribution of versican V2 and tenascin-R remained unchanged (figure 9). Only 
phosphacan disappeared from the nodes of Ranvier after treatment with testicular hyaluronidase, 
while the more specific hyaluronate-lyase had no effect. Consequently, we have attributed the loss 
of phosphacan from the complex to the chondroitinase side-activity of this enzyme. The versican 
V2 immunostaining was also not affected in hyaluronan-depleted cerebellum sections of tenascin-R 
null mutants demonstrating that neither ligand is absolutely necessary for its anchorage in the ECM 
(not shown). 
 Finally, cell surface sulfatides interact in vitro with the C-terminal globular domain of lecticans, 
including versican (Miura et al., 1999). We therefore concluded our studies of the versican ligands 
by analyzing the distribution of the V2 isoform in the myelinated fiber tracts of brains from mice 
deficient in UDP-galactose ceramide galactosyltransferase (CGT) (Bosio et al., 1996). CGT is a key 
enzyme in the biosynthesis of galactocerebroside (GalC) and its sulfated-derivative, sulfatide, both 
major lipid constituents of myelin. Although CGT-knockout mice completely lack axoglial junctions 
in the CNS-paranodes and die shortly after onset of myelination, they displayed about 19 days after 
birth no abnormal distribution of versican V2 and tenascin-R in cerebrum and cerebellum (figure 
10). Even additional enzymatic removal of hyaluronan from the brain sections of CGT null mice did 
not result in the release of versican V2 from the newly formed nodes of Ranvier. In sum, these 
experiments indicate, that the cell surface sulfatide lipids are, unlike versican V2, not directly 
involved in the assembly of the nodal extracellular matrix. 
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Discussion 
 Our previous studies, first identifying the versican isoform V2 as a major constituent of the 
adult brain extracellular matrix (Dours-Zimmermann and Zimmermann, 1994; Schmalfeldt et al., 
1998), then revealing its characteristic expression pattern in myelinated fiber tracts of the central 
nervous system and subsequently demonstrating its potent inhibitory properties on axonal growth 
(Schmalfeldt et al., 2000) in vitro, prompted us to generate a knockout mouse model to further 
explore the function of this CNS-specific lectican in vivo. Due to the early intra-uterine lethality 
caused by the constitutive elimination of all versican splice-variants in hdf mice (Mjaatvedt et al., 
1998), we had to choose between 1) a conditional knockout approach, potentially facing difficulties 
with efficiency, timing and tissue-specificity of the versican gene ablation, or 2) an isoform-selective 
knockout, which would only affect the alternatively spliced exon VII, but would also abolish the 
expression of the more widely distributed V0 splice-variant along with the CNS-restricted versican 
V2. Since versican V0 appears to be always co-expressed together with versican V1 (Dours-
Zimmermann and Zimmermann, 1994; Zimmermann et al., 1994; Landolt et al., 1995; Dutt et al., 
2006), we considered the collateral elimination of versican V0 the minor problem, and finally opted 
for the latter approach. For this purpose, we designed a novel strategy that ultimately left the 
expression of versican V1 and V3 intact, effectively prevented compensation by other versican 
splice-variants and successfully circumvented the secretion of an artificially truncated core protein 
that potentially could cause a dominant side effect. Although we originally attempted to maintain 
normal mRNA levels of all versican splice-variants in the genetically manipulated VCAN(tm1Zim) 
strain and to disrupt V0- and V2-production and secretion only via a premature stop codon and an 
ER-retention signal instead, the complete annihilation of versican V0 and V2 in the mutants has 
most probably to be attributed to a combined action of a nonsense-mediated-decay (NMD) 
mechanism reducing the proportion of V0 and V2 transcripts (for review see (Kuzmiak and Maquat, 
2006)) and an efficient intracellular clearance of the few truncated core proteins translated from the 
mutated mRNAs. 
 The normal reproduction behavior, litter size and the Mendelian distribution of wildtype, 
heterozygous and homozygous progeny indeed confirmed our prediction, that the early embryonic 
lethality of hdf mice is mostly caused by the absence of versican V1 and consequently could be 
overcome by keeping the expression of this isoform unchanged in our mutant strain. Similar to the 
single gene inactivation of other prominent myelin-derived inhibitors of axonal growth like Nogo, 
myelin-associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (OMgp) (Zurn and 
Bandtlow, 2006), the abolition of the CNS-restricted versican V2 alone had no apparent effect on 
the formation of the fiber tracts. Versican V2-deficency neither led to excessive axonal sprouting 
nor caused myelination defects in the developing central nervous system. Albeit very difficult to 
discern from immunofluorescence experiments, increased collateral axon branching at the CNS-
nodes of Ranvier or enlargement of the nodal region were not evident. Since the proper formation 
and stabilization of fiber tracts and synaptic contacts in the CNS certainly involves inhibitory 
activities of many cell surface and ECM molecules, functional redundancy may explain, why  
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dramatic histological changes are only rarely observed in single mutants. These include also the 
brevican and neurocan knockout strains, which both displayed no alterations upon histological 
examination (Zhou et al., 2001; Brakebusch et al., 2002). While neurocan forms mostly part of the 
embryonic and perinatal extracellular matrix of the CNS, brevican expression is initiated postnatally 
and overlaps to a certain extend with versican V2 in the interstitial space between the myelinated 
fibers. It is therefore conceivable that a lack of versican V2 at this location would at least partly be 
compensated by brevican. Eliminating both of these CNS-lecticans that are expressed more or less 
simultaneously during late developmental phases by cross-breeding the strains may provide more 
conclusive answers about their functional relation in regard to fiber tract stabilization. Based on our 
experiments, a rescue of a potential versican V2-null phenotype by compensatory up-regulation of 
other lecticans can be excluded, however. 
 Whereas brevican, aggrecan and neurocan are along with TnR highly concentrated in the 
perineuronal nets engulfing the perikaryon, the proximal dendrites and particularly the axon initial 
segment (AIS) of large neurons in various CNS regions, versican V2 is predominantly deposited in 
an analogous extracellular matrix structure surrounding the CNS nodes of Ranvier. Despite this 
intriguing accumulation that occurs already during the establishment of the nodes (Oohashi et al., 
2002), versican V2 seems not to be directly involved in controlling the initial steps of nodal 
formation. Unaffected clustering of the Nav channels at the CNS nodes and accurate localization of 
paranodal and juxtaparanodal components in our knockout mice argue against a role of versican 
V2 as a functional analogue of gliomedin, the glial organizer of the nodal structure in the peripheral 
nervous system (Eshed et al., 2005). Furthermore, the concomitant absence of node associated 
TnR and phosphacan and the lack of compensatory expression of other lecticans in our mouse 
mutant provide evidence that none of these extracellular matrix proteins are related to the 
oligodendrocyte-derived soluble factors reported to induce node-like Nav clustering in vitro (Kaplan 
et al., 1997). Even a functional redundancy, leading to a substitution of the hypothetical clustering-
activity of versican V2 by its close relative brevican, appears highly unlikely, as brevican retains its 
firm association with perineuronal nets and its uniform distribution along the myelinated fiber tracts 
without particularly concentrating around the nodes of Ranvier in knockout animals. 
 Instead, the data from our versican V0/V2 knockout mouse model clearly point towards a key 
role of versican V2 in the assembly of the extracellular structure surrounding and possibly 
stabilizing the CNS nodes. The conjoint loss of versican V2, tenascin-R and phosphacan from the 
nodal matrix in our mutant strain now confirms in vivo, macromolecular interactions formerly 
postulated on the basis of in vitro-findings. This includes the binding of versican V2 to tenascin-R 
(Aspberg et al., 1997) and the interactions between tenascin-R and phosphacan (Xiao et al., 1997; 
Milev et al., 1998). Since phosphacan is also absent from the nodes of Ranvier in TnR null mice 
(Weber et al., 1999), we conclude that versican V2 first recruits tenascin-R, which in turn integrates 
phosphacan into the matrix. Additional components joining the extracellular complex are 
hyaluronan and its binding partner Bral1, which shortly follows versican V2 expression during 
postnatal development (Oohashi et al., 2002). Bral1 possibly stabilizes the interaction between  
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hyaluronan and the N-terminal G1 domain of versican, whereas TnR may cross-link the versican 
G3 domains at the other end of the core protein. Hyaluronan certainly forms a general backbone for 
the aggregation of versican in the CNS. Yet, hyaluronan is unlikely to increase the versican 
deposition around the nodes of Ranvier because of its uniform distribution along the myelinated 
fiber tracts. Moreover, our hyaluronan-degradation experiments demonstrate that the binding of 
versican V2 is not crucially depending on interactions with hyaluronan and TnR alone or in 
combination. Considering all these observations, we propose a model, in which the accumulation of 
versican V2 around the CNS nodes of Ranvier forms the extracellular nucleation point for the 
subsequent assembly of the perinodal matrix.  
 Accordingly, the deposition of the versican-enriched matrix at the nodes is likely to be initiated 
by a firm interaction of versican V2 with the nodal axolemma or, less probable, with the paranodal 
structure, while previously reported binding activities of its partner TnR and/or phosphacan to 
paranodal contactin (Brummendorf et al., 1993; Peles et al., 1995) and Neurofascin-155 (NF-155) 
(Volkmer et al., 1998) or to the nodal sodium channels (Srinivasan et al., 1998; Ratcliffe et al., 
2000) may either play no or only subordinate roles in matrix-anchoring. The prominent paranodal 
components contactin, NF-155, Caspr and sulfatides (known to interact with versican in vitro (Miura 
et al., 1999)) seem also not to be required for the selective deposition and binding of versican V2 at 
the nodes. In CGT-null mice, they are all virtually absent from the severely disturbed terminal glial 
loop structures of the CNS paranodes (Poliak et al., 2001; Marcus et al., 2002). Nevertheless, 
versican V2 and TnR accumulate normally in CGT-mutants, as demonstrated by our 
immunohistochemical analyses. Hence, cell surface proteins selectively localized within the nodal 
axolemma are more promising candidates for the versican-dependent anchoring of the perinodal 
extracellular matrix. In the adult CNS potential membrane receptors of versican are voltage gated 
sodium channels (mainly Nav 1.6) and neurofascin-186 (NF-186). Hedstrom et al (Hedstrom et al., 
2007) could recently show that the knockdown of NF-186 by RNA interference abolished the 
recruitment of the close versican-relative brevican to the perineuronal net covering the axon initial 
segment (AIS) of several subsets of CNS neurons. Since NF-186 is also crucially involved in the 
nodal assembly (Zonta et al., 2008), it seems conceivable that it similarly accumulates and 
immobilizes the ECM at the CNS nodes of Ranvier via a versican V2-mediated interaction. Yet, a 
direct binding of NF-186 to brevican and versican V2 has still to be demonstrated. 
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Figure 1 
 
 
 
 
Figure 1. Generation of versican V0/V2 KO mice.  
A) Intron/exon organization of the mouse versican gene giving rise to four different versican 
isoforms (V0-V3) due to alternative splicing of exons VII and VIII encoding the GAG-attachment 
domains (GAG- and GAG-). Grey box shows region of interest displayed in B. 
B) Locus diagram and targeting strategy: introduction of an ER retention signal, a translational stop 
codon and a floxed neo-tk cassette into exon VII of the versican gene (V0/V2 neo-tk). Removal of 
selection cassette by cross-breeding with a CRE-deleter strain leaves only the KDEL coding 
sequence and a stop codon plus one loxP site in exon VII of the mutated versican allele (V0/V2–). 
Corresponding restriction fragments detected in Southern blot are depicted below. 
C) Southern blot analysis of genomic DNA from mice and embryonic stem cells (ES): the DIG-
probe downstream of the targeting locus hybridizes to the 17 Kb EcoRI-fragment of the WT allele, 
which converts to a 6.6 Kb-fragment in versican V0/V2 null mutants. BamHI restriction allows a 
distinction between WT, V0/V2 neo-tk –, and V0/V2 –  allele confirming the successful targeting.
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Figure 2. RNA expression analysis.  
A) Northern blot of total RNA from E14.5 embryonic fibroblasts hybridized with a riboprobe 
detecting all versican splice variants. The approximately 10 kb and 13 kb-bands correspond to 
mRNAs of versican V1 and V0, respectively. Minor fragments are products of alternative 
polyadenylation sites. Loading control: 28S ribosomal RNA.  
B) Relative expression of alternative versican transcripts in brains of KO and WT mice at postnatal 
stages P0, P30 and P100 using quantitative RT-PCR. mRNA ratios of mutants versus WT (2–∆∆Ct) 
were calculated as described in 'materials and methods'.  
C) Immunoblot of brain extracts using GAG- domain-specific antibodies demonstrates the 
reduction and the complete loss of versican V2 in heterozygous V0/V2+/- and homozygous V0/V2-/- 
animals, respectively. Note that the main portion of mouse versican V2 from WT mouse brains 
seems to be devoid of chondroitin sulfate (band also visible before chondroitinase ABC digestion). 
The lower V2 core protein band may represent intracellular precursor protein prior to full O-
glycosylation. 
D) Immunoblot with antibodies against the GAG- domain. Supernatants from embryonic fibroblast 
cultures lack the V0 isoform in cells from homozygous mice. Samples in C) and D) were loaded 
with (+) or without (-) preceding treatment with chondroitinase ABC (Ch’ase).  
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Figure 3. Absence of compensatory expression of other ECM components in versican V0/V2-
deficient mice.  
A) Immunohistochemistry of cerebellar sections of two months old littermates with antibodies 
against versican GAG- (versican V2)andGAG- domains (versican V1), brevican, neurocan-C 
and aggrecan reveal no compensatory over-expression of versican V1 and other lecticans in 
V0/V2-deficient mice. In WT mice versican V2 and brevican are both present along myelinated 
fibers, but only versican V2 accumulates at nodes of Ranvier (punctate staining). Brevican and 
aggrecan, but not versican V2, form part of perineuronal nets in the deep cerebellar nuclei, while 
neurocan-C is associated with perineuronal nets of brain stem nuclei (small insets). Scale bars: 
500 m (overview on the left); 10 m (insets); 20 m (remaining images).  
B) Immunoblots corroborate the unaltered content of lecticans, TnR and phosphacan in brain 
extracts of P30 WT and versican V0/V2 deficient mice. Aggrecan and versican V1 evade 
detection due to their limited expression in mature brain tissues. 
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Figure 4. Comparative analysis of myelinated fiber tracts in WT and versican V0/V2-/- mutants. 
Coronal brain sections of postnatal stages P10, P20 and P90 stained with antibodies against myelin basic protein (MBP) display no morphological 
aberrations in spite of the complete absence of versican V2 in the KO mice. Scale bar: 1 mm. 
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Figure 5 
 
 
 
Figure 5. Visualization of the ECM around the CNS nodes of Ranvier. 
Double immunofluorescence of cerebellar sections reveals in wildtype mice the nodal accumulation 
of versican V2 in relation to the myelin component MBP (A: VcV2; green / MBP; red; sagittal view) 
and demonstrates its co-localization with TnR (B to D: VcV2; green / TnR; red, transverse view) 
intermingling with versican in the perinodal ECM (E: 3D-reconstruction based on confocal image 
stack). Scale bars (A and B-E): 1 m.
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Figure 6 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Effect of the versican V2-
deficiency on the distribution of nodal, 
paranodal and juxtaparanodal 
components. 
In triple/double immunofluorescence of 
optic nerve tissue from wildtype (A, C,  
E) and versican V2-deficient mice (B, 
D, F) no difference in the distribution of 
paranodal contactin (Cntn: red in A-D) 
and Caspr (red in E and F) or 
juxtaparanodal potassium channels 
Kv1.2 (turquoise in A-D) can be 
observed (VcV2: green in A and B; 
Hoechst nuclear staining: blue in A-F). 
Also the clustering of the sodium 
channel Nav1.6 (green in C-F) is not 
impaired. The localization of key 
components of the CNS-nodes of 
Ranvier is depicted in the sketch (G) 
modified from (Rasband and Trimmer, 
2001). Scale bars: 10 m; 2.5 m 
(insets).  
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Figure 7 
 
Figure 7. Simultaneous loss of TnR and phosphacan from nodes of Ranvier in versican V2 mutants. 
Immunochemical and immunfluorescence analysis of cerebellum and spinal cord white matter, respectively with antibodies against versican V2 (GAG-
domain), TnR and phosphacan demonstrates their co-localization in the perinodal ECM in wildtype mice. In versican V2-deficient mice, TnR and 
phosphacan are both absent from the CNS-nodes of Ranvier, while keeping their normal distribution in perineuronal nets of deep cerebellar nuclei. 
Paranodal contactin (red) and juxtaparanodal potassium channel Kv1.2 (turquoise) were immunostained in spinal cord for node localization.  
Scale bars: 50 m (cerebellum) and 5 m (spinal cord). 
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Figure 8 
 
 
 
Figure 8. Perinodal localization of versican V2 is not affected by absence of TnR.  
Immunhistochemistry of cerebellar sections demonstrates that TnR is selectively lost from the 
nodes of Ranvier in versican V2-deficient animals, while versican V2 maintains its normal 
distribution in TnR-/- mice. Scale bar: 10 m. 
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Figure 9 
 
Figure 9. Hyaluronan is not responsible for anchoring the perinodal matrix.  
Complete removal of hyaluronan by treating cerebellar sections with Streptomyces hyalurolyticus hyaluronate-lyase (HA-lyase) or with ovine testicular 
hyaluronidase (HAase) has no effect on the distribution of versican V2 and TnR in WT mice. The disappearance of phosphacan upon HAase digestion is 
most likely attributable to a contaminating enzyme activity in this preparation. Sections were stained with corresponding antibodies to reveal the localization 
of the ECM proteins and with biotinylated hyaluronic acid binding protein (B-HABP) to visualize hyaluronan. Scale bar: 20 m.
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Figure 10. The perinodal accumulation of versican V2 does not depend on sulfatide-mediated cell 
surface-binding. 
Immunohistochemical analysis of cerebellar sections reveals the normal deposition of versican V2 
and TnR around the newly formed nodes of Ranvier in 19 days old (CGT–/–) mice in spite of their 
deficiency in the biosynthesis of sulfatides, a glycolipid-ligand of versican in vitro. Scale bar: 20 m. 
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Supplementary table (Materials and Methods) 
 
Quantitative RT-PCR  
 
Isoform-specific versican primers 
 
Splice variant Primer pairs 
all VCs CCACCTCACAAGCATCCTTTCT / TGAGGCCGATCCACTGGTA  
V0* TGAGGTCAGAGAAAACAAGACA / CTGCAAGGTTCCTCTTCTTTAGATTC 
V1* CAGATTTGATGCCTACTGCTTTAAAC / CTGCAAGGTTCCTCTTCTTTAGATTC 
V2* TGAGGTCAGAGAAAACAAGACA / GATAACAGGTGCCTCCGTTGA 
V3* CAGATTTGATGCCTACTGCTTTAAAC / GATAACAGGTGCCTCCGTTGA 
*Primers spanning over splice variant specific exon-exon boundaries. 
 
 
Primers for reference gene expression (GAPDH) 
 
mGAPDH AACGACCCCTTCATTGAC / TCCACGACATACTCAGCAC 
 
 
RT-PCR conditions 
 
30 min at 50°C (Reverse transcription) 
15 min at 95°C 
40 cycles: 
30 sec at 94°C 
30 sec at 60°C 
  1 min at 72°C 
8 min at 72°C 
soak at 4°C 
 
ABI PRISM 7700 Sequence Detection System set-up: 
Dye layer: SYBR, single reporter, internal reference ROX. 
Fluorescence emission was measured at the end of each cycle. For all samples two different 
negative control reactions omitting either the template or the reverse transcription-step were 
performed. 
 
 
4.1.1. Supplementary Methods Part I 
4.1.1.1. Isolation of genomic clones and preparation of the targeting construct 
 Since the complete sequence of the mouse genome was at the beginning of this project not yet 
known, several PCR approaches were used to isolate and sequence the fragments covering the 
target region. Exon VII was cloned by PCR from genomic 129/Sv mouse DNA using Ampli-Taq 
Gold (Applied Biosystems) and primers at the 5' and 3' end of the GAG- encoding sequence 
(suppl. table 1). Likewise, the flanking introns were cloned with Expand-long template PCR kit 
(Roche Applied Science) using a hot start procedure (wax beads, Applied Biosystems) and primers 
hybridizing at the 3' or 5' end of adjacent exons, correspondingly (3' end of exon VI and 5' end of 
exon VII or 3' end of exon VII and 5' end of exon VIII). 
 
Supplementary table 1: Primers and reaction conditions used to subclone the targeting region 
Annealing / Cycles / Primer 
name Sequence PCR-type Product extension elongation 
Intron67up CCCAGTGTGGAGGAGGTC 15 
Intron67low TGATGAAGTTTCTGCGAGGAT 
Expand-long ~6 kb 65°C/6min@68°C 
35 (+20sec) 
Exon7up AAATGAATATCCTCGCAGAAACT 10 
Exon7low GATGGTCTTGTTGGCTGTGT 
ampliTaq- 
Gold ~3 kb 58°C/2min@72°C 30 (+20sec) 
I78-up2 ACACAGCCAACAAGACCATCAGTT 15 
I78-low2 AACACTATGCCCCGTTTACTTCTCTG 
Expand-long ~10 kb 68°C/6min@68°C 
35 (+20sec) 
 
 
All PCR products were subcloned in pGEM-T Easy (Promega) and grown in the E. coli host strains 
SURE or JM110 (Stratagene). Sequencing of the clones was done on an ABI 377 DNA Sequencer 
using dye terminator chemistry (Applied Biosystems). 
 Based on the sequence data obtained from these primary PCR products, specific primers were 
designed and the gene fragment later used as 5'-arm of the targeting construct was amplified from 
genomic DNA by long template-PCR (suppl. table 2 and suppl. fig. 1). For cloning purposes, the 
upper primer (KO5'-up, hybridizing in intron 6-7) had been modified to include a 5'-Not I restriction 
site, while at the 3'-end, a BstZ I site, a translational stop codon and the coding sequence for the 
ER retention signal KDEL had been incorporated into the lower primer sequence (KO5'-low, 
containing 5' end sequence of exon VII, 22 bp up to position 2428, GenBank D28599). The 
resulting Not I-BstZ I fragment was inserted into the Not I site of a pBluescript vector bearing a 
floxed neo-tk cassette under the HSV promoter. The resulting vectors has been named pKO5'Arm-
neotk. 
 To assemble the 3' arm we designed an upper primer hybridizing proximally to the 3'-end of the 
5'-arm in exon VII (KO3'-up) and a lower primer placed in intron 7-8 (KO3'-low). Both primers were 
modified with Cla I sites. The entire fragment had beforehand been joined from two smaller 
amplificates by PCR-ligation (with Expand polymerase). For the generation of these pieces (with  
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AmpliTaq-Gold) the cloned GAG- sequence (GAG--pGEM) and an Nco I-fragment of the intron 
7-8 plasmid had been used as templates, respectively (suppl. fig. 1).  
At last, the completed 3' arm was subcloned into the unique Cla I site of KO5'Arm-neotk and the 
final targeting construct was verified by sequencing. Prior to electroporation into R 1 ES cells, it 
was linearized by cleavage with Not I. 
 
Supplementary table 2: Primers and reaction conditions used to generate the targeting construct 
Primer Sequence PCR type Product Anneal./ extension 
Cycles/ 
elongation 
KO5'-up AAATCGGCCGCAGAATGGCTCAAACAAATGGCACA 
KO5'-low AAATCGGCCGTTAGAGCTCATCCTTCTCAATTGTCAATGCAGGGGAA 
Expand-long ~4 kb 68°C/68°C 15 and 35 (+20sec) 
KO3'-up ATTTATCGATCCAACAGAAGCAAGAGATGT 65°C/72°C 
Exon7low GATGGTCTTGTTGGCTGTGT 
~1.5 kb 
30 cycles 
I78-up2 ACACAGCCAACAAGACCATCAGTT 65°C/72°C 
KO3'-low ATTTATCGATGTTAATGTTTTCATGGGTAAAGT 
Ligation- 
PCR 
/ Expand- 
long ~2.5 kb 
30 cycles 
15 and 25 
(+20sec) 
  
 
CGGCCG: Not I / BstZ I compatiple sites    TTA: stop codon    GAGCTCATCCTT: KDEL coding sequence    ATCGAT: Cla I site 
 
 
Supplementary figure 1: Strategy followed to prepare the targeting construct.  
(Blue box: vector sequence encoding the neo-tk selection cassette; red triangles: loxP sites) 
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4.1.1.2. Preparation of the Southern blot probe 
 Using a cloned Nco I fragment of intron 7-8 as template, the 953 bp-long Southern blot probe 
was PCR amplified (primers GTGCATGCATACTGTTGT and CAGCCATGGTCTCAATA) and 
simultaneously DIG-labeled (Roche Applied Science).   
 
4.1.1.3. Verification of target integration and screening of mutant mice 
 Long distance PCR products from genomic DNA of ES clones and mutant mice were sequenced 
to check the correct transgene integration into the versican locus. Amplifications were performed 
with TaKaRa LA Taq (TaKaRa Biomedicals). The primer pairs employed were complementary to the 
neo-tk and the contiguous intron sequences, respectively (5'PCR-up and 5'PCR-low or 3'PCR-up 
and 3'PCR-low) (suppl. table 3). 
 To screen the mutants by PCR, primers were designed flanking the mutation in exon VII (loxed-
up and loxed-low). CRE-transgenic mice used to remove the neo-tk selection cassette in cross-
breedings were genotyped with cre-up and cre-low primers.  
 
Supplementary table 3: Primers and reaction conditions used to verify integration of the targeting construct 
Primer Sequence PCR type Product Anneal./ extension 
Cycles/ 
elongation 
5'PCR-up GACATTTCTTTGTAGACGGTGTTTTA 
5'PCR-low CCTTAATATGCGAAGTGGACCT 
LD-PCR 
(TaKaRa) ~4.3 kb 65°C/68°C 
15 and 35 
(+20sec) 
3'PCR-up CCACCGAGACCCCATTG 
3'PCR-low CACCCCACAGCATTTTTCAG 
LD-PCR 
(TaKaRa) ~4.7 kb 65°C/68°C 
15 and 35 
(+20sec) 
loxed-up GAGAGGACAGAAACACCAAG WT: 312 bp 
loxed-low ACTGTGGGTCAAATGAACTC 
AmpliTaq 
Gold KO: 454 bp 
55°C/72°C 35 
cre-up CCAAAATTTGCCTGCATTAC 
cre-low CCATTTCCGGTTATTCAACT 
AmpliTaq 
Gold 166 bp 55°C/72°C 35 
 
 
4.1.1.4. Preparation of the Northern blot riboprobe 
 A cDNA fragment covering G1 domain-encoding sequences of mouse versican (positions 458 to 
1203, GenBank D28599) was obtained by RT-PCR from total RNA of brain (OneStep RT-PCR, 
Qiagen; primers mLINK-up/low GGTCAGGACTACAAGGG/ TCAAATCTGCTATCAGG). After T/A 
cloning in pGEM-T, a second amplification was performed using the low-primer modified with the 
T7-promoter sequence at the 5' end. (mLINK-low-T7: CGAAATTAATACGACTCACTATAGGGAGA 
TCAAATCTGCTATCAGG) (T7-sequence in red). The resulting product was then in vitro transcribed 
and DIG labeled (DIG RNA Labeling Kit, Roche Applied Science). 
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4.1.1.5. Generation of domain-specific antibodies against mouse versican and other  
  lecticans 
 Immunization of rabbits or guinea pigs was done using recombinant core protein fragments as 
antigens (suppl. fig. 2). In all cases, PCR amplificates from genomic DNA were cloned into the 
pDS56/RBSII, 6xHis expression vector (= pDS9) (Stüber et al., 1990), previously modified by 
introducing a synthetic cassette with Sfi I and Not I sites (pDS9-cassette) (Zimmermann et al., 
1994). The N-terminally His-tagged fusion proteins were expressed in M15[pREP] bacteria and 
subsequently purified under denaturing conditions on a Ni2+-NTA-agarose (Qiagen) column. Briefly, 
after transformation and consecutive IPTG induction of the protein expression in bacteria cultures, 
the peptides were extracted with 6 M guanidine hydrochloride/100 mM sodium phosphate, pH 8.0. 
Once the lysate was cleared by centrifugation, the supernatant was bound to the Ni2+-column, 
washed with 8 M urea/100 mM sodium phosphate/10 mM Tris pH 8.0, and eluted stepwise by 
lowering the pH to 6.3 and 5.9. For the preparation of bacterial control extracts, M15[pREP] were 
transformed with the empty pDS9-cassette vector and processed similarly. 
 
 
Supplementary figure 2: Cartoon showing the location of recombinant antigens used to immunize rabbits (versicans) and 
guinea pigs (versicans, neurocan and aggrecan); brevican antiserum (Thon et al., 2000) was a gift from Takako Sasaki (MPI 
Martinsried). 
 
 Rabbits were immunized with 300-400 g of purified fusion proteins emulsified in incomplete 
Freund's adjuvant and boosted two to four times with one tenth of the original amount of antigen. 
Rabbit antisera were affinity purified on the corresponding fusion protein column (antigen coupled 
to NHS-activated HiTrap, Amersham) after pre-absorption on a bacterial control extract column. 
Eluted antibodies were then precipitated with (NH4)2SO4 to 50% saturation and resuspended in 
TBS/ 1% BSA/ 0.02% sodium azide. The specificity of antibodies was controlled on immunoblots of 
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fusion proteins and whole brain extracts (not shown) as well as by immunohistochemical analysis 
(suppl. fig. 3). 
 
 
 
 
Supplementary figure 3: Immunohistochemistry of para-sagittal sections of a wildtype E18.5 mouse embryo using the newly 
produced rabbit and guinea pig antibodies. For antigen description see supplementary figure 2. 
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4.1.2. Supplementary Results Part I:  
  Distribution of ECM components in perineuronal nets of versican V0/V2 null mice 
 Since previous reports described an association of versican with perineuronal nets (PNNs) 
(Carulli et al., 2006; Deepa et al., 2006), we have analyzed the distribution of all lecticans as well 
as phosphacan and tenascin-R in the deep cerebellar nuclei and in the brain stem of wildtype and 
of versican V2 null mice (suppl. fig. 4). In these experiments, we did not observe any versican 
immunoreactivity, neither in wildtype nor in knockout PNNs. Moreover, no alterations in the 
localization of the known PNN components could be detected in mutant mice.  
 
 
 
Supplementary figure 4: Immunohistochemistry on adult WT and VCV0/V2 KO brains depicting lecticans, phosphacan and 
Tn-R (bar: 8 m). DCN: deep cerebellar nuclei; Sp5l: spinal trigeminal nucleus. 
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AND V2 IN THE MOUSE DORSAL ROOT ENTRY ZONE
A. T. BEGGAH,a,b M. T. DOURS-ZIMMERMANN,c
F.M. BARRAS,a,b1 A. BROSIUS,a,b D. R. ZIMMERMANNc
AND A. D. ZURNa,b*
aDepartment of Experimental Surgery, University Medical School,
Pavillon 4, CHUV, CH-1011 Lausanne, Switzerland
bLaboratory of Stem Cell Dynamics, School of Life Sciences, Swiss
Federal Institute of Technology, CH-1015 Lausanne, Switzerland
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Abstract—Lack of regeneration in the CNS has been attributed
to many causes, including the presence of inhibitory molecules
such as chondroitin sulfate proteoglycans (CSPGs). However,
little is known about the contribution of CSPGs to regeneration
failure in vivo, in particular at the dorsal root entry zone (DREZ),
a unique CNS region that blocks regeneration of sensory ﬁbers
following dorsal root injury without glial scar formation. The
goal of the present study was to evaluate the presence, regula-
tion, and cellular identity of the proteoglycans Brevican, Neu-
rocan, Versican V1 and Versican V2 in the DREZ using CSPG-
speciﬁc antibodies and nucleic acid probes. Brevican and Ver-
sican V2 synthesized before the lesion were still present at high
levels in the extracellularmatrix of the DREZ several weeks after
injury. In addition, Brevican was transiently expressed by reac-
tive oligodendrocytes, and by a subset of astrocytes thereafter.
Versican V2 mRNA appeared in NG2-positive cells with the
morphology of oligodendrocyte precursor cells. Neurocan and
Versican V1 levels were low before injury, and appeared in
nestin-positive astrocytes and in NG2-positive cells, respec-
tively, following lesion. Versican V1, but not V2, was also tran-
siently increased in the peripheral dorsal root post-lesion. This
is the ﬁrst thorough description of the expression and cell
association of individual proteoglycans following dorsal root
lesion. It demonstrates that the proteoglycans Brevican, Neuro-
can, Versican V1, and Versican V2 are abundant in the DREZ at
the time regenerating sensory ﬁbers reach the PNS/CNS border
andmay therefore participate in growth-inhibition in this region.
© 2005 IBRO. Published by Elsevier Ltd. All rights reserved.
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Traumatic injuries to the brain and spinal cord cause se-
vere and irreversible disabilities due to the inability of the
CNS, in contrast to the peripheral nervous system (PNS),
to regenerate injured ﬁbers. For instance, although sen-
sory axons can regenerate through the peripheral dorsal
root after dorsal root injury (rhizotomy), they stop growing
once they reach the spinal cord at the dorsal root entry
zone (DREZ), and do not cross the PNS/CNS border.
Connections within the dorsal horn of the spinal cord can
thus not be restored (Carlstedt, 1983). In humans, brachial
plexus injury results in severe impairment of hand function
associated with chronic pain (Carlstedt, 1995). CNS injury
leads to a reaction which is characterized by a number of
changes, including astrocyte hypertrophy, up-regulation of
intermediate ﬁlament proteins and various extracellular
matrix (ECM) molecules, and to the formation of a glial
scar (reviewed in Fawcett and Asher, 1999). Similarly,
rhizotomy results in reactive gliosis at the DREZ associ-
ated with disintegration of axons and myelin sheaths dur-
ing Wallerian degeneration, but no scar formation (Murray
et al., 1990; Liu et al., 2000; reviewed in Ramer et al.,
2001a). Chondroitin sulfate proteoglycans (CSPGs) are
the ﬁrst ECM molecules with growth-inhibitory properties
that have been described to be enhanced around the
lesion site following various types of CNS injuries (Rudge
and Silver, 1990; McKeon et al., 1991). Further evidence
for a role of CSPGs in restricting regeneration is provided
by the demonstration that enzymatic treatment to remove
the carbohydrate side chains of CSPGs allows partial re-
generation after spinal cord lesion in rats (Bradbury et al.,
2002). In addition, grafts of adult sensory neurons can
regenerate axons in degenerating white matter tracts of
the spinal cord, but not through the central area of the glial
scar containing high concentrations of CSPGs (Davies
et al., 1999). Current evidence thus suggests that CSPGs
contribute, together with other inhibitory molecules, to growth
inhibition in the CNS.
CSPGs are ECM glycoproteins carrying varying de-
grees of covalently bound sulfated glycosaminoglycan
(GAG) chains (for review, see Bandtlow and Zimmermann,
2000). The CSPGs Brevican, Neurocan, and the V1 and
V2 isoforms of Versican belong to a subgroup of proteo-
glycans called hyalectans which share similar globular
N-terminal hyaluronan-binding domains and C-terminal
selectin-like domains, but have a central region which is
not conserved (for review see Yamaguchi, 2000). Hyalec-
tans thus cross-link hyaluronan to other ECM components,
including tenascins and surface molecules such as L1,
neural cell adhesion molecule (N-CAM), and integrins
1 Present address: Department of Otorhinolaryngology and Head and
Neck Surgery, University Medical School, Lausanne, Switzerland.
*Correspondence to: A. D. Zurn, Department of Experimental Surgery,
University Medical School, Pavillon 4, CHUV, CH-1011 Lausanne,
Switzerland. Tel: 41-21-314-2462; fax: 41-21-314-2468.
E-mail address: Anne.Zurn@chuv.hospvd.ch (A. D. Zurn).
Abbreviations: APC, Adenomatous polyposis coli; CGRP, calcitonin
gene-related peptide; CSPG, chondroitin sulfate proteoglycan; dpl,
days post-lesion; DREZ, dorsal root entry zone; DRG, dorsal root
ganglion; ECM, extracellular matrix; GAG, glycosaminoglycan; GFAP,
glial ﬁbrillary acidic protein; IHC, immunohistochemistry; ISH, in situ
hybridization; NGS, normal goat serum; OPC, oligodendrocyte precur-
sor cells; PBS, phosphate buffered saline; PNS, peripheral nervous
system; ROD, relative optical density; SSC, standard saline citrate.
Neuroscience 133 (2005) 749–762
0306-4522/05$30.000.00 © 2005 IBRO. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.neuroscience.2005.03.005
749
(Hagihara et al., 1999; Grumet et al., 1994; Wu et al.,
2002). Brevican and Versican V2 are the most abundant
hyalectans in the adult CNS and are, together with Neuro-
can, exclusively expressed in the CNS (Yamaguchi, 1996;
Bode-Lesniewska et al., 1996; Schmalfeldt et al., 1998;
Niederöst et al., 1999; Rauch et al., 2001). In contrast, the
V1 isoform of Versican has a wider tissue distribution,
being expressed in embryonic tissues that act as barriers
for neural crest migration and in the adult aorta (Yao et al.,
1994; Landolt et al., 1995). Brevican, Neurocan, and Ver-
sican V2 have been shown to inhibit neurite outgrowth
from cerebellar granule cells and/or dorsal root ganglion
(DRG) neurons in vitro (Friedlander et al., 1994; Yamada
et al., 1997; Niederöst et al., 1999; Schmalfeldt et al.,
2000). In addition, various reports have shown that Neu-
rocan and Brevican expression is increased around the
lesion following brain injury, supporting a physiological
contribution of CSPGs as growth-inhibitors in vivo (Haas et
al., 1999; Jaworski et al., 1999; McKeon et al., 1999; Thon
et al., 2000). The role of CSPGs in the DREZ is however
less clear. Although there have been reports of the in-
crease in CSPG expression in the DREZ following rhizot-
omy (Pindzola et al., 1993; Zhang et al., 2001), none has
addressed the presence, potential regulation, and cell as-
sociation of the individual proteoglycans Neurocan, Brevi-
can, Versican V1, and Versican V2 in this area. The DREZ
is a particularly attractive region to study the potential
involvement of CSPGs in regeneration failure since it is
inhibitory in the absence of direct CNS damage and glial
scar formation.
EXPERIMENTAL PROCEDURES
Animals and surgery
Dorsal cervical spinal roots of 2–3 month-old C57BL/6 mice were
unilaterally transected based on the model described previously in
the rat (Ramer et al., 2000). Brieﬂy, animals were anesthetized
with an i.p. injection of a mix of xylazine (7 mg/kg) and ketamine
(140 mg/kg). Hemilaminectomy of the right side of the dorsolateral
cervical spine was performed from C5 to T1 to expose the dorsal
roots. A longitudinal slit in the dura matter allowed the insertion of
a pair of microscissors to completely transect dorsal roots C6 to
C8, midway between the DRG and the entry zone (0.5–0.8 mm
from each). This was done very carefully to avoid even minimal
damage to the spinal cord. Six animals were subjected to sham
operations: hemilaminectomy was performed and the meninges
were opened, but the roots were left intact. The wound was then
closed with sutures. Particular care was taken to minimize the
number of animals used. Furthermore, the mice were injected
intraperitoneally with bupremorphine (2.5 mg/Kg) at the time of the
operation to attenuate post-operation suffering. All animal proto-
cols were approved by the local veterinary commission in Lau-
sanne, Switzerland, and carried out in accordance with their
guidelines.
Immunohistochemistry (IHC)
At 3, 7, 14 or 28 days post-rhizotomy, the animals were anesthe-
tized with a lethal dose of pentobarbital and transcardially per-
fused with phosphate buffered saline (PBS), followed by perfusion
ﬁxation with 50 ml 4% paraformaldehyde in PBS. The cervical part
of the spinal cord together with DRGs was carefully removed and
postﬁxed overnight at 4 °C. For Versican V2 immunolabeling, the
animals were perfused with 50 ml saline only. The spinal cords
were subsequently cryoprotected in 30% sucrose in PBS and
rapidly frozen in O.C.T. compound (Tissue-Teck, Netherlands)
over liquid nitrogen. Ten to 12 m thick transverse sections were
cut on a cryostat (CM3000, Leica, Germany), collected on Super-
frost Plus slides (Menzel-Glaser, Braunschweig, Germany), and
processed for immunohistochemistry as follows: Brevican
[1:5000; raised in rabbits against the entire core protein of the
recombinant secreted form of rat Brevican (kind gift of Dr. R,
Timpl, Max-Planck-Institute for Biochemistry, Martinsried, Ger-
many)]; Neurocan [1:200; raised in rabbits against puriﬁed rat
Neurocan (Haas et al., 1999), or 1:1000; raised in guinea-pigs
against a C-portion of the GAG-binding region of mouse Neurocan
(amino acids 645–944; D. Zimmermann, unpublished observa-
tions)]; Versican V1 and V2 [1:1000 and 1:200, respectively;
raised in rabbits against the recombinant core protein fragments of
the GAG (amino acids 362–585) and GAG domains (amino
acids 2751–3041) of Versican V0 (Schmalfeldt et al., 2000; and
Dours-Zimmermann et al., manuscript in preparation, respec-
tively); glial ﬁbrillary acidic protein (GFAP, 1:500, mouse clone
G-A-5, Chemicon International, Germany) for astrocytes; nestin
(mouse Rat 401 clone, Chemicon International, Germany) for
reactive astrocytes; NG2 (1:400; rabbit anti-rat NG2, Chemicon
International, Germany) for oligodendrocyte precursor cells
(OPCs) or more generally for NG2-positive cells; Adenomatous
polyposis coli antigen (APC, 1:100, mouse clone Ab-7, Oncogene
Research Products, USA) for mature oligodendrocyte cell bodies;
calcitonin gene-related peptide (CGRP, 1:10,000, Peninsula Lab-
oratories, San Carlos, CA, USA) for the identiﬁcation of a sub-
population of regenerating sensory ﬁbers; laminin (1:100, mouse
monoclonal antibodies to the 2-chain of laminin) (Alexis Bio-
chemicals, Lausen, Switzerland) as a marker of the dorsal root;
Mac-1 (CD11b) (1:50, Serotec, France) as a marker of activated
microglia and macrophages. The slides were air-dried for 1 h at
room temperature, then incubated with 0.1% phenylhydrazine
(Merck, Switzerland) in PBS for 30 min at 37 °C. After extensive
washing in PBS, the slides were blocked with normal goat serum
(NGS, Vector Laboratoires, USA) in PBS. The sections were then
exposed overnight at 4 °C to the primary antibody diluted in
NGS/PBS solution. After washing, the slides were incubated with
a biotin-conjugated IgG secondary antibody (Vector Laboratories,
USA) in NGS/PBS for 1 h at room temperature. The sections were
then incubated for 30 min in avidin-biotinylated peroxidase com-
plex using the Vectastain ABC ampliﬁcation kit (Vector Laborato-
ries, USA) according to the manufacturer’s recommendations.
When mouse monoclonal antibodies were used, the immunohis-
tochemistry was performed using the M.O.M.TM kit (Vector Labo-
ratories, USA) according to the manufacturer’s recommendations.
The signal was visualized using a DAB/Ni solution (0.05% 3,3=-
diaminobenzidine, 2% ammonium nickel sulfate, 0.1 M sodium
acetate, 0.1 M acetic acid, 0.001% H2O2). The sections were
lightly counterstained with Fast Red (Sigma, Switzerland), dehy-
drated, and coverslipped using Permount mounting medium
(Fisher Scientiﬁc, Switzerland). Controls for non-speciﬁc labeling
were performed in the absence of primary antibodies. An average
of three to four animals per lesion time-point was analyzed.
For immunoﬂuorescence double labeling, sections were blocked
with 5% NGS in PBS and exposed to primary antibodies (Neurocan,
1:2000; GFAP, 1:4000; NG2, 1:150; CGRP, 1:10,000) overnight at
4 °C as described above. Primary antibodies were visualized with the
Alexa Fluor 594 goat anti-guinea-pig secondary antibody, Alexa
Fluor 488 goat anti-mouse or Alexa Fluor 488 goat anti-rabbit anti-
body (at 1:250; Molecular Probes, Netherlands). The slides were
then coverslipped using Gel MountTM (Sigma-Aldrich, Switzerland).
Digital images were captured with an Axioskop epiﬂuorescence mi-
croscope (Zeiss, Germany) equipped with an Axiocam MRc digital
camera (Zeiss, Germany), and processed using Adobe Photoshop
software (Adobe Systems, USA).
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Densitometric analysis
Semi-quantitative analysis of the relative amounts of Brevican,
Neurocan, Versican V1 and Versican V2 immunoreactivity present
in the DREZ before and after rhizotomy were determined by
densitometric analysis of digital images (Axiocam MRc digital
camera, Zeiss, Germany) of immunoperoxidase-labeled spinal
cord sections using the MetaMorph 3 image analysis system
(Visitron, Puchheim, Germany). Multiple densitometric measure-
ments were made for each proteoglycan as well as for the astro-
cyte marker GFAP by delineating a ﬁeld of approximately 5 m2
within the main DREZ area. Microscope settings were kept con-
stant, stored, and recalled throughout all measurements. The
relative optical densities (ROD) were calculated as follows. Brieﬂy,
the background ROD present in the DREZ on the lesioned and
non-lesioned side of sections exposed to the second antibody
alone (no primary antibody) was always subtracted from all data in
the same series of experiments. The labeling intensities were then
quantiﬁed and expressed as the percentage difference in ROD of
the lesioned DREZ compared with the contralateral control DREZ
of the same spinal cord section. A minimum of 11 and a maximum
of 21 different sections were evaluated per proteoglycan and per
time point after lesion.
Nucleic acid probes for in situ hybridization (ISH)
The digoxigenin-labeled cRNA probes were generated on the
basis of the mouse cDNAs of Versican V1 (Ito et al., 1995),
Versican V2 (Ito et al., 1995), Brevican (Rauch et al., 1997), and
Neurocan (Rauch et al., 1995). The sense and antisense DNA
templates, fused to the T7 DNA polymerase promoter, were ob-
tained by PCR using the oligonucleotide primers. The Versican V1
probe extends over the bases 5371–6240 of the mouse Verscian
V1 cDNA located within the 3=-end portion of the GAG domain
(GenBank accession number D16263). The Versican V2 probe
covers the ﬁrst 655 bp of the GAG domain including bases
1262–1916 of the mouse Versican cDNA (GenBank accession
number D28599). The Brevican probe covers the 570 bp of the
non-homologous central domain, common to the secreted and
GPI-anchored splice variants, including bases 1444–2013 of
the mouse Brevican cDNA (GenBank accession number
X87096). The Neurocan probe covers the 720 bp starting from
86 in the untranslated region, to 659 in the ﬁrst N-terminal
region (GenBank accession number X84727). All in vitro tran-
scripts were partially hydrolyzed at alkaline pH prior to hybrid-
ization. Sense strands served as probes in negative control
experiments. The relative amount of digoxigenin-labeled sense
and antisense probe was estimated by comparison with the
DIG-labeled control RNA (Roche, Switzerland).
ISH
ISH with DIG-labeled riboprobes was performed as described by
Schaeren-Wiemers and Gerﬁn-Moser (1993). Brieﬂy, spinal cord
cryostat sections cut at 12 m were thaw-mounted onto Super-
frost Plus slides (Menzel-Glaser). The sections were air-dried 30
min at room temperature and ﬁxed with 4% paraformaldehyde in
PBS 10 min at 4 °C. After washing in PBS, sections were treated
with 1% Triton X-100 in PBS, then washed in PBS, incubated in
0.1 M triethanolamine containing 0.25% acetic anhydride, and
again washed in PBS. Prehybridization was carried out at room
temperature for 3 h with prehybridization buffer (50% formamid,
5 SSC, 5 Denhardt’s solution, 100 mM maleic acid pH 7.5,
150 mM NaCl, 400 g/ml herring sperm DNA, 250 g/ml baker’s
yeast RNA). Fifty nanograms of cRNA probe were mixed with the
prehybridization buffer. Sections were coverslipped using Hybri-
shipR membranes (Schleicher and Schuell, Germany) to ensure
the presence of a homogeneous volume of probe over the tissue.
Hybridization was performed overnight at 63 °C in a moist, sealed
container. After hybridization, sections were washed in 5 stan-
dard saline citrate (SSC, containing 750 mM NaCl and 75 mM
sodium citrate, pH 7.0) for 5 min at 63 °C, then washed in 0.1
SSC for 1 h at 63 °C and ﬁnally washed again in the same buffer
for 5 min at room temperature. Sections were equilibrated with 1
maleic acid buffer (100 mM maleic acid, 150 mM NaCl; pH 7.5)
and incubated in buffer 1 [1% blocking reagent (Roche Diagnos-
tics, Switzerland) in 1 maleic acid buffer] for 1 h at room tem-
perature, then incubated with alkaline phosphatase-coupled anti-
bodies to digoxigenin (Roche Diagnostics, Switzerland) at a dilu-
tion of 1:2000 in buffer 1 for 5 h at room temperature. Sections
were washed twice with 1 maleic acid buffer, equilibrated in
buffer 2 (100 mM Tris–HCl, 100 mM NaCl, 50 mM MgCl2; pH 9.5)
and developed in the dark with buffer 2 containing 0.34 mg/ml
4-nitroblue-tetrazolium-chloride (Roche Diagnostics, Switzerland),
0.175 mg/ml 5-bromo-4-chloro-3-indolylphosphate (Roche Diag-
nostics, Switzerland), and 0.25 mg/ml levamisol (Sigma-Aldrich,
Switzerland). Development was stopped by washing in buffer 3
(10 mM Tris–HCl, 1 mM EDTA, pH 8.0). Finally the slides were
coverslipped with long term storage buffer (50% glycerol, 5%
gelatin). Digital images were captured as described for immuno-
cytochemistry. The number of ISH signals present in the DREZ
region, i.e. the number of cells expressing CSPG mRNA, was
evaluated non-stereologically in an average of 56 sections from
four distinct experiments for each proteoglycan and each time-
point after lesion. The data were expressed as number of cells in
the DREZ/section.
Double labeling ISH/IHC
ISH for Brevican, Neurocan, Versican V1, and Versican V2 mRNA
was combined with immunohistochemistry for GFAP, nestin, APC,
or NG2. Tissue sections processed for ISH were rinsed exten-
sively in PBS, followed by a blocking step in PBS containing 1%
NGS or the M.O.M.TM kit (Vector Laboratoires, USA) for 1 h.
Primary antibodies were incubated overnight at 4 °C and detected
using biotinylated secondary antibodies and diaminobenzidine/
nickel intensiﬁcation as described above for immunohistochemical
(IHC) staining alone. The slides were then coverslipped with long
term storage buffer (50% glycerol, 5% gelatin). Digital images
were captured with an Axioskop microscope (Zeiss), a digital
camera (Axiocam MRc, Zeiss, Germany), and processed using
Adobe Photoshop software (Adobe Systems, USA).
Statistical analysis
The Prism 4 Graph statistic program (GraphPad Software, USA)
was used. For the densitometric analysis, the paired Student’s
t-test was applied to compare the ROD of the DREZ region on the
lesioned versus the contralateral control side. The difference in
the number of cells expressing CSPG mRNA in the DREZ before
and after lesion was evaluated using one-way ANOVA followed by
the Kruskal-Wallis test.
RESULTS
Brevican, Neurocan, Versican V1, and Versican V2
expression in the unlesioned DREZ and spinal cord
Proteoglycan type-speciﬁc antibodies were used to evaluate
the expression patterns of individual CSPGs in transverse
sections of the DREZ and spinal cord of unlesioned mice.
Labeling with antibodies raised against the entire core protein
of Brevican revealed strong expression of the proteoglycan
throughout the spinal cord gray and white matter, including
the cone of the DREZ protruding into the dorsal root, but not
in the peripheral dorsal root itself (Fig. 1b). Brevican immu-
noreactivity, like immunoreactivity for GFAP, a marker of
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astrocytes, thus allows to delineate the PNS/CNS border
(Fig. 1b and f, arrows). Intense Brevican staining was also
present in perineuronal nets surrounding neurons of the ven-
tral and dorsal spinal cord gray matter (Fig. 1b, inset). A
similar, although less intense staining pattern was found for
Neurocan throughout the white matter, the DREZ, and in
perineuronal nets in the gray matter (Fig. 1c, and inset).
Using antibodies speciﬁc for the V1 and V2 isoforms of
Versican, entirely distinct labeling patterns were observed in
the spinal cord and DREZ. Only weak Versican V1 immuno-
reactivity, was seen in the DREZ and throughout the spinal
cord gray and white matter (Fig. 1d). Conversely, strong
punctate immunoreactivity was observed throughout the spi-
nal cord gray and white matter, including the DREZ, using
Versican V2-speciﬁc antibodies (Fig. 1e). No signal was
present in the peripheral dorsal root.
Astrocyte activation and CSPG expression
following rhizotomy
Dorsal root lesion has previously been shown to lead to
strong astrocyte activation in the DREZ of the rat (Mur-
ray et al., 1990). Because the response to rhizotomy has
not been described in mice so far, we ﬁrst evaluated
astrocyte activation at the murine DREZ using anti-
GFAP antibodies. At 7 days post-lesion (dpl), the signal
intensity of GFAP immunoreactivity was increased by
314.5% compared with control. Hypertrophic astro-
cytic processes were mainly conﬁned to the original
outlines of the DREZ (Fig. 2a and b). No upregulation of
GFAP expression was observed on the contralateral,
unlesioned side when compared with unlesioned control
animals (not shown). The contralateral side was there-
fore used as an internal control in all experiments. By
28dpl, astrocytic processes were tightly packed in the
distal cone of the DREZ protruding into the root, with
hypertrophic processes extending as far as 300–
500 m into the root (Fig. 2c). Brevican immunoreactiv-
ity in the DREZ was increased by 284.2% compared
with the control side at 7dpl (Fig. 2e, f and h) and by
376.4% at 28dpl (Fig. 2g and h). However, hypertro-
phic astrocytic processes extending into the root beyond
the PNS/CNS border, as well as the peripheral dorsal
root itself, were not labeled. Immunoreactivity for Neu-
rocan was also exclusively increased in the DREZ, with
increases of 585.4% and 516.4% compared with
control at 7 and 28dpl, respectively, but not on astrocytic
processes beyond the PNS/CNS interface nor in the
dorsal root (Fig. 2i–l). Increased intensity of staining was
already observed at 3dpl (not shown). Immunolabeling
with the isoform-speciﬁc Versican V1 and V2 antibodies
revealed a distinct expression pattern in the DREZ and
dorsal root following lesion. Versican V1 expression
strongly increased, both in the DREZ (9531%) and the
dorsal root at 7dpl (Fig. 2n and p). Increased intensity of
staining was already observed at 3dpl (not shown).
Strong immunoreactivity was still detected throughout
the entire DREZ at 28dpl (24926.5%), but it had dis-
appeared from the dorsal root (Fig. 2o). From 7–28dpl,
staining was also present in the ﬁbrous tissue over the
DREZ (Fig. 2n and o, asterisk). In contrast, there was a
small increase in Versican V2 immunoreactivity in the
DREZ at 7dpl (255.5%) (Fig. 2r and t), but not in the
dorsal root. By 28dpl, immunolabeling was slightly, but
Fig. 1. Immunoreactivity for Brevican, Neurocan, Versican V1, Versican V2 and GFAP in the non-lesioned control spinal cord and DREZ. Schematic
representation of a transverse section of spinal cord and dorsal root (DR) (a): DC, dorsal column; DH, dorsal horn; GM, gray matter; WM, white matter.
Transverse spinal cord sections labeled with antibodies against Brevican (b), Neurocan (c), Versican V1 (d), Versican V2 (e) and the astrocyte marker
GFAP (f). Strong immunoreactivity for Brevican and Versican V2 is present throughout the spinal cord GM and WM, including the DREZ (b, e).
Neurocan staining is lower, particularly in the DREZ (c), whereas Versican V1 labeling is very weak over the entire spinal cord and DREZ (d). The
arrows indicate the PNS/CNS border at the tip of the DREZ. Note the absence of labeling in the DR of all sections (b–f). Perineuronal nets of ventral
spinal cord motoneurons stained for Brevican and Neurocan are shown in the insets (b, c). No immunoreactivity is observed in the absence of primary
antibodies (not shown); Scale bar	50 m; 10 m in insets.
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not signiﬁcantly decreased compared with control (Fig.
2s and t).
Brevican, Neurocan, and Versican V1 and V2 mRNA
expression in the DREZ following rhizotomy
ISH in unlesioned animals revealed the presence of Brevican
mRNA in most of the neurons of spinal cord gray matter, as
well as lower mRNA expression in scattered cells of the
white matter and the DREZ (Fig. 3a). The hybridization signal
was particularly intense in motoneurons (not shown). The
number of Brevican mRNA-expressing cells was tran-
siently decreased in the DREZ at 3dpl from a mean number
of 4.320.4–2.860.22 cells per section (Fig. 3b and e). At
7dpl, the number of positive cells was back to control values
(4.60.25 cells/section), but the intensity of the signals was
increased (Fig. 3c and e). At 14dpl, Brevican mRNA was
mainly present in the distal portion of the DREZ protruding
into the dorsal root (Fig. 3d).
Using the Neurocan-speciﬁc nucleic acid probe, no
Neurocan mRNA-expressing cells could be detected over
the entire spinal cord and DREZ in unlesioned controls
(Fig. 3f). Neurocan mRNA-positive cells appeared in the
proximal area and the tip of the DREZ at 3dpl (3.670.33
cells/section, Fig. 3g, j). Their number progressively de-
creased at 7dpl (2.320.14) and 14dpl (1.90.38 cells/
section) (Fig. 3h–j). At 14dpl, the ISH signals were mainly
found in the tip of the DREZ (Fig. 3i).
Low Versican V1 mRNA levels were detected in isolated
cells scattered throughout the spinal cord white matter, in-
cluding the DREZ, of non-lesioned animals (Fig. 3k). The
number of Versican V1-expressing cells present in the DREZ
transiently increased from an average of 0.70.12–2.51.5
cells per section at 3dpl (Fig. 3l and o) and returned to control
levels at 7 and 14dpl (Fig. 3m–o). Cells expressing Versican
V1 mRNA were also present in the dorsal root at 3 and 7, but
not at 14dpl (l–n; arrowheads in m). Note the presence of
V1-positive cells in the ﬁbrous tissue at 7 and 14dpl (Fig. 3m
and n, asterisks).
Versican V2 mRNA was detected in isolated cells scat-
tered throughout the spinal cord white and gray matter, in-
cluding the DREZ, of non-lesioned animals (Fig. 3p). The
number of V2 mRNA-positive cells progressively increased to
a maximal level of 3.40.25 cells/section at 7dpl (Fig. 3q–t).
Hybridization with the sense probes for Brevican, Neurocan,
Fig. 2. Immunolocalization of GFAP, Brevican, Neurocan, Verican V1 and Versican V2 in the DREZ following dorsal root lesion. GFAP immunore-
activity at 7dpl shows hypertrophic astrocytic processes present mainly within the limits of the original DREZ area (a, b, arrowheads). At 28dpl, glial
processes have extended as far as 300–500 m into the peripheral root (c). The distribution of Brevican immunoreactivity is more compact at 7dpl
(f) compared with non-lesioned controls (e). The PNS/CNS border is clearly visible (arrowhead), with strong Brevican labeling persisting in the DREZ
until 28dpl, but none present in the dorsal root (g). Neurocan immunoreactivity is low in the DREZ of controls (i) and is increased at 7dpl and until 28dpl
(j, k). Versican V1 expression is very weak in the control DREZ (m) and is strongly increased at 7 and 28dpl (n, o). An important and transient increase
in immunoreactivity is also observed in the dorsal root (n). Note also the labeling of the ﬁbrous tissue at 7 and 28dpl (n, o; asterisk). A periodic punctate
Versican V2 staining pattern is revealed in the DREZ of controls (q). The pattern of immunoreactivity is altered at 7dpl (r) and 28dpl (s). The PNS/CNS
border is indicated with arrowheads. Scale bar	20 m in a–s except c, 50 m. Densitometric analysis showing the ROD of the immunoreactivity for
GFAP (d), Brevican (h), Neurocan (l), Versican V1 (p) and Versican V2 (t) post-lesion compared with control (CTL). The data are expressed as mean
valuesS.E.M. ns, not signiﬁcant. (11
n
21, *** P
0.001).
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or Versican V1 and V2 did not show any hybridization signals,
conﬁrming the speciﬁcity of the ISH protocols (Fig. 3d, i, n, s;
insets). Taken together, these results demonstrate that ex-
pression of Brevican, Neurocan, Versican V1 and Versican
V2 is regulated in a differential spatial and temporal manner
in the DREZ following lesion.
Identity of Brevican, Neurocan, Versican V1, and
Versican V2 mRNA expressing cells
Because most CSPGs are secreted ECM molecules, it is
difﬁcult to identify their cellular origin using double-im-
munoﬂuorescence techniques. We therefore performed
ISH with CSPG-speciﬁc probes, followed by IHC with
cell type-speciﬁc antibodies. To assess the identity of
the Brevican mRNA expressing cells present in the
DREZ and spinal cord white matter, ISH was combined
with IHC detection of astrocytes (GFAP), reactive astro-
cytes (nestin, an intermediate ﬁlament protein re-ex-
pressed in activated astrocytes {Clarke et al., 1994;
Levine and Nishima, 1996}), oligodendrocyte precursor
cells (NG2; Levine and Nishiyama, 1996), and oligoden-
drocytes (APC, a marker of mature oligodendrocytes
labeling only the cell soma and not myelin sheaths
{Watanabe et al., 2002}). At 3dpl, Brevican mRNA was
detected in APC- (Fig. 4c), occasionally in NG2- (Fig.
4d), but not in GFAP- (Fig. 4a), or nestin- (Fig. 4b)
positive cells in the DREZ. Conversely, at 7dpl, the
transcripts were exclusively found in GFAP-positive
DREZ astrocytes (Fig. 4e), but not in nestin-, APC-, or
NG2-positive cells (Fig. 4f–h). This suggests that Brevi-
can is transiently expressed by reactive oligodendro-
cytes post-lesion and in a subpopulation of astroglial
cells that are nestin-negative thereafter. On the con-
tralateral, non-lesioned side, most Brevican transcripts
in the spinal cord white matter and the DREZ were
associated with a subpopulation of astrocytes (Fig. 4i),
Fig. 3. ISH with Brevican-, Neurocan-, Versican V1-, and Versican V2-speciﬁc nucleic acid probes. Brevican mRNA transcripts are present in the
DREZ of controls (a), and are maintained until 14dpl (b–d). Strong hybridization signals are also found in neurons of the gray matter (a; asterisk).
Neurocan transcripts are not found in the DREZ and the entire control spinal cord (f). They appear in the DREZ at 3dpl (g) and are maintained, but
decreased, at 7 and 14dpl (h, i). Versican V1 transcripts are found in scattered cells throughout the spinal cord of controls (k). There is a transient
increase in the number of signals in the DREZ at 3dpl (l, asterisk) which returns to control levels at 7 and 14dpl (m, n). Versican V1 transcripts are
also increased in the dorsal root at 3 and 7dpl (l, m, arrowheads) and are present in ﬁbrous tissue (m, n, astersks). Versican V2 transcripts are also
found in scattered cells throughout the control spinal cord (p). The number of Versican V2 hybridization signals is exclusively increased in the DREZ
at 3, 7, and 14dpl (q–s). No signal was observed with any of the sense probes (insets d, i, n, s). Scale bar	50 m. Quantiﬁcation of the number of
ISH signals per DREZ and per section is indicated in e, j, o, and t. The data are expressed as mean valuesS.E.M. ns, not signiﬁcant. (10
n
124,
** P
0.01; *** P
0.001).
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but not with APC- (Fig. 4j) or NG2-positive cells (Fig.
4k). Fig. 4j shows rows of APC-positive oligodendro-
cytes with interposed Brevican-positive cells in the
DREZ of an unlesioned animal (arrowheads). This is
reminiscent of the rows of contiguous oligodendrocytes
with interspersed isolated astrocytes previously de-
scribed in longitudinal sections of the rat ﬁmbria (Suzuki
and Raisman, 1992).
Neurocan mRNA transcripts that appeared in the
DREZ at 3dpl were associated with both nestin (Fig. 5a
and b) and GFAP immunoreactivity (Fig. 5c). The same
cell-association was revealed at 7dpl (GFAP, Fig. 5d and e;
nestin not shown). The hybridization signal was only oc-
casionally found to be co-localized with NG2 (Fig. 5f), but
not with APC immunoreactivity (not shown).
Versican V1 mRNA transcripts were expressed by a
subpopulation of NG2-positive cells in both the DREZ at
3dpl (Fig. 6a) and in the control spinal cord white matter
(Fig. 6e). No co-localization of the signal was found with
GFAP, neither in the DREZ post-lesion (Fig. 6b), nor in the
control white matter (Fig. 6f). The transcripts present in the
dorsal root were located on the PNS side of the PNS/CNS
border, marked by the extremity of the GFAP-positive as-
trocytic processes (Fig. 6c, arrowheads). High peripheral
Versican V1 immunoreactivity was shown to delineate the
DREZ in the lesioned dorsal root at 3dpl (Fig. 6d). Immu-
nolabeling was still present at 7dpl (see Fig. 2n), but had
disappeared from the dorsal root by 14dpl (not shown)
(see Fig. 2o for 28dpl). The Versican V1 mRNA-expressing
cells present in the dorsal root post-lesion did not co-
localize with NG2 immunolabeling (Fig. 7b), and only oc-
casionally with the macrophage marker Mac-1 (Fig. 7f–h).
In addition, Versican V1 immunostaining only partially
overlaps with laminin, an ECM glycoprotein produced by
Schwann cells (Fig. 7c–e). Note the presence of Versican
V1 transcripts in the meninges (Fig. 7a, arrowheads).
Most Versican V2 mRNA transcripts were detected in
NG2-positive cells with the morphology of oligodendrocyte
precursor cells present in the DREZ after lesion (Fig. 8a),
but did not co-localize with GFAP or the oligodendrocyte
marker APC (Fig. 8b, c). Similarly, the hybridization signal
was expressed by many NG2-positive cells throughout the
control spinal cord white matter (Fig. 8d), but not by APC-
and GFAP-positive cells (Fig. 8e, f).
A comparative overview of the IHC stainings, message
distribution (ISH), and cell association (ISH/IHC) of Brevican
Neurocan, Versican V1 and Versican V2 in the DREZ area
before and after rhizotomy is shown in Table 1.
Regeneration of CGRP-positive sensory ﬁbers
following lesion
To evaluate whether there was a correlation between
the presence of CSPGs in the DREZ and the failure of
axonal regeneration through this region after rhizotomy,
spinal cord cryosections from animals killed at 28dpl
were processed for double-immunoﬂuorescence label-
ing using antibodies raised against CGRP (a peptide
Fig. 4. Identity of Brevican mRNA expressing cells. DREZ labeled with a Brevican-speciﬁc probe (brown), followed by immunohistochemistry for
GFAP (a, e, i), nestin (b, f), APC (c, g, j), and NG2 (d, h, k) (black). At 3dpl, Brevican mRNA co-localizes in the DREZ with APC (c, arrowheads), but
not with GFAP (a), nestin (b), or NG2 (d) immunoreactivity. In contrast, at 7dpl, the in situ signal appears in GFAP-positive astrocytes (e), but is not
present in nestin- (f), APC- (g), nor NG2-positive cells (h). The same cell-association is found in spinal cord white matter and DREZ of controls (i–k).
Arrowheads in i indicate Brevican mRNA-expressing resting astrocytes in control white matter. Rows of APC-positive oligodendrocytes in the DREZ
of an unlesioned animal are shown in j, with two interposed Brevican-positive cells (arrowheads). The in situ signal is not co-localized with with NG2
in control white matter (k). Scale bar	20 m in a, c, e, f, i–k; 10 m in b, d, g, h.
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present in a subpopulation of large diameter myelinated
and small diameter non-myelinated sensory ﬁbers) and
against Neurocan, GFAP, or laminin. Many CGRP-pos-
itive ﬁbers regenerated through the dorsal root (PNS),
but they stopped growing as soon as they reached the
DREZ (CNS) containing high Neurocan concentrations
(Fig. 9a–c). Failure to regrow through the PNS/CNS
transitional zone was also visualized by double-labeling
with GFAP, a marker of astrocytes (Fig. 9d–f), and lami-
nin, an ECM glycoprotein produced by Schwann cells
present in the dorsal root (Fig. 9g–i). CGRP-positive
axons can grow along astrocytic processes that extend
long distances into the dorsal root (Fig. 9f, inset, arrows)
and are occasionally seen to penetrate short distances
into the outskirts of the DREZ, but not through the DREZ
(Fig. 9b, c; asterisk).
Fig. 5. Identity of Neurocan mRNA expressing cells. DREZ 3dpl labeled with a Neurocan-speciﬁc probe (a), followed by immunohistochemistry for
nestin (b). The asterisks indicate the ISH signal in a (brown), and nestin-immunoreactivity in b (black), revealing the expression of Neurocan in
nestin-positive cells. Co-localization of Neurocan mRNA with GFAP staining is shown in c (arrowhead). Neurocan transcripts are often found at the
tip of the DREZ at 7dpl (d) and co-localize with GFAP immunostaining (e). The inset in e shows co-localization of Neurocan mRNA and GFAP staining
in another DREZ section of the same animal. The Neurocan signal was only occasionally found to be co-localized with NG2 immunoreactivity (f). Scale
bar	20 m in a, b, d–f; 10 m in c.
Fig. 6. Identity of Versican V1 mRNA expressing cells. Spinal cord sections labeled with a Versican V1-speciﬁc probe, followed by immunohisto-
chemistry for NG2 or GFAP. The ISH signal is present in a subpopulation of NG2- (a, e, arrowhead), but not GFAP- (b, c, f) positive cells, both in the
DREZ 3dpl (a–c) and in the spinal cord white matter of controls (e and f). Note that not all NG2-positive cells express the Versican V1 transcripts in
the control white matter (e, arrows). The transcripts visible at the PNS/CNS border in Fig. 3C, are located on the PNS side of the transition zone marked
by GFAP-positive astrocytic processes (c, arrowheads). Similarly, the presence of Versican V1 immunolabeling in the dorsal root allows to delineate
the PNS/CNS border (d). Scale bar	10 m in b; 20 m in a, c–f.
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DISCUSSION
Brevican, Neurocan, Versican V1 and Versican V2 have all
been shown to have potent growth-inhibitory properties
in vitro. However, little is known about their involvement in
regeneration failure in vivo, especially in the DREZ, a region
that is particularly inhibitory following dorsal root lesion, and
Fig. 7. Versican V1 expression in the dorsal root. Spinal cord section labeled with a Versican V1 speciﬁc probe reveals positive cells in meningeal
membranes (a, arrowheads). Cells expressing Versican V1 transcripts in the dorsal root (b, arrowhead) do not co-localize with NG2 immunoreactivity
(b, arrows). Double-immunoﬂuorescence labeling using antibodies against Versican V1 and laminin (c–e) or Mac-1, a macrophage marker (f–h),
shows only partial overlap with laminin and only rarely co-localization with Mac-1. Note the Versican V1 labeling of the meninges in c and e (arrows).
Scale bar	50 m in a; 20 m in b–h.
Fig. 8. Identity of Versican V2 mRNA expressing cells. Spinal cord sections labeled with a Versican V2-speciﬁc probe followed by immunohisto-
chemistry for NG2 (a, d), APC (b, e), and GFAP (c, f). The ISH signal only co-localizes with NG2-positive cells both in the DREZ 7dpl (a–c) and in
the control spinal cord white matter (d–f). Scale bar	10 m.
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this in the absence of glial scar formation. The present study
demonstrates, using CSPG-speciﬁc antibodies and nucleic
acid probes, that the investigated proteoglycans are differen-
tially distributed in the DREZ of unlesioned mice and that
changes in their spatiotemporal expression occur upon dor-
sal root lesion. Furthermore, these proteoglycans are ex-
Table 1. Summary of immunohistochemical staining, message distribution, and cell-association of Brevican, Neurocan, Versican V1 and Versican V2
in the DREZ before and after rhizotomy
Increase in
immunoreactivity
post-lesion (fold-increase)
Number of mRNA
expressing cells/DREZ/section Cell-association of CSPGs
7 dpl 28 dpl Control 3 dpl 7 dpl 14 dpl Non-lesioned Lesioned
GFAP 1.310.04 1.670.04 ND ND ND ND — —
Brevican 1.280.04 1.370.06 4.30.4 2.90.2 4.60.2 4.20.3 Astrocytes Oligodendrocytes (transient),
astrocytes (nestin-neg.)
Neurocan 1.580.05 1.510.06 0 3.70.3 2.30.1 1.90.4 — Astrocytes (nestin-pos.)
Versican V1 1.950.03 2.490.03 0.70.1 2.50.1 0.50.1 0.40.1 OPCs OPCs
Versican V2 1.250.05 0.60.05 0.70.1 2.40.2 3.40.3 3.10.2 OPCs OPCs
Fig. 9. Regeneration of CGRP-positive sensory ﬁbers following rhizotomy. Double-immunoﬂuorescence labeling using antibodies raised against
CGRP (b, e, h), Neurocan (a), GFAP (d), or laminin (g). Merged images (c, f, i) illustrate the inability of the nerve ﬁbers to regenerate through the DREZ
containing high Neurocan concentrations (c). In addition, CGRP-positive axons stop at the PNS/CNS transitional zone marked on the CNS side with
GFAP (f), and on the PNS side with laminin, an ECM glycoprotein produced by Schwann cells (i). CGRP-positive axons can grow along astrocytic
processes extending into the dorsal root (f, inset) and into the ﬁbrous tissue above the DREZ (b, c, arrows). They can occasionally be seen to penetrate
short distances into the outskirts of the DREZ (c; asterisks). Scale bar	20 m.
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pressed by distinct reactive glial cells post-injury and are
abundant in the DREZ at the time regenerating sensory ﬁbers
reach the PNS-CNS transitional zone.
CSPG expression in the unlesioned DREZ and
spinal cord
Immunohistochemistry using CSPG-speciﬁc antibodies re-
vealed the presence and differential distribution of Brevican,
Neurocan, and Versican V1 and V2, in the DREZ and
spinal cord of unlesioned animals. Labeling with Brevican
antibodies recognizing both the secreted and the GPI-
anchored isoform of the proteoglycan (Seidenbecher et al.,
1995) revealed strong expression throughout the spinal
cord gray and white matter, but not in the dorsal root. This
conﬁrms previous observations demonstrating that Brevi-
can is CNS-speciﬁc and is abundantly expressed in adult
brain (Yamada et al., 1997; Seidenbecher et al., 1998;
reviewed in Yamaguchi, 1996). Neurocan immunoreactiv-
ity showed a pattern of distribution similar to that of Brevi-
can, but labeling was less intense (Margolis et al., 1996).
Perineuronal nets surrounding gray matter neurons, in
particular ventral motoneurons, were also immunoreactive.
In the rat, perineuronal Neurocan has been demonstrated
to be expressed by glial cell processes surrounding neu-
ronal cell bodies (Matsui et al., 1998). Using antibodies
speciﬁc for the V1 and V2 isoforms of Versican, entirely
distinct labeling patterns were observed in the spinal cord
and DREZ of unlesioned mice. Only weak immunoreactiv-
ity for Versican V1 was present throughout the spinal cord,
and labeling was absent from the dorsal root. In contrast,
Versican V2 was strongly expressed throughout the spinal
cord gray and white matter, but not in the peripheral dorsal
root. Immunolabeling revealed a punctate staining pattern
reminiscent of the distribution of nodes of Ranvier (see Fig.
2q), in agreement with the recent ﬁnding that Versican V2
is highly concentrated at nodes of Ranvier in adult mouse
cerebellum (Oohashi et al., 2002). Despite strong labeling
revealed by immunohistochemistry, relatively low mRNA
levels for Brevican and Versican V2 were detected in the
control spinal cord white matter and DREZ. This discrep-
ancy may be due to the slow turnover rate of these pro-
teoglycans in unlesioned tissue and the difﬁculty to detect
very low abundant mRNA transcripts by ISH. This also
holds true for Neurocan.
Astrocyte activation at the murine DREZ following
rhizotomy
Cervical rhizotomy in mice led to astrocyte activation in the
DREZ characterized by astrocyte hypertrophy and upregu-
lation of GFAP. Starting a few days after injury, astrocytic
processes started to elongate beyond the PNS/CNS bor-
der into the peripheral environment of the dorsal root and
reached several hundred micrometers (up to 500 m at
28dpl). Thus, astrogliosis at the DREZ in mice, as evalu-
ated with antibodies against GFAP, appears to be largely
similar to the response previously observed in the rat (Liu
et al., 2000; Ramer et al., 2001b). This is interesting to note
since the reaction to spinal cord injury in mice has been
described to be different from that in rats and human,
probably due to a distinct inﬂammatory reaction (Inman
et al., 2002; Sroga et al., 2003). The similarity in the
astrogliotic response to dorsal root lesion may therefore be
related to the weak inﬂammatory reaction occurring in the
DREZ upon rhizotomy (George and Grifﬁn, 1994; Liu et al.,
2000).
Brevican expression in the DREZ following
rhizotomy
Brevican has previously been demonstrated to be up-
regulated in the glial scar following CNS injury (Jaworski et
al., 1999; Thon et al., 2000). However, the glial reaction
that occurs at the DREZ following rhizotomy is distinct from
the cellular response to direct CNS injury that leads to
breakage of the blood–brain-barrier and to glial scar for-
mation. Semi-quantitative evaluation of the labeling inten-
sity by densitometric analysis revealed the maintenance,
but only a small increase in Brevican immunostaining at
both 7 and 28dpl. This small increase may be in part due
to the reduced size of the DREZ subsequent to the loss of
the integrity of the axons and myelin sheaths during
Wallerian degeneration. It may also be due to newly syn-
thesized Brevican produced by glial cells since the inten-
sity, although not the number, of the ISH signals was
increased in the DREZ at 7dpl. Thus, in the absence of
glial scar formation and breakage of the blood–brain-
barrier, only moderate increases in Brevican immunoreac-
tivity were observed which could be attributed to a combi-
nation of slow degradation, shrinkage of the DREZ, and
increased production by activated glial cells. Note that
Brevican immunolabeling could only be detected in the
DREZ region that contains tightly packed astrocytic pro-
cesses, but not on glial processes extending long dis-
tances into the peripheral root, i.e. beyond the PNS/CNS
border. This may indicate a possible differential distribution
of the CSPG on astrocytes. Combined ISH and immuno-
histochemistry revealed that Brevican mRNA was tran-
siently expressed by APC-positive oligodendrocytes at
3dpl. This increase in Brevican expression may be a reac-
tive response of oligodendrocytes to axonal loss during
Wallerian degeneration, leading to re-expression of the
proteoglycan in these cells (Ogawa et al., 2001). At 7dpl,
Brevican was no longer detected in oligodendrocytes, but
appeared in GFAP-positive astrocytes. Interestingly, no co-
localization of Brevican was found with nestin, an intermedi-
ate ﬁlament protein present in glial and neuronal precursors
and re-expressed in some activated astrocytes (Clarke et al.,
1994; Lin et al., 1995). Brevican thus appears to be mainly
expressed by a subset of reactive astrocytes in the DREZ
that are nestin-negative.
Neurocan expression in the DREZ following
rhizotomy
Both Neurocan immunoreactivity and Neurocan mRNA
were increased in the DREZ upon rhizotomy, as has pre-
viously been shown to occur upon direct CNS injury (Haas
et al., 1999; McKeon et al., 1999). The Neurocan tran-
scripts were present as early as 3dpl and were maintained
there until 14dpl. Neurocan is thus present in the DREZ at
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the time sensory ﬁbers reach the PNS/CNS interface (be-
tween 3 and 7 days following lesion {unpublished obser-
vation; Wujek and Lasek, 1983}). Neurocan mRNA co-
localized both with GFAP and nestin immunoreactivity in
the DREZ. Co-localization with NG2 was found only occa-
sionally. Neurocan thus appears to be mainly produced by
a sub-population of nestin-positive reactive astrocytes.
This is in agreement with previous studies reporting Neu-
rocan expression by activated astrocytes following direct
CNS injury (Haas et al., 1999; McKeon et al., 1999). Alter-
natively, Neurocan may be synthesized by nestin-positive
glial precursor cells that have been described to appear in
the spinal cord following rhizotomy in the rat. These cells
have been suggested to originate from the subpial region
of the dorsal spinal cord and migrate ventrally (Kozlova,
2003). However, lateral migration of these precursors from
the pial region into the DREZ has not been evaluated in
this work. Taken together, reactive astrocytes in the DREZ
may consist of a heterogeneous population of cells, some
expressing Brevican but not nestin, while others express
Neurocan and nestin.
Versican V1 expression in the DREZ following
rhizotomy
Although there have been reports showing modulation of
Versican expression upon CNS injury (Asher et al., 2002;
Tang et al., 2003), these studies were performed with a
monoclonal antibody that recognizes an epitope in the
protein domain that is common to all Versican isoforms.
Using an isoform-speciﬁc antibody, Versican V1 immuno-
reactivity that is low in the entire control spinal cord, was
shown to be increased three-four-fold in the DREZ post-
injury and to remain high until 28dpl. In contrast, Versican
V1 mRNA was only transiently increased post-lesion. This
discrepancy could reﬂect a slow turnover rate of this pro-
teoglycan, leading to its persistence in the DREZ for sev-
eral weeks. Versican V1 mRNA was localized to a sub-
population of NG2-positive cells with the morphology of
oligodendrocyte precursors, both in the DREZ post-injury
and in the spinal cord white matter of controls. This indi-
cates that Versican V1, which is predominantly expressed
outside the CNS (Yao et al., 1994; Bode-Lesniewska et al.,
1996), may participate in growth-inhibition in the brain follow-
ing injury. A growth-inhibitory role for Versican V1 in periph-
eral tissues has previously been suggested since it is present
in regions that act as barriers for the migration of neural crest
cells (Landolt et al., 1995). Furthermore, Versican V1 strongly
inhibits neurite outgrowth from chicken embryonic DRG neu-
rons in a stripe choice assay in vitro (S. Dutt and D. R.
Zimmermann, manuscript in preparation).
In addition to an increase in the DREZ, there was a
strong increase in both Versican V1 mRNA and immuno-
staining in the dorsal root at 3 and 7dpl. Both the tran-
scripts and the immunoreactivity had disappeared from the
dorsal root by 14dpl. This transient expression appears to
coincide with axonal destruction, macrophage invasion,
and Schwann cell proliferation occurring during the ﬁrst
few days of Wallerian degeneration. Because Versican V1
is still present at the time the ﬁrst regenerating sensory
axons reach the DREZ (3–7dpl, unpublished observation),
its inhibitory properties may be masked by the presence of
growth-promoting molecules such as laminin and tenascin
C that are strongly up-regulated in the dorsal root after
lesion (Kozlova et al., 1997; Zhang et al., 2001). A balance
between growth-inhibitory and growth-promoting molecules
has been postulated to be important for inhibition to be effec-
tive (Jones et al., 2003). Laminin, for instance, has been
shown to override the inhibitory effects of myelin-associated
glycoprotein, a growth-inhibitor present in both CNS and PNS
myelin (David et al., 1995). Furthermore, NG2, a growth-
inhibitory proteoglycan that is up-regulated after CNS injury
(Levine, 1994), is also increased in the growth-permissive
environment of the rat sciatic nerve after lesion (Morgenstern
et al., 2003). Thus, although Versican V1 may inhibit axonal
growth in other contexts, growth-permissive molecules
present in the lesioned dorsal root may override its inhibitory
properties.
Versican V1 was found to be present in the ﬁbrous
tissue forming above the DREZ, as well as in cells of the
meninges, probably ﬁbroblasts. Versican V1 may therefore
be expressed by endoneurial ﬁbroblasts present in the root
following lesion. NG2 proteoglycan has recently been sug-
gested to be expressed by endoneurial and perineurial
ﬁbroblasts in the peripheral nerve following sciatic nerve
lesion in the rat (Morgenstern et al., 2003). However, no
co-localization of Versican V1 mRNA and NG2 was found
in our hands in the mouse. The lack of availability of
appropriate markers for mouse ﬁbroblasts did not allow us
to evaluate further the cellular identity of Versican V1
expressing cells in the lesioned dorsal root.
Versican V2 expression in the DREZ following
rhizotomy
Using Versican V2-speciﬁc antibodies, immunoreactivity
was found to be slightly, but signiﬁcantly increased in the
DREZ at 7dpl. This increase may be due to Versican V2
mRNA production by reactive cells in the DREZ post-
lesion, as visualized using ISH. Concomitantly, constitu-
tively expressed Versican V2 visualized by IHC appears to
remain in the DREZ for several weeks post-lesion. Like
Brevican, Versican V2 may therefore be rather stable de-
spite the ongoing Wallerian degeneration. This may also
explain the low mRNA expression detected in spinal cord
white matter using in situ hybridization that contrasts with
the high intensity of both Brevican and Versican V2 immu-
nostaining (Fig. 1b and e; Fig. 3a and p). Combined ISH
and immunohistochemistry revealed the selective co-local-
ization of Versican V2 mRNA with NG2-immunoreactivity,
both in the DREZ after lesion, and in the intact spinal cord
white matter. Versican V2 therefore appears to be mainly
produced by a subpopulation of NG2-positive cells with the
morphology of oligodendrocyte precursors, as previously
shown to occur after direct cortical injury (Asher et al.,
2002). Taken together, there are spatiotemporal changes
in the expression pattern of Versican V1 and Versican V2
following dorsal root lesion. Both Versican isoforms appear
to be expressed by NG2-positive cells of the oligodendro-
cyte lineage in the DREZ. However, it remains to be de-
A. T. Beggah et al. / Neuroscience 133 (2005) 749–762760
termined whether they are expressed by the same popu-
lation, or by distinct subpopulations of oligodendrocyte
lineage cells.
Regenerating sensory ﬁbers stop at the DREZ
following rhizotomy
Regeneration of sensory ﬁbers after dorsal root lesion, as
evaluated using antibodies against the peptide CGRP, was
shown to stop as soon as the axons reached the DREZ
containing high Neurocan concentrations. There is there-
fore a good correlation between the presence of this pro-
teoglycan in the DREZ and the failure of axonal regeneration
through this region. Thus, together with other CSPGs, Neu-
rocan produced by reactive astrocytes may participate in
the non-permissiveness of this area. In addition, the high
levels of laminin present in the root post-lesion may pre-
vent the regenerating axons from leaving the growth-
promoting environment of the peripheral root, as sug-
gested recently using in vitro models of regeneration (Ad-
cock et al., 2004; Grimpe et al., 2005).
Taken together, this is a detailed description showing
that Brevican, Neurocan, and Versican V1 and V2 are
abundant in the DREZ following rhizotomy at the time
regenerating sensory axons reach the PNS/CNS border.
Furthermore, we demonstrate that Brevican and Neurocan
are produced by two distinct subpopulations of reactive
astrocytes, and Versican V1 and V2 by subpopulations of
cells of the oligodendrocyte lineage. These four proteogly-
cans are thus appropriately located to contribute to the
non-permissive environment of the DREZ.
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4.2.1. Supplementary Methods and Results Part II: 
  Spinal Cord Contusion-Lesions – Preliminary Studies  
 For a preliminary analysis of the distribution of different lecticans in spinal cord injuries, a 
limited series of animals were lesioned (suppl. fig. 5) in collaboration with Dr. Lisa Schnell from the 
group of Prof. Martin Schwab at the Brain Research Institute, University/ETH Zurich. 
 For this purpose, three to four months old wildtype mice were deeply anesthetized by a 
subcutaneous injection of Hypnorm® (fentanyl citrate plus fluanisone, Janssen-Cilag Ltd.) and 
Dormicum® (midazolam, Roche). The spinal cord was exposed by a narrow dorsal laminectomy at 
thoracic level T8. A contusion lesion on the spine at this level was then performed using a NYU 
(New York University) weight drop device that can control and calculate the impact. A 12 g weight 
for 3 sec was applied onto the spinal cord provoking a mild lesion. The wound was closed and 
sutured. Control animals underwent only a laminectomy (“sham” lesion) (Frei et al., 2000). Four 
and seven days post lesion, the mice were sacrificed by pentobarbital injection and perfusion 
through the left ventricle with Ringer's solution containing heparin (Liquemin, Roche) and sodium 
nitrite, followed by 4% PFA in PBS. Whole spines and brains were dissected and post-fixed 
overnight in the same fixative. Bone included in the biopsies was decalcified by an EDTA-based 
ultrasonic procedure (Reineke et al., 2006) and then the entire spines were paraffin embedded 
according to routine protocols. Immunohistochemistry, preceded when needed by an antigen 
retrieval treatment, was performed on sagittal sections applying the ABC method. 
 
   
 
Supplementary figure 5: Cartoon showing the contusion lesion areas of interest around the site of impact. The secondary 
injury zone surrounds the most affected part, but some tissue remains spared. Wallerian degeneration is seen both above 
and below the impact site (from (Kostyk et al., 2003)). 
 
 
 Currently, only stainings for versicans and NG2 have been performed. NG2, a transmembrane 
CSPG with axonal growth inhibitory properties is associated with oligodendrocyte precursor cells. 
As markers we used in these experiments MBP for myelin, neurofilament-200 for axonal fibers and 
GFAP for astrocytes. Immunostainings (suppl. fig. 6 to 8) show that the versican isoform V2 
(antibodies against versican GAG-), normally present along myelinated fibers, is rapidly degraded  
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within the lesion site, whereas NG2 and versican V1 (versican GAG-) are up-regulated in this 
area. The staining for these CSPGs is more prominent at the outher edge of the lesion. NG2 
accumulation seems to precede the versican V1 deposition (suppl. fig. 7 and 8). 
 
 
 
 
Supplementary figure 6: Hematoxylin/ Eosin and immunohistochemistry of spinal cords from sham lesioned animals, 4 days 
post lesion. Bars: 100 m (overviews; left) and 20 m (close-up pictures; right). 
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Supplementary figure 7: Hematoxylin/ Eosin and immunohistochemistry on spinal cords 4 days post contusion lesion. Bars: 
100 m (overviews; left) and 20 m (close-up pictures; right). 
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Supplementary figure 8: Hematoxylin/ Eosin and immunohistochemistry on spinal cords 7 days post contusion lesion.  
Bars: 100 m (overviews; left) and 20 m (close-up pictures; right). 
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 5. Conclusion and outlook 
 The primary goal of this thesis to generate an isoform-specific versican V0/V2 knockout mouse 
strain has been accomplished, and the early embryonic lethality associated with the constitutive 
inactivation of all versicans could be effectively circumvented by our new targeting strategy. This 
fact implies that the fatal defect in the heart development of hdf-mice (Mjaatvedt et al., 1998) is 
mainly caused by the absence of the V1 isoform and less likely the V3 splice-variant. In our 
previous immunohistochemical analysis of wildtype mice and chicken, we had regularly observed a 
co-expression of versican V1 and its larger relative V0. Both display a wide expression during 
embryonic development and are particularly associated with forming mesenchymal tissues, 
including those in the heart. Since our mouse strain lacks the V0 isoform apart from the adult CNS-
specific versican V2, we can assume that the remaining versican V1 substitutes in most tissues the 
missing V0 and hereby guarantees normal survival and life span in our knockout strain. 
 From the technical viewpoint, we could demonstrate that our targeting approach introducing an 
ER-retention signal and a translational stop codon in exon VII of the versican gene is highly 
effective in abolishing versican V2 deposition in the CNS. Albeit we intended to leave this way the 
mRNA levels untouched and to ablate truncated versican core proteins via ER and lysosomes, we 
observed an unexpected reduction of the target-transcripts. The basis for this phenomenon is 
probably an activation of nonsense mediated decay (NMD) mechanisms in the knockout animals, 
which trigger degradation of aberrant messages. Indeed, the premature termination codon 
introduced in exon VII is located more than 55 nucleotides upstream of the next exon-exon junction 
and consequently complies with the rule that most cells obey to remove 'nonsense' mRNAs. 
Nevertheless, this NMD-mediated removal is in general not complete, leaving about 5-25% of the 
altered mRNA behind (Kuzmiak and Maquat, 2006). Our real-time RT-PCR experiments are fully in 
line with these observations. Despite some leftover of the V2 and V0 mRNAs, no truncated protein 
can be detected in our mutant mice, suggesting that the elimination on protein level functions as 
well. Although we have no final confirmation for this mechanism, our novel procedure has been 
suitable to suppress the deposition of artificial core protein fragments and to evade compensation 
through other alternative splice-variants or related proteins. 
 In contrast to our initial hopes, the absence of the axonal growth inhibiting versican V2 does not 
destabilize the fiber tract formation or cause excessive axonal sprouting and/or provoke 
myelination defects. In retrospect, this is however, not particularly surprising as also the elimination 
of other prominent myelin-derived inhibitors of axonal growth such as Nogo, myelin-associated 
glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (OMgp) did not result in gross 
anatomical changes in the CNS of single mutants (Li et al., 1994; Kim et al., 2003; Simonen et al., 
2003; Zheng et al., 2003; Huang et al., 2005; Zurn and Bandtlow, 2006). Similarly, mouse brains 
lacking the CNS-restricted lecticans neurocan or brevican presented no alterations upon 
histological examination (Zhou et al., 2001; Brakebusch et al., 2002). Co-expression and functional 
redundancy of different myelin inhibitors or ECM molecules may explain, why single mutants often  
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 do not show striking phenotypes. Therefore, simultaneous eliminating of the partly co-localizing 
versican V2 and brevican, may provide more conclusive answers about their functions in fiber tract 
organization and stabilization. Nevertheless, based on our observations, we can exclude a rescue 
of a potential versican V2-null phenotype by compensatory up-regulation of other lecticans. 
 From our analysis of versican V0/V2 null mutants, we have obtained so far clear evidence that 
versican is the key organizer of the extracellular matrix surrounding the CNS nodes of Ranvier. The 
mechanisms of nodal assembly and stabilization of intracellular and extracellular contacts and the 
recruitment of ion channels is of great importance for electrical conductance and has, also in the 
context of regeneration and neurological diseases, gained increasing attention in recent years 
(Poliak and Peles, 2003; Salzer, 2003; Sherman and Brophy, 2005; Hedstrom and Rasband, 2006; 
Schafer and Rasband, 2006). 
 In regard to the assembly of nodal structures, we could confirm in vivo some of the interactions 
that had been previously postulated on the basis of in vitro assays. This includes the binding of 
versican and tenascin-R (Tn-R) (Aspberg et al., 1997) as well as of Tn-R and phosphacan (Xiao et 
al., 1997; Milev et al., 1998; Weber et al., 1999). Moreover, we show that Tn-R strictly requires 
versican V2 to maintain its association with the nodes of Ranvier, while it seems not to be held at 
this site by the binding to contactin and/or the -subunits of sodium channelsas formerly 
suggested from in vitro data (Srinivasan et al., 1998; Xiao et al., 1999; Ratcliffe et al., 2000; Isom, 
2002).  
 While versican V2 deposition is crucial for the ECM assembly, our experiments also clearly 
demonstrate that the absence of versican V2 and even of the entire perinodal matrix does not 
affect the clustering of voltage-gated ion channels and the formation of paranodal and 
juxtaparanodal structures, as previously suspected by other groups. From our data, we can also 
conclude that neither versican V2, Tn-R, phosphacan nor other lecticans are related to the 
oligodendrocyte-derived soluble factors reported to induce node-like Nav-clustering in vitro (Kaplan 
et al., 1997).  
 The way the perinodal matrix and versican V2 itself is anchored is currently not clear. The 
versican interaction seems to depend on binding partners other than hyaluronan or sulfatide and 
probably occurs via distinct axonal cell surface proteins. In the adult CNS, potential membrane 
receptors of versican are voltage-gated sodium channels (mainly Nav 1.6) and in particular also the 
Ig-CAM neurofascin-186 (Nfasc-186). Especially the in vivo-assessment of the putative interaction 
with the latter will be difficult, as Nfasc-null mice die early after birth being not able to switch to 
saltatory conduction (Sherman et al., 2005). Since versican V2 is first detected at the nodal area in 
the second postnatal week, the hypothesis that Nfasc-186 recruits V2 will have to be tested in vitro. 
For this purpose, we could perform similar experiments to those of Hedstrom et al. (Hedstrom et 
al., 2007), who showed cell surface binding of recombinant brevican after addition to Nfasc-186-
transfected COS cell cultures. Alternatively, we might try to establish embryonic neuron-glial co-
cultures (Svenningsen et al., 2003) from Nfasc-/- animals and analyze the deposition of versican 
V2, in case that cells survive long enough to proceed to myelination. 
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  Apart from the search for the nodal binding partner(s) of versican V2, investigations of its 
functions in vivo need also to be extended to other levels. For instance, the ultrastructure of the 
axoglial junctions should be examined in our knockout strain in detail, paying special attention to 
the space around the nodes, including the contacting perinodal astrocytes. In a very preliminary 
attempt we have already looked at axoglial junctions in electron microscopy. So far, we have 
neither noticed everted paranodal loops or abnormal branching of neurites at the CNS nodes of 
Ranvier. To draw a final conclusion more versican V0/V2 knockout animals should be studied, 
however.  
  Versican V2 aggregates around the node provide a strongly negatively charged matrix. It has 
been hypothesized that this ECM, which is able to bind cations, potentially acts as reservoir and/or 
diffusion barrier for sodium and potassium ions. If this extracellular metal ion pool is missing, 
reduced ion flux and slower conduction in the CNS may result. In fact, optic nerve-compound action 
potentials (CAP) measured with suction electrodes followed slightly slower kinetics in Tn-R null 
mice (Weber et al., 1999). Similar recordings of CAP in optic nerves of mice deficient in all three 
isoforms of RPTP were mostly normal (Harroch et al., 2000). Since versican V2 carries among the 
nodal ECM components the highest proportion of negative charges one would expect, that the 
conduction velocity would be lowest in our knockout strain, if these former CAP measurements 
were indeed representative. It is conceivable that such a change would potentially also translate 
into slower reaction times in a sensitive behavioral test.  
 To learn about versican V2 functions in the CNS, challenging the mutants with more aggressive 
means may be another option. This could include analyses of demyelination and remyelination in 
experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, or studies of the 
CNS response to injuries.  
 In the second part of this thesis project, done in collaboration with the laboratory of Anne Zurn 
in Lausanne, we therefore analyzed the putative roles of versicans in the dorsal root lesion model. 
The initial experiments were done in wildtype mice to explore first the differential distribution of all 
lecticans in the dorsal root entry zone (DREZ), the transition border between PNS and CNS. In this 
comparative study, we found that after rhizotomy, there is an up-regulation of versican V1 and 
neurocan, even in the absence of a glial scar, which is considered the major source of CSPGs in 
other types of lesions. Conversely, the normal constituents of the CNS white matter, brevican and 
versican V2, remained virtually unchanged. As a continuation of this project, we plan to analyze 
now the consequences of such lesions in knockout strains that lack versican V2. In fact, our 
collaborators could already show that some sensory axons of neurocan/brevican double deficient 
mice can grow across the DREZ, if an additional conditioning lesion is performed (Quaglia et al., 
2008). From the experiments with versican V2 single and/or brevican/versican V2 double knockout 
strain we expect an even more pronounced regenerative effect after rhizotomy and delayed growth 
stimulation, as the up-regulation of neurocan and versican V1 isoform is only transient, and the 
resident inhibitory lecticans would be absent in this strain.  
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  Finally, spinal cord contusion lesions could provide a new view into the role of versicans in glial 
scar-forming injuries. Our preliminary experiments done in wildtype animals could, for instance, be 
extended to versican V0/V2 knockout mice. Nevertheless, according to our recent observation, 
versican V1 seems to be the main isoform in glial scar tissues and not V2, as previously suggested 
(Asher et al., 2002). Hence, a yet to be generated conditional knockout strain, eliminating all 
versican splice-variants in central nervous tissues, may be more suitable for these experiments. 
Moreover, it would be interesting to cross versican-deficient strains with other null mice, in 
particular with the NgR-/- animals (Zheng et al., 2005), since the NgR/p75NTR complex apparently 
transmits the signals of the white matter inhibitors Nogo, MAG and OMgp, but not of CSPGs.  
 Summing-up all the data from this thesis work, one can assume that our new mouse strain not 
only provides a model to gain new insights into the establishment of specialized matrices at the 
CNS-nodes of Ranvier, but will also be of use to explore the roles of CSPGs in suppressing axonal 
regeneration in the mature CNS. 
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